[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 193
1. Rifatbegović Z, Mesić D, Ljuca F, Zildzić M, Morankić M: [Incidence and surgical treatment of cancer in gallbladder]. Med Arh; 2007;61(1):30-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Incidence and surgical treatment of cancer in gallbladder].
  • The gallbladder cancer is the most common primary cancer of the hepatobiliary system, and ranks fifth of the cancers of the gastrointestinal system.
  • GOAL: Show the incidence, clinical state, and suplement the diagnostic procedure of the patients with the risk factors for gallbladder cancer.
  • Find proper surgical treatment in every stage of the disease according to Nevin-Moran system and the hystological type of the cancer.
  • We established the incidence of gallbladder cancer and we tried to discover the common characteristics of this group of patients.
  • We analized the histological type of the cancer, and the stage of the disease in correlation with clinical presentation, results of the surgical treatment , and the survival and the quality of life.
  • RESULTS: In three years we performed 2553 cholecystectomies, and in 1,7 % of patients -43 patient we discovered the cancer of gallbladder.
  • The mean age of the patients with gallbladder cancer is 65 years (55 - 82 years).
  • In 5 (11,6 %) patients cancer is discovered preoperatively.
  • Other morphologic types are analplastic cancer, carcinosarcoma, and "squamous cell carcinoma".
  • Radical resective procedures on liver were performed in 5 (11,6%) patients.
  • According to the localisation in 60% of cases the cancer was located in fundus, in 30% of cases in corpus,and 10% of cases in the neck of the gallbladder.
  • CONCLUSION: The incidence of the gallbladder cancer in our series is in the slight increase.
  • The quality of life and the survival are inversely correlated with the depth of the invasion and the extent of the spread of the cancer.
  • The extensive surgical procedures in advanced stage of the disease, because of the grim prognosis, does not justify the risk of the operative treatment.
  • [MeSH-minor] Adult. Aged. Cholecystectomy. Female. Humans. Incidence. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17582972.001).
  • [Journal-full-title] Medicinski arhiv
  • [ISO-abbreviation] Med Arh
  • [Language] bos
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Bosnia and Herzegovina
  •  go-up   go-down


2. Desai SP, El-Rayes BF, Ben-Josef E, Greenson JK, Knol JA, Huang EH, Griffith KA, Philip PA, McGinn CJ, Zalupski MM: A phase II study of preoperative capecitabine and radiation therapy in patients with rectal cancer. Am J Clin Oncol; 2007 Aug;30(4):340-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of preoperative capecitabine and radiation therapy in patients with rectal cancer.
  • OBJECTIVES: The purpose of this study was to evaluate the safety and efficacy of preoperative capecitabine and radiation therapy (RT) in patients with locally advanced rectal cancer (LARC).
  • Patients with metastatic disease were eligible provided that operative intervention on primary site was anticipated.
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Adenocarcinoma / secondary. Adult. Aged. Aged, 80 and over. Capecitabine. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Male. Middle Aged. Preoperative Care. Treatment Outcome

  • Genetic Alliance. consumer health - Rectal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17762432.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K08 CA091975
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


3. Kozloff M, Chuang E, Starr A, Gowland PA, Cataruozolo PE, Collier M, Verkh L, Huang X, Kern KA, Miller K: An exploratory study of sunitinib plus paclitaxel as first-line treatment for patients with advanced breast cancer. Ann Oncol; 2010 Jul;21(7):1436-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An exploratory study of sunitinib plus paclitaxel as first-line treatment for patients with advanced breast cancer.
  • BACKGROUND: Sunitinib has shown single-agent activity in patients with previously treated metastatic breast cancer (MBC).
  • We investigated the safety of the combination of sunitinib and paclitaxel in an exploratory study of patients with locally advanced or MBC.
  • Study endpoints included safety (primary endpoint), pharmacokinetics, and antitumor activity.
  • CONCLUSIONS: These data indicate that sunitinib and paclitaxel in combination are well tolerated in patients with locally advanced or MBC.


Advertisement
4. Law WL, Chu KW: Outcomes of resection of stage IV rectal cancer with mesorectal excision. J Surg Oncol; 2006 Jun 1;93(7):523-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes of resection of stage IV rectal cancer with mesorectal excision.
  • BACKGROUND: There is no consensus as to the management of the primary rectal cancer in the presence of distant metastasis and data on the outcomes of radical resection in stage IV rectal cancer are limited.
  • This study aims to evaluate the results of resection of rectal cancer in the patients with stage IV disease and to analyze the factors that might affect the survival of these patients.
  • METHODS: Of the 744 patients with radical resection of primary rectal and rectosigmoid cancer during the study period from August 1993 to July 2002, 70 had stage IV disease on the initial presentation.
  • The median cancer-specific survival of the patients who survived the surgery was 15.2 months.
  • Multivariate analysis showed that the presence of gross residual local disease, lymph node metastasis, liver involvement of over 50%, the absence of surgical management of liver metastasis and those without chemotherapy were independent factors associated with poor survival.
  • CONCLUSIONS: Postoperative mortality and morbidity were acceptable in patients with stage IV rectal cancer.
  • However, in patients with extensive liver involvement and advanced local disease, resection is not worthwhile because of the poor survival.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Liver Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Peritoneal Neoplasms / secondary. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • (PMID = 16705728.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


5. Nan KJ, Ruan ZP, Jing Z, Qin HX, Wang HY, Guo H, Xu R: Expression of fragile histidine triad in primary hepatocellular carcinoma and its relation with cell proliferation and apoptosis. World J Gastroenterol; 2005 Jan 14;11(2):228-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of fragile histidine triad in primary hepatocellular carcinoma and its relation with cell proliferation and apoptosis.
  • AIM: To evaluate the expression of fragile histidine triad (FHIT) gene protein, product of a candidate tumor suppressor, and to investigate the relationship between FHIT, cell apoptosis and proliferation, and pathological features of primary hepatocellular carcinoma (HCC).
  • METHODS: Forty-seven HCC and ten normal liver specimens were collected during surgical operation between 2001 and 2003.
  • RESULTS: All normal liver tissues showed a strong expression of FHIT, whereas 28 of 47 (59.6%) carcinomas showed a significant loss or absence of FHIT expression (P = 0.001).
  • Apoptotic incidence in advanced TNM stage carcinoma and those with positive FHIT expression was higher than that in early stage carcinoma (P = 0.030) and in those with negative FHIT expression (P = 0.044) respectively.
  • [MeSH-major] Acid Anhydride Hydrolases / genetics. Apoptosis / genetics. Carcinoma, Hepatocellular / genetics. Carcinoma, Hepatocellular / pathology. Cell Division / genetics. Genes, Tumor Suppressor. Histidine / genetics. Liver Neoplasms / genetics. Liver Neoplasms / pathology. Neoplasm Proteins / genetics
  • [MeSH-minor] Adult. Female. Humans. Liver / physiology. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Reference Values

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. (L)-HISTIDINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15633221.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / fragile histidine triad protein; 4QD397987E / Histidine; EC 3.6.- / Acid Anhydride Hydrolases
  • [Other-IDs] NLM/ PMC4205407
  •  go-up   go-down


6. Wang ZM, Chen KM, Gong J, Wu CX, Zheng YF: [Dual interventional therapy for malignant gastroduodenal obstruction]. Ai Zheng; 2007 Oct;26(10):1107-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND & OBJECTIVE: The patients with malignant gastroduodenal obstruction usually have unresectable primary lesion and distant metastasis.
  • This study was to evaluate the clinical safety and efficacy of dual interventional therapy on advanced malignant gastroduodenal obstruction.
  • Of the 65 patients, 33 had pyloric antrum obstruction, 22 had duodenal obstruction, and 10 had gastroduodenal obstruction with gastrojejunostomal obstruction; 9 had liver metastasis.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Female. Humans. Infusions, Intra-Arterial. Liver Neoplasms / secondary. Male. Middle Aged. Palliative Care. Pancreatic Neoplasms / complications. Stomach Neoplasms / complications. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17927882.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Alloys; 0 / Antineoplastic Agents
  •  go-up   go-down


7. Conrad R, Remberger M, Cederlund K, Ringdén O, Barkholt L: A comparison between low intensity and reduced intensity conditioning in allogeneic hematopoietic stem cell transplantation for solid tumors. Haematologica; 2008 Feb;93(2):265-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DESIGN AND METHODS: Allogeneic stem cell transplantation was performed in 48 patients with metastatic renal cell cancer (n=17), colo-rectal cancer (n=15), non-metastatic advanced primary liver cancer after orthotopic liver transplantation (n=11), and other solid tumors (n=5).
  • The best graft-versus-tumor effect was demonstrated in patients with advanced primary liver cancer who had previously undergone liver transplantation (p=0.018).
  • [MeSH-minor] Adult. Aged. B-Lymphocytes / immunology. Disease-Free Survival. Female. Graft Survival. Graft vs Host Disease / immunology. Graft vs Host Disease / mortality. Graft vs Host Disease / therapy. Humans. Male. Middle Aged. Survival Rate. Time Factors. Transplantation, Homologous

  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18245651.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


8. Astigueta JC, Abad MA, Morante C, Pow-Sang MR, Destefano V, Montes J: [Characteristics of metastatic prostate cancer occurring in patients under 50 years of age]. Actas Urol Esp; 2010 Apr;34(4):327-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Characteristics of metastatic prostate cancer occurring in patients under 50 years of age].
  • OBJECTIVE: To identify the clinical features, diagnostic approach, and treatment of metastatic prostate cancer in young adult patients.
  • METHODS: A retrospective review was made of the clinical histories of patients under 50 years of age diagnosed with prostate cancer at the urology department of the National Institute for Neoplastic Diseases from 1952 to 2005.
  • RESULTS: There were 69 patients aged less than 50 years who had been diagnosed with prostate cancer, 60% of whom had metastatic tumors.
  • All patients had bone metastases, of which 14.6% were in solid organs (lung and liver), 48.7% in retroperitoneum, and 7.3% in mediastinum.
  • Initially, three patients were diagnosed a lymphoproliferative syndrome, one patient a retroperitoneal tumor of unknown etiology, and four patients a metastasis from an unknown primary tumor.
  • CONCLUSIONS: Advanced prostate cancer is an uncommon condition in young adults.
  • [MeSH-minor] Adult. Humans. Male. Middle Aged. Neoplasm Metastasis. Retrospective Studies


9. Zhu Lz, Yang Rj: [Digital subtraction angiography manifestation and interventional therapy of arteriovenous shunting in primary hepatocellular carcinoma of advanced stage]. Beijing Da Xue Xue Bao; 2008 Apr;40(2):129-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Digital subtraction angiography manifestation and interventional therapy of arteriovenous shunting in primary hepatocellular carcinoma of advanced stage].
  • CONCLUSION: Primary hepatic carcinoma with AVS increases difficulty of interventional therapyìbut as long as we take active and proper treating measureìwe could acquire satisfactory curative effect without serious syndrome.
  • DSA can demonstrate the type, the site and the degree of AVS completely and directly, thus having important value in treating primary hepatic carcinoma and improving prognosis.
  • [MeSH-major] Angiography, Digital Subtraction. Arteriovenous Fistula / radiography. Arteriovenous Fistula / therapy. Chemoembolization, Therapeutic / methods. Liver Neoplasms / radiography
  • [MeSH-minor] Adult. Aged. Carcinoma, Hepatocellular / complications. Carcinoma, Hepatocellular / radiography. Female. Hepatic Artery / abnormalities. Humans. Male. Middle Aged. Portal Vein / abnormalities. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18458684.001).
  • [ISSN] 1671-167X
  • [Journal-full-title] Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences
  • [ISO-abbreviation] Beijing Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


10. Ballo MT, Ross MI, Cormier JN, Myers JN, Lee JE, Gershenwald JE, Hwu P, Zagars GK: Combined-modality therapy for patients with regional nodal metastases from melanoma. Int J Radiat Oncol Biol Phys; 2006 Jan 1;64(1):106-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Surgery was a therapeutic procedure for clinically apparent nodal disease in 434 patients (regionally advanced nodal disease).
  • By multivariate analysis, increasing number of involved lymph nodes and primary ulceration were associated with an inferior 5-year actuarial disease-specific and distant metastasis-free survival.
  • Also, the number of involved lymph nodes was associated with the development of brain metastases, whereas thickness was associated with lung metastases, and primary ulceration was associated with liver metastases.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Analysis of Variance. Chemotherapy, Adjuvant / methods. Disease-Free Survival. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Radiotherapy, Adjuvant / adverse effects. Radiotherapy, Adjuvant / methods. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16182463.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 06294
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


11. Stone P, Kelly L, Head R, White S: Development and validation of a prognostic scale for use in patients with advanced cancer. Palliat Med; 2008 Sep;22(6):711-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development and validation of a prognostic scale for use in patients with advanced cancer.
  • The aim of this study was to develop a new prognostic indicator to help predict survival in advanced cancer patients more accurately.
  • Four variables were found to be associated with worse survival: primary lung cancer, secondary liver cancer, raised C-Reactive protein and poor performance status (ECOG 4).
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Life Expectancy. London. Male. Middle Aged. Prognosis. Proportional Hazards Models. Survival Analysis. Young Adult

  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18715969.001).
  • [ISSN] 1477-030X
  • [Journal-full-title] Palliative medicine
  • [ISO-abbreviation] Palliat Med
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Validation Studies
  • [Publication-country] England
  •  go-up   go-down


12. Sloane D, Chen H, Howell C: Racial disparity in primary hepatocellular carcinoma: tumor stage at presentation, surgical treatment and survival. J Natl Med Assoc; 2006 Dec;98(12):1934-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Racial disparity in primary hepatocellular carcinoma: tumor stage at presentation, surgical treatment and survival.
  • OBJECTIVES: The incidence and mortality rates from primary hepatocellular carcinoma (HCC) are higher in black Americans compared to whites.
  • CONCLUSIONS: Black HCC patients have more advanced tumor stage at diagnosis and lower rates of both surgical intervention and survival.

  • MedlinePlus Health Information. consumer health - African American Health.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2002 Mar 6;94(5):334-57 [11880473.001]
  • [Cites] Am J Gastroenterol. 2003 Sep;98(9):2060-3 [14499788.001]
  • [Cites] Ann Intern Med. 2003 Nov 18;139(10):817-23 [14623619.001]
  • [Cites] CA Cancer J Clin. 2004 Mar-Apr;54(2):78-93 [15061598.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Mar;4(3):355-60 [16527700.001]
  • [Cites] Cancer Causes Control. 2004 Aug;15(6):601-9 [15280639.001]
  • [Cites] Cancer Pract. 1998 May-Jun;6(3):182-7 [9652250.001]
  • [Cites] N Engl J Med. 1999 Mar 11;340(10):745-50 [10072408.001]
  • [Cites] J Clin Oncol. 2006 Jan 20;24(3):413-8 [16365180.001]
  • [Cites] Liver Transpl. 2004 Jul;10(7):834-41 [15237365.001]
  • (PMID = 17225837.001).
  • [ISSN] 1943-4693
  • [Journal-full-title] Journal of the National Medical Association
  • [ISO-abbreviation] J Natl Med Assoc
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / 1 K24 DK072036-01
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2569668
  •  go-up   go-down


13. Peng SY, Lai PL, Pan HW, Hsiao LP, Hsu HC: Aberrant expression of the glycolytic enzymes aldolase B and type II hexokinase in hepatocellular carcinoma are predictive markers for advanced stage, early recurrence and poor prognosis. Oncol Rep; 2008 Apr;19(4):1045-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant expression of the glycolytic enzymes aldolase B and type II hexokinase in hepatocellular carcinoma are predictive markers for advanced stage, early recurrence and poor prognosis.
  • Cancer cells with a high glycolytic rate have an advantage in tumor growth.
  • HKII mRNA was overexpressed in 70 (35%) primary HCCs.
  • In conclusion, the aberrant expression of ALDOB and HKII is associated with advanced disease, ETR and poor prognosis, and ALDOB down-regulation in stage II HCC is a predictive marker of ETR and an unfavorable outcome.
  • [MeSH-major] Carcinoma, Hepatocellular / enzymology. Fructose-Bisphosphate Aldolase / genetics. Hexokinase / genetics. Liver Neoplasms / enzymology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Gene Expression Regulation, Enzymologic. Genes, p53. Humans. Male. Middle Aged. Mutation. Neoplasm Recurrence, Local. Neoplasm Staging. Prognosis. RNA, Messenger / analysis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18357395.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 2.7.1.1 / Hexokinase; EC 4.1.2.13 / Fructose-Bisphosphate Aldolase
  •  go-up   go-down


14. Tsukamoto T, Iida J, Dobashi Y, Furukawa T, Konishi F: Overexpression in colorectal carcinoma of two lysosomal enzymes, CLN2 and CLN1, involved in neuronal ceroid lipofuscinosis. Cancer; 2006 Apr 1;106(7):1489-97
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Lysosomal proteases are implicated in cancer progression and metastasis.
  • RESULTS: The mRNA levels of CLN1 and cathepsins B, D, and L were significantly higher in metastatic lesions than in primary tumors.
  • In the primary tumors, mRNA expressions of CLN2 and cathepsin D were associated with advanced clinical stages (P < .015 and P < .031, respectively).
  • Among the lysosomal enzymes examined, only the mRNA expression of CLN2 in both the primary tumors of all patients and the pT3 tumors was correlated with the presence of liver metastases (P < .0049 and P < .029, respectively).
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Aminopeptidases. Cathepsins. Cloning, Molecular. Dipeptidyl-Peptidases and Tripeptidyl-Peptidases. Disease Progression. Female. Gene Expression Profiling. Humans. Male. Middle Aged. RNA, Messenger / analysis. RNA, Messenger / biosynthesis. Reverse Transcriptase Polymerase Chain Reaction. Serine Proteases

  • Genetic Alliance. consumer health - Neuronal Ceroid Lipofuscinosis.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 American Cancer Society.
  • (PMID = 16518810.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Membrane Proteins; 0 / PPT1 protein, human; 0 / RNA, Messenger; EC 3.4.- / Cathepsins; EC 3.4.- / Endopeptidases; EC 3.4.- / Serine Proteases; EC 3.4.11.- / Aminopeptidases; EC 3.4.14.- / Dipeptidyl-Peptidases and Tripeptidyl-Peptidases; EC 3.4.14.9 / tripeptidyl-peptidase 1
  •  go-up   go-down


15. Stintzing S, Hoffmann RT, Heinemann V, Kufeld M, Rentsch M, Muacevic A: Radiosurgery of liver tumors: value of robotic radiosurgical device to treat liver tumors. Ann Surg Oncol; 2010 Nov;17(11):2877-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiosurgery of liver tumors: value of robotic radiosurgical device to treat liver tumors.
  • BACKGROUND: The treatment of isolated liver metastases has become a rapidly developing field with many new, technically advanced methods.
  • Here we present the therapeutic efficacy of a robotic radiosurgery for local control of liver metastases from solid tumors.
  • METHODS: Patients with tumorous lesions to the liver, not qualifying for surgery, were treated with single-session radiosurgery (24 Gy) that used robotic image-guided real-time tumor tracking.
  • Metastases originated from colon cancer (n = 19), ovarian cancer (n = 3), pancreatic cancer (n = 2), breast cancer (n = 2), and others (n = 6).
  • Four lesions were of primary liver origin (hepatocellular carcinoma and cholangiocellular carcinoma).
  • CONCLUSIONS: Robotic radiosurgery with image-guided real-time tumor tracking of liver neoplasm is a new and promising approach for patients with disease that is not eligible for surgical resection and might enhance the possibilities of multidisciplinary oncological treatment concepts.
  • [MeSH-major] Liver Neoplasms / surgery. Radiosurgery. Robotics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Prospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20574773.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Ramanathan RK, Egorin MJ, Eiseman JL, Ramalingam S, Friedland D, Agarwala SS, Ivy SP, Potter DM, Chatta G, Zuhowski EG, Stoller RG, Naret C, Guo J, Belani CP: Phase I and pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with refractory advanced cancers. Clin Cancer Res; 2007 Mar 15;13(6):1769-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I and pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with refractory advanced cancers.
  • PURPOSE: The primary objective was to establish the dose-limiting toxicity (DLT) and recommended phase II dose of 17-(allylamino)-17-demethoxygeldanamycin (17AAG) given twice a week.
  • Grade 3/4 toxicities seen in >5% of patients were reversible elevations of liver enzymes (47%), nausea (9%), vomiting (9%), and headache (5%).

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Cancer Res. 2007 Mar 15;13(6):1625-9 [17363512.001]
  • (PMID = 17363531.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01-CA099168; United States / NCATS NIH HHS / TR / UL1 TR000005; United States / NCI NIH HHS / CA / P30 CA47904; United States / NCRR NIH HHS / RR / 5 M01 RR00056; United States / NCI NIH HHS / CA / U01-CA69855
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzoquinones; 0 / HSP70 Heat-Shock Proteins; 0 / Lactams, Macrocyclic; 4GY0AVT3L4 / tanespimycin
  •  go-up   go-down


17. Bège T, Le Treut YP, Hardwigsen J, Ananian P, Richa H, Campan P, Garcia S: Prognostic factors after resection for hepatocellular carcinoma in nonfibrotic or moderately fibrotic liver. A 116-case European series. J Gastrointest Surg; 2007 May;11(5):619-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors after resection for hepatocellular carcinoma in nonfibrotic or moderately fibrotic liver. A 116-case European series.
  • The purpose of this study was to identify factors influencing prognosis after resection for hepatocellular carcinoma in the noncirrhotic liver and to measure the impact of moderate fibrosis on presentation and prognosis.
  • A series of 116 primary procedures were performed for hepatocellular carcinoma in the noncirrhotic liver.
  • Hepatocellular carcinoma in the nonfibrotic liver was associated with younger age and female sex, but there was no difference with other hepatocellular carcinoma with regard to histological or prognostic features.
  • Although hepatocellular carcinoma in the noncirrhotic liver is generally diagnosed at an advanced stage, its resectability remains high.
  • As a result, hepatocellular carcinoma in the noncirrhotic liver accounts for a large proportion of cases in surgical series and has a better prognosis than hepatocellular carcinoma in the cirrhotic liver.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Liver Cirrhosis / complications. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Cohort Studies. Female. Follow-Up Studies. Hepatectomy / methods. Hepatitis B / complications. Hepatitis C / complications. Humans. Liver Transplantation. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local / pathology. Neoplasm, Residual / pathology. Postoperative Complications. Prognosis. Reoperation. Retrospective Studies. Sex Factors. Survival Rate. Treatment Outcome. alpha-Fetoproteins / analysis

  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1954 May;7(3):462-503 [13160935.001]
  • [Cites] J Am Coll Surg. 2005 Nov;201(5):663-70 [16256907.001]
  • [Cites] Br J Surg. 2001 Apr;88(4):515-22 [11298618.001]
  • [Cites] Ann Surg. 1999 Jun;229(6):790-9; discussion 799-800 [10363892.001]
  • [Cites] Arch Surg. 2004 Mar;139(3):320-5; discussion 326 [15006892.001]
  • [Cites] J Am Coll Surg. 2000 Nov;191(5):531-7 [11085733.001]
  • [Cites] Am J Clin Pathol. 1996 Jan;105(1):65-75 [8561091.001]
  • [Cites] J Gastrointest Surg. 2006 Jun;10 (6):855-62 [16769542.001]
  • [Cites] Ann Surg. 2005 Dec;242(6):824-8, discussion 828-9 [16327492.001]
  • [Cites] Arch Surg. 2001 May;136(5):528-35 [11343543.001]
  • [Cites] J Am Coll Surg. 2005 Nov;201(5):656-62 [16256906.001]
  • [Cites] Chirurgie. 1999 Nov;124(5):485-93 [10615775.001]
  • [Cites] Arch Surg. 2005 May;140(5):450-7; discussion 457-8 [15897440.001]
  • [Cites] Hepatology. 1996 Aug;24(2):289-93 [8690394.001]
  • [Cites] World J Surg. 1995 Jan-Feb;19(1):35-41 [7740808.001]
  • [Cites] World J Surg. 2003 Apr;27(4):443-7 [12658490.001]
  • [Cites] J Hepatol. 1987 Feb;4(1):140-7 [3033058.001]
  • [Cites] Br J Surg. 2005 Feb;92(2):198-202 [15609381.001]
  • [Cites] Rev Prat. 2005 Mar 31;55(6):599-606 [15913111.001]
  • [Cites] Eur J Surg. 1999 May;165(5):446-53 [10391161.001]
  • [Cites] Ann Surg. 2000 Nov;232(5):665-72 [11066138.001]
  • [Cites] Ann Surg. 2001 Mar;233(3):379-84 [11224626.001]
  • [Cites] Lancet. 1981 Nov 21;2(8256):1129-33 [6118576.001]
  • [Cites] Hepatology. 2005 Nov;42(5):1208-36 [16250051.001]
  • (PMID = 17468920.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / alpha-Fetoproteins
  •  go-up   go-down


18. Wardley AM, Pivot X, Morales-Vasquez F, Zetina LM, de Fátima Dias Gaui M, Reyes DO, Jassem J, Barton C, Button P, Hersberger V, Torres AA: Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer. J Clin Oncol; 2010 Feb 20;28(6):976-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer.
  • PURPOSE To evaluate trastuzumab (H) and docetaxel (T) with or without capecitabine (X) as first-line combination therapy for human epidermal growth factor receptor 2 (HER2) -positive advanced breast cancer.
  • PATIENTS AND METHODS Patients with HER2-positive locally advanced or metastatic breast cancer were randomly assigned to H (8 mg/kg loading; 6 mg/kg every 3 weeks) plus T (75 mg/m(2) in HTX arm, 100 mg/m(2) in HT arm, every 3 weeks) with or without X (950 mg/m(2) twice per day on days 1 to 14 every 3 weeks).
  • The primary end point was overall response rate (ORR).
  • CONCLUSION HTX is an effective and feasible first-line therapy for HER2-positive locally advanced or metastatic breast cancer, although it should be reserved for patients with good performance status who are not receiving long-term steroids.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / drug therapy. Breast Neoplasms / drug therapy. Liver Neoplasms / drug therapy. Receptor, ErbB-2 / metabolism. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Capecitabine. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Feasibility Studies. Female. Fluorouracil / administration & dosage. Fluorouracil / analogs & derivatives. Humans. In Situ Hybridization, Fluorescence. International Agencies. Middle Aged. Neoplasm Staging. Prognosis. Survival Rate. Taxoids / administration & dosage. Trastuzumab. Treatment Outcome. Young Adult


19. Boudreaux JP, Putty B, Frey DJ, Woltering E, Anthony L, Daly I, Ramcharan T, Lopera J, Castaneda W: Surgical treatment of advanced-stage carcinoid tumors: lessons learned. Ann Surg; 2005 Jun;241(6):839-45; discussion 845-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical treatment of advanced-stage carcinoid tumors: lessons learned.
  • OBJECTIVE: To evaluate clinical outcomes in a large group of advanced-stage carcinoid patients (stage IV) following multimodal surgical therapy.
  • SUMMARY BACKGROUND DATA: Patients with advanced-stage carcinoid have traditionally experienced poor 5-year survival (18%-30%).
  • Two- and four-year survival for patients with no or unilateral liver metastases (n = 23) was 89%, while 2- and 4-year survival for patients with bilateral liver disease (n = 59) was 68% and 52% (P = 0.072), respectively.
  • CONCLUSION: We think that all patients with advanced-stage carcinoid should be evaluated for possible multimodal surgical therapy.
  • Primary tumors should be resected, even in the presence of distant metastases to prevent future intestinal obstruction.
  • The "wait and see" method of management of this slow-growing cancer no longer has merit.
  • [MeSH-minor] Adolescent. Adult. Aged. Algorithms. Antineoplastic Agents, Hormonal / administration & dosage. Chemoembolization, Therapeutic. Female. Humans. Intestinal Obstruction / etiology. Liver Neoplasms / secondary. Male. Malignant Carcinoid Syndrome / etiology. Middle Aged. Neoplasm Staging. Octreotide / administration & dosage. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am Surg. 2002 Aug;68(8):667-71; discussion 671-2 [12206599.001]
  • [Cites] Endocr Relat Cancer. 2003 Dec;10(4):469-81 [14713260.001]
  • [Cites] J Gastrointest Surg. 2004 Sep-Oct;8(6):742-56 [15358337.001]
  • [Cites] Surgery. 1990 Dec;108(6):1091-6 [1701060.001]
  • [Cites] Am J Surg. 1995 May;169(5):523-8 [7747834.001]
  • [Cites] World J Surg. 1996 Sep;20(7):908-14; discussion 914-5 [8678970.001]
  • [Cites] Endocr Relat Cancer. 2003 Dec;10(4):463-8 [14713259.001]
  • [Cites] J Am Coll Surg. 1998 Jul;187(1):88-92; discussion 92-3 [9660030.001]
  • [Cites] Ann Oncol. 2004 Jun;15(6):966-73 [15151956.001]
  • [Cites] Ann Surg. 2003 Jun;237(6):790-8; discussion 798-800 [12796575.001]
  • [Cites] Surgery. 2003 Dec;134(6):1057-63; discussion 1063-5 [14668741.001]
  • [Cites] Am J Surg. 2004 Jan;187(1):39-46 [14706584.001]
  • [Cites] Surgery. 2001 Oct;130(4):677-82; discussion 682-5 [11602899.001]
  • (PMID = 15912033.001).
  • [ISSN] 0003-4932
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; RWM8CCW8GP / Octreotide
  • [Other-IDs] NLM/ PMC1357164
  •  go-up   go-down


20. Furuta K, Sato S, Yamauchi T, Ozawa T, Harada M, Kakumu S: Intrahepatic gene expression profiles in chronic hepatitis B and autoimmune liver disease. J Gastroenterol; 2008;43(11):866-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intrahepatic gene expression profiles in chronic hepatitis B and autoimmune liver disease.
  • BACKGROUND: DNA microarray technology has enabled genomewide analysis of gene transcript levels, yielding insight into the molecular nature of liver disease.
  • METHODS: We compared gene expression of liver biopsy specimens in 16 patients with different stages of chronic hepatitis B, five with autoimmune hepatitis (AIH), five with primary biliary cirrhosis (PBC), and six with druginduced hepatitis.
  • Genes associated with extracellular matrix, cell growth, and DNA repair were noted in the advanced fibrotic stage of chronic hepatitis B (B-3), while gene expression regarding complement activation and the innate immune response decreased.
  • CONCLUSIONS: Analysis of gene expression in liver may be useful for understanding features of distinct liver diseases and for guiding disease progression, particularly in chronic hepatitis B.
  • [MeSH-minor] Adult. Biopsy. Disease Progression. Epithelial Cell Adhesion Molecule. Female. Gene Expression Profiling. Genetic Predisposition to Disease. Humans. Liver / metabolism. Liver / pathology. Lumican. Male. Middle Aged. Oligonucleotide Array Sequence Analysis. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Hepatitis.
  • Genetic Alliance. consumer health - Liver Disease.
  • Genetic Alliance. consumer health - Autoimmune Hepatitis.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastroenterology. 2005 Dec;129(6):2064-75 [16344072.001]
  • [Cites] N Engl J Med. 1993 Jun 24;328(25):1797-801 [7684822.001]
  • [Cites] J Hepatol. 1999 Nov;31(5):929-38 [10580593.001]
  • [Cites] Cancer Res. 1999 Mar 15;59(6):1315-22 [10096565.001]
  • [Cites] Lancet. 2003 Jul 5;362(9377):53-61 [12853201.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):2129-37 [11280777.001]
  • [Cites] Hepatology. 2004 Sep;40(3):667-76 [15349906.001]
  • [Cites] Hepatology. 2001 Dec;34(6):1225-41 [11732013.001]
  • [Cites] Hepatology. 2001 Apr;33(4):832-40 [11283847.001]
  • [Cites] Hepatology. 2006 Nov;44(5):1122-38 [17058214.001]
  • [Cites] Gastroenterology. 2001 Mar;120(4):955-66 [11231949.001]
  • [Cites] Hepatol Res. 2007 Oct;37(10):820-7 [17517078.001]
  • [Cites] Hepatology. 2005 Aug;42(2):481-9 [16025496.001]
  • [Cites] Hepatology. 2003 Jan;37(1):198-207 [12500205.001]
  • [Cites] N Engl J Med. 1997 Jan 16;336(3):196-204 [8988900.001]
  • [Cites] Hepatology. 1994 Jun;19(6):1513-20 [8188183.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Jan 10;300(2):443-7 [12504104.001]
  • [Cites] Hepatology. 2005 Aug;42(2):273-81 [15986378.001]
  • [Cites] Transl Res. 2006 Sep;148(3):103-13 [16938647.001]
  • [Cites] Clin Liver Dis. 2000 Feb;4(1):73-96, vi [11232192.001]
  • (PMID = 19012040.001).
  • [ISSN] 0944-1174
  • [Journal-full-title] Journal of gastroenterology
  • [ISO-abbreviation] J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Cell Adhesion Molecules; 0 / Chondroitin Sulfate Proteoglycans; 0 / EFEMP1 protein, human; 0 / EPCAM protein, human; 0 / Epithelial Cell Adhesion Molecule; 0 / Extracellular Matrix Proteins; 0 / LUM protein, human; 0 / Lumican; 63231-63-0 / RNA; 9056-36-4 / Keratan Sulfate
  •  go-up   go-down


21. Park JW, Kim JH, Kim SK, Kang KW, Park KW, Choi JI, Lee WJ, Kim CM, Nam BH: A prospective evaluation of 18F-FDG and 11C-acetate PET/CT for detection of primary and metastatic hepatocellular carcinoma. J Nucl Med; 2008 Dec;49(12):1912-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A prospective evaluation of 18F-FDG and 11C-acetate PET/CT for detection of primary and metastatic hepatocellular carcinoma.
  • We prospectively evaluated the value of PET/CT using these 2 tracers for the detection of primary and metastatic HCC.
  • RESULTS: The overall sensitivities of (18)F-FDG, (11)C-acetate, and dual-tracer PET/CT in the detection of 110 lesions in 90 patients with primary HCC were 60.9%, 75.4%, and 82.7%, respectively.
  • Elevated serum alpha-fetoprotein levels, an advanced tumor stage, portal vein tumor thrombosis, large tumors, and multiple tumors were significantly associated with positive (18)F-FDG PET/CT results.
  • In analysis based on biopsied lesions, the sensitivity of (18)F-FDG PET/CT was 64.4% for primary HCC and 84.4% for (11)C-acetate PET/CT.
  • CONCLUSION: The addition of (11)C-acetate to (18)F-FDG PET/CT increases the overall sensitivity for the detection of primary HCC but not for the detection of extrahepatic metastases. (18)F-FDG, (11)C-acetate, and dual-tracer PET/CT have a low sensitivity for the detection of small primary HCC, but (18)F-FDG PET/CT has a relatively high sensitivity for the detection of extrahepatic metastases of HCC.
  • [MeSH-major] Acetates. Carbon. Carcinoma, Hepatocellular. Fluorodeoxyglucose F18. Liver Neoplasms / diagnosis. Liver Neoplasms / mortality. Positron-Emission Tomography / statistics & numerical data. Tomography, X-Ray Computed / statistics & numerical data
  • [MeSH-minor] Adult. Female. Humans. Incidence. Korea / epidemiology. Male. Middle Aged. Prognosis. Prospective Studies. Radiopharmaceuticals. Reproducibility of Results. Risk Assessment / methods. Risk Factors. Sensitivity and Specificity. Subtraction Technique / statistics & numerical data. Survival Analysis. Survival Rate

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CARBON .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18997056.001).
  • [ISSN] 0161-5505
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Acetates; 0 / Radiopharmaceuticals; 0 / carbon-11 acetate; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 7440-44-0 / Carbon
  •  go-up   go-down


22. Mizutani S, Oyama T, Hatanaka N, Uchikoshi F, Yoshidome K, Tori M, Ueshima S, Okuma K, Hiraoka K, Yamagami Y, Takahashi H, Sueyoshi K, Taira M, Nakahara M, Nakao K: [Combined chemotherapy with weekly Paclitaxel and doxifluridine for advanced and recurrent gastric cancers]. Gan To Kagaku Ryoho; 2006 Mar;33(3):327-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Combined chemotherapy with weekly Paclitaxel and doxifluridine for advanced and recurrent gastric cancers].
  • We conducted combined therapy of weekly paclitaxel and doxifluridine (5'-DFUR) for 23 cases of advanced and recurrent gastric carcinomas to investigate their efficacy and safety.
  • One of the CR cases was an unresectable case involving a primary tumor, liver metastasis, and abdominal lymph node metastasis, while the other was a recurrent case involving abdominal lymph node metastasis.
  • Combination therapy of weekly paclitaxel and 5'-DFUR can be an effective and safe therapy for advanced and recurrent gastric carcinomas.
  • [MeSH-minor] Adult. Aged. Drug Administration Schedule. Female. Floxuridine / administration & dosage. Humans. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Lymph Nodes / pathology. Lymphatic Metastasis. Male. Middle Aged. Paclitaxel / administration & dosage. Retrospective Studies. Survival Analysis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. FLOXURIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16531712.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 039LU44I5M / Floxuridine; P88XT4IS4D / Paclitaxel; V1JK16Y2JP / doxifluridine
  •  go-up   go-down


23. Park JW: [Hepatocellular carcinoma in Korea: introduction and overview]. Korean J Gastroenterol; 2005 Apr;45(4):217-26
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • HCC accounts for over 80% of all primary liver cancers which ranks fourth among the organ-specific causes of cancer-related deaths worldwide.
  • Infection with hepatitis B virus (HBV) or hepatitis C virus (HCV) or presence of liver cirrhosis are important risk factors for HCC development globally.
  • Recently, five year survival rate of primary liver cancer is 9.6% in Korea.
  • Such poor prognosis of HCC results from the late detection of cancer, an aggressive tumor biology and underlying chronic liver diseases.
  • Because almost eighty percent of HCC is diagnosed in late stage, we launched a nationwide surveillance program to screen high risk groups (HBV or HCV carriers or liver cirrhosis, over 40 years old) and formulated the Korean practice guideline for the diagnosis and treatment of HCC with special emphasis on advanced stage of HCC.
  • [MeSH-major] Carcinoma, Hepatocellular / epidemiology. Liver Neoplasms / epidemiology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Incidence. Korea / epidemiology. Male. Middle Aged. Prevalence. Risk Factors

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15843747.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


24. Hashimoto K, Ueno H, Ikeda M, Kojima Y, Hagihara A, Kondo S, Morizane C, Okusaka T: Do recurrent and metastatic pancreatic cancer patients have the same outcomes with gemcitabine treatment? Oncology; 2009;77(3-4):217-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Do recurrent and metastatic pancreatic cancer patients have the same outcomes with gemcitabine treatment?
  • BACKGROUND: Whether recurrence after surgery and primary metastatic pancreatic cancer should be included in the same category when conducting gemcitabine-based clinical trials remains controversial.
  • METHODS: 326 patients who received gemcitabine monotherapy as a first-line treatment for advanced pancreatic cancer between 2001 and 2007 were reviewed.
  • RESULTS: There were 65 recurrent and 261 metastatic cancer patients.
  • Recurrent cancer patients had a significantly longer time to treatment failure and survival (respective medians 138 and 77 days, p = 0.017) than the metastatic patients (respective medians 270 and 185 days, p = 0.0003).
  • Multivariate analysis revealed poor Karnofsky performance status (<80), presence of liver or peritoneal metastasis, elevated lactate dehydrogenase (>220 U/l), elevated alkaline phosphatase (>330 U/l) and elevated C-reactive protein (>1.0 mg/dl) to be significantly correlated with short survival, while neither recurrent nor metastatic status were related to survival (hazard ratio 0.76, 95% CI 0.53-1.09, p = 0.14).
  • CONCLUSION: When conducting clinical trials, it appears to be acceptable to treat recurrent pancreatic cancer after surgery and pancreatic cancer with primary metastasis under the same category.
  • [MeSH-minor] Adult. Aged. C-Reactive Protein / analysis. Female. Humans. Male. Middle Aged. Neoplasm Metastasis

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19729980.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; 9007-41-4 / C-Reactive Protein; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


25. Mentha G, Majno PE, Andres A, Rubbia-Brandt L, Morel P, Roth AD: Neoadjuvant chemotherapy and resection of advanced synchronous liver metastases before treatment of the colorectal primary. Br J Surg; 2006 Jul;93(7):872-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant chemotherapy and resection of advanced synchronous liver metastases before treatment of the colorectal primary.
  • BACKGROUND: In many patients with advanced synchronous liver metastases from colorectal tumours, the metastases progress during treatment of the primary, precluding curative treatment.
  • The authors have investigated a management strategy that involves high-impact chemotherapy first, resection of liver metastases second and finally removal of the primary tumour in patients with adverse prognostic factors.
  • METHODS: Twenty consecutive patients with non-obstructive colonic (nine patients) or rectal (11 patients) cancer and advanced synchronous liver metastases were treated according to this strategy.
  • Sixteen of the 20 patients had complete removal of liver metastases and colorectal tumours (resectability rate 80 per cent).
  • It allows initial control and downstaging of liver metastases, and delivery of preoperative radiotherapy for rectal cancer without the fear that liver metastases will meanwhile progress beyond the possibility of cure.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Colorectal Neoplasms / surgery. Liver Neoplasms / drug therapy. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoadjuvant Therapy / methods. Neoplasm Staging. Prospective Studies. Survival Rate. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 British Journal of Surgery Society Ltd.
  • [CommentIn] Br J Surg. 2006 Dec;93(12):1564; author reply 1564 [17115402.001]
  • [CommentIn] Br J Surg. 2007 Feb;94(2):250 [17256815.001]
  • [CommentIn] Br J Surg. 2006 Nov;93(11):1434; author reply 1434 [17058298.001]
  • (PMID = 16671066.001).
  • [ISSN] 0007-1323
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


26. Campos SM, Guastalla JP, Subar M, Abreu P, Winer EP, Cameron DA: A comparative study of exemestane versus anastrozole in patients with postmenopausal breast cancer with visceral metastases. Clin Breast Cancer; 2009 Feb;9(1):39-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A comparative study of exemestane versus anastrozole in patients with postmenopausal breast cancer with visceral metastases.
  • PURPOSE: Patients developing visceral breast cancer metastases generally receive chemotherapy rather than endocrine therapy.
  • PATIENTS AND METHODS: Postmenopausal women with advanced breast cancer and > or = 1 visceral (liver or lung) lesion were randomized to anastrozole (1 mg/day orally) or exemestane (25 mg/day orally) for > or = 8 weeks.
  • The primary endpoint was objective response in visceral lesions based on modified Response Evaluation Criteria in Solid Tumors.
  • Both treatments were generally well tolerated in patients with postmenopausal breast cancer with visceral metastases.
  • Aromatase inhibitors can be considered as a treatment option in postmenopausal patients with hormone receptor-positive visceral breast cancer metastases.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Brain Neoplasms / drug therapy. Brain Neoplasms / secondary. Female. Humans. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Middle Aged. Pilot Projects. Postmenopause. Prognosis. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. EXEMESTANE .
  • Hazardous Substances Data Bank. ANASTROZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19299239.001).
  • [ISSN] 1526-8209
  • [Journal-full-title] Clinical breast cancer
  • [ISO-abbreviation] Clin. Breast Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Androstadienes; 0 / Aromatase Inhibitors; 0 / Nitriles; 0 / Triazoles; 107868-30-4 / exemestane; 2Z07MYW1AZ / anastrozole
  •  go-up   go-down


27. Mitsunaga S, Kinoshita T, Hasebe T, Nakagohri T, Konishi M, Takahashi S, Gotohda N, Ochiai A: Low serum level of cholinesterase at recurrence of pancreatic cancer is a poor prognostic factor and relates to systemic disorder and nerve plexus invasion. Pancreas; 2008 Apr;36(3):241-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low serum level of cholinesterase at recurrence of pancreatic cancer is a poor prognostic factor and relates to systemic disorder and nerve plexus invasion.
  • OBJECTIVES: Systemic disorder is a characteristic of advanced pancreatic cancer.
  • This study aimed to find the associations between these sensitive markers and morphological factors of primary tumor that may indicate finding a way of pathogenesis of systemic disorder.
  • METHODS: The current study examined 75 patients who received macroscopic curative resection for pancreatic cancer in our institution as follows:.
  • (1) identification of clinical prognostic factors at initial recurrence after resection of primary tumor and (2) analysis of correlations between clinical prognostic factors and histological findings in primary tumor.
  • Only low levels of serum cholinesterase correlated to nerve plexus invasion in histological findings of primary tumor.
  • CONCLUSIONS: Nerve invasion may thus result in low functional state of the liver followed by systemic disorder.
  • This mechanism may be useful for elucidating cancer cachexia in future studies.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Pancreatic Ductal / enzymology. Carcinoma, Pancreatic Ductal / pathology. Carcinoma, Pancreatic Ductal / surgery. Enteric Nervous System / pathology. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local / enzymology. Prognosis. Recurrence

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18362836.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.1.1.8 / Cholinesterases
  •  go-up   go-down


28. Kosmidis PA, Kalofonos HP, Christodoulou C, Syrigos K, Makatsoris T, Skarlos D, Bakogiannis C, Nicolaides C, Bafaloukos D, Bamias A, Samantas E, Xiros N, Boukovinas I, Fountzilas G, Dimopoulos MA: Paclitaxel and gemcitabine versus carboplatin and gemcitabine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group. Ann Oncol; 2008 Jan;19(1):115-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paclitaxel and gemcitabine versus carboplatin and gemcitabine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group.
  • BACKGROUND: This phase III study was designed to compare the combination paclitaxel (Taxol)-gemcitabine (PG) versus carboplatin-gemcitabine (CG) in patients with advanced inoperable non-small-cell lung cancer.
  • Primary end point was overall survival (OS).

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CIMETIDINE .
  • Hazardous Substances Data Bank. DIPHENHYDRAMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17938425.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 4AF302ESOS / Ondansetron; 7S5I7G3JQL / Dexamethasone; 80061L1WGD / Cimetidine; 8GTS82S83M / Diphenhydramine; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


29. Peschel C, Hartmann JT, Schmittel A, Bokemeyer C, Schneller F, Keilholz U, Buchheidt D, Millan S, Izquierdo MA, Hofheinz RD: Phase II study of plitidepsin in pretreated patients with locally advanced or metastatic non-small cell lung cancer. Lung Cancer; 2008 Jun;60(3):374-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of plitidepsin in pretreated patients with locally advanced or metastatic non-small cell lung cancer.
  • OBJECTIVE: To evaluate the progression-free rate (PFR) at 3 months (13+/-1 weeks), antitumor response, time-to-event efficacy endpoints, and toxicity profile of plitidepsin administered as a 3-h continuous i.v. infusion at a dose of 5mg/m(2), every 2 weeks, to patients with chemotherapy pretreated advanced non-small cell lung cancer (NSCLC).
  • PFR (primary efficacy endpoint) and objective response rate (secondary efficacy endpoint) were evaluated according to RECIST, while the toxic profile of plitidepsin was assessed using the NCI-CTC, version 2.0.
  • RESULTS: A total of 21 patients with a median age of 61 years and with locally advanced or metastatic non-resectable NSCLC, who had previously received only one line of chemotherapy in an advanced setting, received a total of 54 cycles of treatment (median of two cycles per patient; range: 1-8).
  • One patient was responder for the primary (PFR at 13+/-1 weeks) and secondary efficacy endpoint (stable disease according to RECIST).
  • Other two patients were non-responders for the primary efficacy endpoint, but had stable disease (not confirmed at weeks 13+/-1 due to previous withdrawal due to adverse events).
  • The most common side effects were anemia, and asymptomatic and non-cumulative increases of gamma-glutamyltransferase (GGT) and liver transaminase levels.
  • [MeSH-minor] Adult. Aged. Anemia / chemically induced. Animals. Disease Progression. Disease-Free Survival. Female. Humans. Infusions, Intravenous. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Transaminases / blood. gamma-Glutamyltransferase / blood


30. Mudali SV, Fu B, Lakkur SS, Luo M, Embuscado EE, Iacobuzio-Donahue CA: Patterns of EphA2 protein expression in primary and metastatic pancreatic carcinoma and correlation with genetic status. Clin Exp Metastasis; 2006;23(7-8):357-65
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patterns of EphA2 protein expression in primary and metastatic pancreatic carcinoma and correlation with genetic status.
  • EphA2 overexpression has been correlated with increased invasive and metastatic ability in pancreatic cancer cell lines.
  • We collected clinicopathologic data and paraffin-embedded materials from 98 patients with primary and/or metastatic pancreatic cancer and performed immunohistochemical labeling for EphA2 protein.
  • When evaluated specifically for labeling intensity, primary and metastatic carcinomas were more strongly positive compared to benign ducts and PanIN lesions (P < 0.00001 and P < 0.01, respectively) and poorly differentiated carcinomas were more strongly positive for EphA2 than well and moderately differentiated tumors (P < 0.005).
  • When primary carcinomas without metastatic disease were specifically compared to carcinomas with associated metastatic disease, the advanced carcinomas showed relatively less strong positive labeling for EphA2 (P < 0.008).
  • Moreover, decreased EphA2 labeling was more commonly found in liver (P < 0.002), lung (P < 0.004) or peritoneal metastases (P < 0.01) as compared to distant lymph node metastases (P < 0.01).
  • Genetic sequencing of the tyrosine kinase domain of EPHA2 in 22 samples of xenograft enriched pancreatic cancer did not reveal any inactivating mutations.
  • Our data confirms that EphA2 is overexpressed in pancreatic cancer, but suggests a relative loss of EphA2 in co-existent pancreatic cancer metastases as well as a role for EPHA2 in organ specific metastasis.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Physiol. 1997 Oct;273(4 Pt 1):G824-32 [9357823.001]
  • [Cites] Cell Growth Differ. 1999 Sep;10(9):629-38 [10511313.001]
  • [Cites] Cancer Gene Ther. 2004 Nov;11(11):757-66 [15359289.001]
  • [Cites] Clin Cancer Res. 2005 Jan 1;11(1):226-31 [15671550.001]
  • [Cites] Oncogene. 2005 Apr 14;24(16):2684-94 [15829979.001]
  • [Cites] Anticancer Res. 2005 Jul-Aug;25(4):2943-50 [16080548.001]
  • [Cites] Cancer Biol Ther. 2005 May;4(5):548-54 [15846069.001]
  • [Cites] Cancer Genet Cytogenet. 2005 Oct 1;162(1):63-7 [16157202.001]
  • [Cites] J Biol Chem. 2005 Oct 7;280(40):34008-18 [16051609.001]
  • [Cites] Neoplasia. 2005 Aug;7(8):717-22 [16207473.001]
  • [Cites] Gynecol Oncol. 2005 Nov;99(2):278-86 [16061279.001]
  • [Cites] Adv Surg. 2005;39:223-44 [16250554.001]
  • [Cites] Mol Cancer Res. 2005 Oct;3(10):541-51 [16254188.001]
  • [Cites] FASEB J. 2005 Nov;19(13):1884-6 [16166198.001]
  • [Cites] Oncogene. 2005 Nov 24;24(53):7859-68 [16103880.001]
  • [Cites] J Biol Chem. 2005 Dec 23;280(51):42375-82 [16236711.001]
  • [Cites] Clin Cancer Res. 2006 Jan 15;12(2):353-60 [16428472.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] Oncogene. 2000 Nov 20;19(49):5614-9 [11114742.001]
  • [Cites] Oncol Rep. 2001 Jan-Feb;8(1):89-92 [11115575.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):1833-8 [11280733.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):2301-6 [11280802.001]
  • [Cites] Virchows Arch. 2001 Dec;439(6):798-802 [11787853.001]
  • [Cites] Cancer Res. 2002 Feb 1;62(3):819-26 [11830538.001]
  • [Cites] Cancer Res. 2002 May 15;62(10):2840-7 [12019162.001]
  • [Cites] J Biol Chem. 2002 Oct 18;277(42):39274-9 [12167657.001]
  • [Cites] Oncogene. 2002 Oct 31;21(50):7690-9 [12400011.001]
  • [Cites] Mol Cancer Res. 2002 Nov;1(1):79-87 [12496371.001]
  • [Cites] Clin Cancer Res. 2003 Feb;9(2):613-8 [12576426.001]
  • [Cites] Am J Pathol. 2003 Apr;162(4):1037-42 [12651595.001]
  • [Cites] Science. 2003 May 9;300(5621):949 [12738854.001]
  • [Cites] Oncol Rep. 2004 Mar;11(3):605-11 [14767510.001]
  • [Cites] Oncogene. 2004 Feb 19;23(7):1448-56 [14973554.001]
  • [Cites] Clin Chem. 2004 Mar;50(3):490-9 [14726470.001]
  • [Cites] Am J Clin Pathol. 2004 Feb;121(2):226-30 [14983936.001]
  • [Cites] J Cell Sci. 2004 Apr 15;117(Pt 10):2037-49 [15054110.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Aug 6;320(4):1096-102 [15249202.001]
  • [Cites] Clin Cancer Res. 2004 Aug 1;10(15):5145-50 [15297418.001]
  • [Cites] Gynecol Oncol. 2004 Aug;94(2):312-9 [15297167.001]
  • [Cites] Nat Genet. 2004 Sep;36(9):979-83 [15300251.001]
  • [Cites] Mol Cell Biol. 1990 Dec;10(12):6316-24 [2174105.001]
  • [Cites] Cancer. 1992 Apr 1;69(7):1674-81 [1551052.001]
  • [Cites] Science. 1994 Nov 4;266(5186):816-9 [7973638.001]
  • [Cites] Science. 1995 Apr 28;268(5210):567-9 [7536959.001]
  • [Cites] Cancer Res. 1995 Jun 1;55(11):2394-9 [7757992.001]
  • (PMID = 17146615.001).
  • [ISSN] 0262-0898
  • [Journal-full-title] Clinical & experimental metastasis
  • [ISO-abbreviation] Clin. Exp. Metastasis
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA106610-04; United States / NCI NIH HHS / CA / P50 CA062924; United States / NCI NIH HHS / CA / CA62924; United States / NCI NIH HHS / CA / K08 CA106610-04; United States / NCI NIH HHS / CA / CA106610; United States / NCI NIH HHS / CA / K08 CA106610
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, EphA2
  • [Other-IDs] NLM/ NIHMS147177; NLM/ PMC2755224
  •  go-up   go-down


31. Falcone A, Ricci S, Brunetti I, Pfanner E, Allegrini G, Barbara C, Crinò L, Benedetti G, Evangelista W, Fanchini L, Cortesi E, Picone V, Vitello S, Chiara S, Granetto C, Porcile G, Fioretto L, Orlandini C, Andreuccetti M, Masi G, Gruppo Oncologico Nord Ovest: Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol; 2007 May 1;25(13):1670-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest.
  • METHODS: Selection criteria included unresectable metastatic colorectal cancer, age 18 to 75 years, and no prior chemotherapy for advanced disease.
  • The primary end point was response rate (RR).
  • The R0 secondary resection rate of metastases was greater in the FOLFOXIRI arm (6% v 15%; P = .033, among all 244 patients; and 12% v 36%; P = .017 among patients with liver metastases only).
  • CONCLUSION: The FOLFOXIRI regimen improves RR, PFS, and OS compared with FOLFIRI, with an increased, but manageable, toxicity in patients with metastatic colorectal cancer with favorable prognostic characteristics.
  • [MeSH-minor] Adult. Aged. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Female. Fluorouracil / administration & dosage. Humans. Leucovorin / administration & dosage. Male. Middle Aged. Neoplasm Metastasis. Organoplatinum Compounds / administration & dosage. Quality of Life. Recurrence. Survival Analysis

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17470860.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 7673326042 / irinotecan; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


32. Aft R, Naughton M, Trinkaus K, Watson M, Ylagan L, Chavez-MacGregor M, Zhai J, Kuo S, Shannon W, Diemer K, Herrmann V, Dietz J, Ali A, Ellis M, Weiss P, Eberlein T, Ma C, Fracasso PM, Zoberi I, Taylor M, Gillanders W, Pluard T, Mortimer J, Weilbaecher K: Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncol; 2010 May;11(5):421-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial.
  • BACKGROUND: Treatment with bisphosphonates decreases bone loss and can increase disease-free survival in patients with breast cancer.
  • The aim of our study was to assess the effect of zoledronic acid on clearance of disseminated tumour cells (DTCs) from the bone marrow in women undergoing neoadjuvant chemotherapy for breast cancer.
  • Eligible patients had clinical stage II-III (> or = T2 and/or > or = N1) newly diagnosed breast cancer, Eastern Cooperative Oncology Group performance status of 0 or 1, and normal cardiac, renal, and liver function.
  • The primary endpoint was the number of patients with detectable DTCs at 3 months.
  • [MeSH-minor] Adult. Aged. Bone Marrow / pathology. Female. Humans. Middle Aged. Neoadjuvant Therapy

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Ltd. All rights reserved.
  • [Cites] J Dent Res. 2007 Nov;86(11):1022-33 [17959891.001]
  • [Cites] J Clin Oncol. 2007 Mar 1;25(7):820-8 [17159195.001]
  • [Cites] Cancer. 2008 Mar 1;112(5):1001-10 [18205185.001]
  • [Cites] J Clin Oncol. 2008 Jun 1;26(16):2644-52 [18427147.001]
  • [Cites] Oncologist. 2008 May;13(5):503-14 [18515735.001]
  • [Cites] Cancer Treat Rev. 2008;34 Suppl 1:S19-24 [18486348.001]
  • [Cites] J Bone Miner Res. 2008 Jun;23(6):826-36 [18558816.001]
  • [Cites] Cancer. 2008 Jul 1;113(1):193-201 [18459173.001]
  • [Cites] J Natl Cancer Inst. 2008 Aug 20;100(16):1167-78 [18695136.001]
  • [Cites] Lancet Oncol. 2008 Sep;9(9):840-9 [18718815.001]
  • [Cites] J Clin Oncol. 2008 Oct 10;26(29):4739-45 [18711172.001]
  • [Cites] N Engl J Med. 2009 Feb 12;360(7):679-91 [19213681.001]
  • [Cites] Nat Rev Clin Oncol. 2009 Jun;6(6):339-51 [19399023.001]
  • [Cites] Br J Cancer. 2010 Mar 30;102(7):1099-105 [20234364.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(1):80-6 [10623696.001]
  • [Cites] Blood. 2000 Jul 15;96(2):384-92 [10887096.001]
  • [Cites] Br J Cancer. 2001 Apr 20;84(8):1126-34 [11308265.001]
  • [Cites] N Engl J Med. 2002 Feb 28;346(9):653-61 [11870242.001]
  • [Cites] Cancer. 2003 Feb 1;97(3 Suppl):834-9 [12548583.001]
  • [Cites] Am J Med. 2003 Jun 1;114(8):653-9 [12798453.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):2893-7 [12912933.001]
  • [Cites] Blood. 1994 Feb 1;83(3):623-5 [7905297.001]
  • [Cites] Blood. 1994 Feb 1;83(3):636-40 [7507729.001]
  • [Cites] Dtsch Med Wochenschr. 2008 Feb;133(7):285-9 [18253918.001]
  • [Cites] J Hematother. 1994 Fall;3(3):165-73 [7530132.001]
  • [Cites] N Engl J Med. 1998 Aug 6;339(6):357-63 [9691101.001]
  • [Cites] Acta Oncol. 2004;43(7):650-6 [15545185.001]
  • [Cites] J Clin Oncol. 2005 Jan 20;23(3):619-29 [15545664.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3314-21 [15738536.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Jun;90(6):3209-14 [15769994.001]
  • [Cites] N Engl J Med. 2005 Aug 25;353(8):793-802 [16120859.001]
  • [Cites] Pathol Oncol Res. 2005;11(3):186-7 [16299941.001]
  • [Cites] Future Oncol. 2005 Apr;1(2):149-59 [16555985.001]
  • [Cites] Tumour Biol. 2006;27(2):92-103 [16582586.001]
  • [Cites] Breast Cancer Res. 2006;8(2):R13 [16542503.001]
  • [Cites] Cancer. 2006 Sep 1;107(5):885-92 [16874814.001]
  • [Cites] Clin Cancer Res. 2006 Oct 15;12(20 Pt 2):6309s-6314s [17062720.001]
  • [Cites] J Clin Oncol. 2007 Mar 1;25(7):829-36 [17159193.001]
  • [CommentIn] Lancet Oncol. 2010 May;11(5):402-3 [20434707.001]
  • (PMID = 20362507.001).
  • [ISSN] 1474-5488
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00242203
  • [Grant] United States / NCI NIH HHS / CA / P01 CA100730; United States / NCI NIH HHS / CA / R01 CA097250
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Diphosphonates; 0 / Imidazoles; 6XC1PAD3KF / zoledronic acid
  • [Other-IDs] NLM/ NIHMS405760; NLM/ PMC3792651
  •  go-up   go-down


33. Kassahun WT, Fangmann J, Harms J, Hauss J, Bartels M: Liver resection and transplantation in the management of hepatocellular carcinoma: a review. Exp Clin Transplant; 2006 Dec;4(2):549-58
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver resection and transplantation in the management of hepatocellular carcinoma: a review.
  • Hepatocellular carcinoma (HCC) accounts for more than 80% of all primary liver cancers and is one of the most common malignancies worldwide.
  • Most patients with HCC also suffer from concomitant cirrhosis, which is the major clinical risk factor for hepatic cancer and results from alcoholism, infection with the hepatitis B or hepatitis C virus, and other causes.
  • HCC is often diagnosed at an advanced stage, when established treatment options provide limited benefit.
  • Effective treatment for HCC includes liver resection and liver transplantation.
  • Partial hepatectomy is the therapy of choice in patients with HCC and a noncirrhotic liver.
  • Usually, liver transplantation is not indicated for such patients, although in individual cases, transplantation may be considered.
  • For most cirrhotic patients who fulfill the Milan criteria, liver transplantation is the ultimate treatment option.
  • Liver transplantation restores liver function and ensures the removal of all hepatic foci of tumor as well as tissue with a high oncogenic potential for early tumor recurrence.
  • Because of the present lack of available organs, living-donor liver transplantation (LDLT) is an increasingly popular alternative.
  • Strategies to reduce tumor growth in patients who are awaiting liver transplantation are important to ensure that those individuals continue to fulfill the Milan criteria for transplantation.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Hepatectomy / methods. Liver Neoplasms / surgery. Liver Transplantation / physiology. Tissue Donors. Tissue and Organ Harvesting / methods
  • [MeSH-minor] Adult. Female. Humans. Male. Middle Aged. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • MedlinePlus Health Information. consumer health - Organ Donation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17238857.001).
  • [ISSN] 1304-0855
  • [Journal-full-title] Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation
  • [ISO-abbreviation] Exp Clin Transplant
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Turkey
  • [Number-of-references] 99
  •  go-up   go-down


34. Tabata M, Kozuki T, Ueoka H, Kiura K, Harita S, Tada A, Shibayama T, Takigawa N, Yonei T, Gemba K, Segawa Y, Kishino D, Tada S, Hiraki S, Tanimoto M, Okayama Lung Cancer Study Group: A triplet chemotherapy with cisplatin, docetaxel and gemcitabine in patients with advanced non-small-cell lung cancer: a phase I/II study. Cancer Chemother Pharmacol; 2007 Jun;60(1):53-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A triplet chemotherapy with cisplatin, docetaxel and gemcitabine in patients with advanced non-small-cell lung cancer: a phase I/II study.
  • PURPOSE: We conducted a phase I/II study of triplet chemotherapy consisting of cisplatin (CDDP), docetaxel (DCT) and gemcitabine (GEM) in patients with advanced non-small-cell lung cancer (NSCLC).
  • In the phase I portion, a dose escalation study of GEM with starting dose of 400 mg/m(2) was conducted and primary objective in the phase II portion was response rate.
  • RESULTS: The maximally tolerated dose (MTD) and recommended dose (RD) of GEM were determined as 800 mg/m(2) because grade 3 non-hematological toxicity (liver damage, diarrhea, and fatigue) developed in three of nine patients evaluated at that dose level.
  • CONCLUSION: These results indicate that this triplet chemotherapy is feasible and effective in patients with advanced NSCLC.
  • [MeSH-minor] Adult. Aged. Area Under Curve. Cisplatin / administration & dosage. Cisplatin / adverse effects. Cisplatin / pharmacokinetics. Deoxycytidine / administration & dosage. Deoxycytidine / adverse effects. Deoxycytidine / analogs & derivatives. Deoxycytidine / pharmacokinetics. Dose-Response Relationship, Drug. Female. Humans. Leukopenia / chemically induced. Male. Metabolic Clearance Rate. Middle Aged. Nausea / chemically induced. Neoplasm Recurrence, Local. Neoplasm Staging. Pregnancy. Survival Analysis. Taxoids / administration & dosage. Taxoids / adverse effects. Taxoids / pharmacokinetics. Treatment Outcome. Vomiting / chemically induced


35. Zhu AX, Sahani DV, Duda DG, di Tomaso E, Ancukiewicz M, Catalano OA, Sindhwani V, Blaszkowsky LS, Yoon SS, Lahdenranta J, Bhargava P, Meyerhardt J, Clark JW, Kwak EL, Hezel AF, Miksad R, Abrams TA, Enzinger PC, Fuchs CS, Ryan DP, Jain RK: Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol; 2009 Jun 20;27(18):3027-35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study.
  • PURPOSE: To assess the safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma (HCC) and explore biomarkers for sunitinib response.
  • PATIENTS AND METHODS: We conducted a multidisciplinary phase II study of sunitinib, an antivascular endothelial growth factor receptor tyrosine kinase inhibitor, in advanced HCC.
  • The primary end point was progression-free survival (PFS).
  • CONCLUSION: Sunitinib shows evidence of modest antitumor activity in advanced HCC with manageable adverse effects.
  • Our study suggests that control of inflammation might be critical for improving treatment outcome in advanced HCC.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Biomarkers / blood. Carcinoma, Hepatocellular / drug therapy. Indoles / therapeutic use. Liver Neoplasms / drug therapy. Pyrroles / therapeutic use
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemokine CXCL12 / blood. Female. Humans. Interleukin-6 / blood. Magnetic Resonance Imaging. Male. Middle Aged. Stem Cells / cytology

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2006 Feb 10;24(5):769-77 [16391297.001]
  • [Cites] Nat Clin Pract Oncol. 2006 Jan;3(1):24-40 [16407877.001]
  • [Cites] Oncologist. 2006 Jul-Aug;11(7):790-800 [16880238.001]
  • [Cites] Lancet. 2006 Oct 14;368(9544):1329-38 [17046465.001]
  • [Cites] N Engl J Med. 2007 Jan 11;356(2):115-24 [17215529.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):83-95 [17222792.001]
  • [Cites] J Clin Oncol. 2007 Mar 1;25(7):884-96 [17327610.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2007 Apr;19(3):204-8 [17359908.001]
  • [Cites] Nat Protoc. 2007;2(4):805-10 [17446880.001]
  • [Cites] Gastroenterology. 2007 Jun;132(7):2557-76 [17570226.001]
  • [Cites] Nat Biotechnol. 2007 Aug;25(8):911-20 [17664940.001]
  • [Cites] Trends Mol Med. 2008 Mar;14(3):109-19 [18261959.001]
  • [Cites] J Natl Cancer Inst. 2008 May 21;100(10):698-711 [18477802.001]
  • [Cites] N Engl J Med. 2008 Jul 24;359(4):378-90 [18650514.001]
  • [Cites] Nat Rev Cancer. 2008 Aug;8(8):618-31 [18633355.001]
  • [Cites] J Clin Oncol. 2008 Oct 1;26(28):4672-8 [18824714.001]
  • [Cites] Lancet Oncol. 2009 Jan;10(1):25-34 [19095497.001]
  • [Cites] J Natl Cancer Inst. 2006 Mar 1;98(5):326-34 [16507829.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Gut. 2001 Jan;48(1):87-96 [11115828.001]
  • [Cites] Lancet Oncol. 2001 Sep;2(9):533-43 [11905707.001]
  • [Cites] Nat Med. 2003 Jun;9(6):789-95 [12740570.001]
  • [Cites] J Clin Oncol. 2003 Nov 1;21(21):3955-64 [14517187.001]
  • [Cites] Br J Radiol. 2003;76 Spec No 1:S83-6 [15456717.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):7099-109 [15466206.001]
  • [Cites] Cancer Res. 1996 Jul 1;56(13):3004-9 [8674055.001]
  • [Cites] J Magn Reson Imaging. 1999 Sep;10(3):223-32 [10508281.001]
  • [Cites] Science. 2005 Jan 7;307(5706):58-62 [15637262.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2005 Feb;19(1):3-23 [15757802.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2005 Sep;289(3):G571-8 [15860640.001]
  • [Cites] Oncology. 2005;69(5):363-71 [16319507.001]
  • [Cites] Nat Rev Cancer. 2006 Jan;6(1):24-37 [16397525.001]
  • [CommentIn] J Clin Oncol. 2009 Dec 10;27(35):e248-50; author reply e251-2 [19901099.001]
  • (PMID = 19470923.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / M01 RR001066; United States / NCI NIH HHS / CA / P01 CA080124; United States / NCI NIH HHS / CA / P01 CA80124; United States / NCI NIH HHS / CA / K23 CA139005; United States / NCRR NIH HHS / RR / M01-RR-01066; United States / NCI NIH HHS / CA / R01 CA115767
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers; 0 / Chemokine CXCL12; 0 / Indoles; 0 / Interleukin-6; 0 / Pyrroles; V99T50803M / sunitinib
  • [Other-IDs] NLM/ PMC2702235
  •  go-up   go-down


36. Yoon YJ, Ahn SH, Park JY, Chon CY, Kim DY, Park YN, Han KH: What is the role of diagnostic laparoscopy in a gastroenterology unit? J Gastroenterol; 2007 Nov;42(11):881-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our aim was to examine the role of diagnostic laparoscopy in a gastroenterology unit in the era of advanced imaging techniques.
  • Among the indications were evaluation of chronic liver disease (n = 673), liver tumor (n = 15), ascites of unknown origin and peritoneal disease (n = 142), and staging of intra-abdominal malignancy (n = 25).
  • In patients with chronic liver disease, 461 were diagnosed as having chronic viral hepatitis, based on clinical data including imaging studies, but the diagnosis was changed to cirrhosis after a laparoscopic exam in 69 patients (15.0%).
  • The confirmed diagnoses were mainly primary peritoneal disease, including peritoneal tuberculosis, in 17 patients, peritoneal metastatic carcinoma in five, and mesothelioma in two.
  • CONCLUSIONS: Diagnostic laparoscopy in a gastroenterology unit is safe and useful, especially for confirmation of liver cirrhosis and primary peritoneal disease evaluation.
  • [MeSH-major] Gastroenterology / methods. Laparoscopy / statistics & numerical data. Laparoscopy / utilization. Liver Cirrhosis / diagnosis. Peritoneal Diseases / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Chronic Disease. Female. Hospital Units. Humans. Liver Diseases / diagnosis. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • MedlinePlus Health Information. consumer health - Peritoneal Disorders.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastrointest Endosc. 1990 Jan-Feb;36(1):34-8 [2138106.001]
  • [Cites] Cancer. 1997 Apr 1;79(7):1315-9 [9083152.001]
  • [Cites] QJM. 1995 Aug;88(8):559-64 [7648242.001]
  • [Cites] Clin Chest Med. 2005 Jun;26(2):247-71, vi [15837109.001]
  • [Cites] Surg Clin North Am. 2000 Aug;80(4):1111-26 [10987027.001]
  • [Cites] QJM. 1997 Apr;90(4):297-304 [9307765.001]
  • [Cites] Gastrointest Endosc. 1984 Aug;30(4):237-40 [6237020.001]
  • [Cites] Am J Surg. 1991 Mar;161(3):326-31 [1825751.001]
  • [Cites] Respirology. 2005 Mar;10(2):257-60 [15823196.001]
  • [Cites] AJR Am J Roentgenol. 1996 Sep;167(3):743-8 [8751693.001]
  • [Cites] Aliment Pharmacol Ther. 2005 Oct 15;22(8):685-700 [16197489.001]
  • [Cites] Am J Gastroenterol. 1992 Jan;87(1):109-12 [1530803.001]
  • [Cites] Dig Dis Sci. 1997 Mar;42(3):546-8 [9073137.001]
  • [Cites] Curr Surg. 2005 Jan-Feb;62(1):35-7 [15708141.001]
  • [Cites] Gastrointest Endosc. 1994 May-Jun;40(3):285-9 [8056229.001]
  • [Cites] Gastrointest Endosc. 1996 Jun;43(6):568-71 [8781934.001]
  • [Cites] Dig Dis Sci. 1983 Jan;28(1):39-43 [6217961.001]
  • [Cites] Gastrointest Endosc. 1985 Apr;31(2):104-6 [3158566.001]
  • [Cites] Br Med J. 1978 Nov 4;2(6147):1276-8 [152141.001]
  • [Cites] Surg Endosc. 2004 Jan;18(1):6-10 [12958680.001]
  • [Cites] Gastrointest Endosc. 1987 Dec;33(6):417-20 [2965049.001]
  • [Cites] Am J Surg Pathol. 1995 Dec;19(12):1409-17 [7503362.001]
  • [Cites] Am J Gastroenterol. 1995 Aug;90(8):1258-62 [7639226.001]
  • [Cites] Can J Surg. 2004 Oct;47(5):364-8 [15540690.001]
  • [Cites] Dig Dis Sci. 1987 Jul;32(7):677-81 [2954796.001]
  • [Cites] Curr Probl Surg. 2007 Apr;44(4):228-69 [17467404.001]
  • [Cites] Eur J Radiol. 2005 Aug;55(2):173-80 [15908155.001]
  • [Cites] Endoscopy. 2000 Feb;32(2):153-8 [10696844.001]
  • [Cites] Am J Gastroenterol. 1989 Sep;84(9):1051-4 [2528288.001]
  • [Cites] Endoscopy. 2005 Jan;37(1):33-7 [15657855.001]
  • [Cites] Endoscopy. 2002 Feb;34(2):146-53 [11822010.001]
  • (PMID = 18008032.001).
  • [ISSN] 0944-1174
  • [Journal-full-title] Journal of gastroenterology
  • [ISO-abbreviation] J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


37. Rizell M, Andersson M, Cahlin C, Hafström L, Olausson M, Lindnér P: Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer. Int J Clin Oncol; 2008 Feb;13(1):66-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer.
  • BACKGROUND: Hepatocellular cancer (HCC), as well as cholangiocellular cancer (CCC), has an extremely poor prognosis due to the extent of tumor at diagnosis and the underlying liver disease.
  • METHODS: In a prospective single-arm protocol, the tumor response to sirolimus as the primary endpoint was studied in 21 patients with advanced HCC and nine with CCC.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Bile Duct Neoplasms / drug therapy. Bile Ducts, Intrahepatic. Carcinoma, Hepatocellular / drug therapy. Cholangiocarcinoma / drug therapy. Liver Neoplasms / drug therapy. Phosphatidylinositol 3-Kinases / antagonists & inhibitors. Protein Kinases / metabolism. Sirolimus / therapeutic use
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. TOR Serine-Threonine Kinases

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Gastroenterol. 2004 Mar 1;10(5):649-53 [14991931.001]
  • [Cites] Liver Transpl. 2004 Oct;10(10):1301-11 [15376305.001]
  • [Cites] J Clin Invest. 2006 Jul;116(7):1843-52 [16767220.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 [10655437.001]
  • [Cites] Nat Med. 2002 Feb;8(2):128-35 [11821896.001]
  • [Cites] Hum Pathol. 1998 Sep;29(9):986-91 [9744316.001]
  • [Cites] Transplant Proc. 2002 Aug;34(5):1392-3 [12176410.001]
  • [Cites] Radiology. 2004 Jan;230(1):300-1; author reply 301-2 [14695404.001]
  • [Cites] World J Gastroenterol. 2005 Mar 14;11(10):1420-5 [15770715.001]
  • [Cites] Biochem Biophys Res Commun. 1998 Aug 10;249(1):226-30 [9705862.001]
  • [Cites] Transpl Int. 2005 Jan;18(1):89-94 [15612989.001]
  • [Cites] Cancer Res. 1999 Feb 15;59(4):886-94 [10029080.001]
  • [Cites] Liver Transpl. 2001 Jun;7(6):473-84 [11443573.001]
  • [Cites] Ann Neurol. 2006 Mar;59(3):490-8 [16453317.001]
  • [Cites] J Clin Oncol. 2004 Nov 15;22(22):4442-5 [15483011.001]
  • [Cites] Anticancer Res. 2005 Mar-Apr;25(2A):789-93 [15868910.001]
  • [Cites] Acta Oncol. 2005;44(5):496 [16118084.001]
  • [Cites] Eur J Cancer. 2006 May;42(8):1031-9 [16616487.001]
  • [Cites] Cell. 2002 Jul 26;110(2):163-75 [12150925.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8421-5 [15623621.001]
  • [Cites] Oncogene. 2006 Jun 26;25(27):3818-22 [16799623.001]
  • (PMID = 18307022.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; EC 2.7.- / Protein Kinases; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


38. Agarwala A, Fisher W, Bruetman D, McClean J, Taber D, Titzer M, Juliar B, Yu M, Breen T, Einhorn LH, Hanna N: Gefitinib plus celecoxib in chemotherapy-naïve patients with stage IIIB/IV non-small cell lung cancer: a phase II study from the Hoosier Oncology Group. J Thorac Oncol; 2008 Apr;3(4):374-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gefitinib plus celecoxib in chemotherapy-naïve patients with stage IIIB/IV non-small cell lung cancer: a phase II study from the Hoosier Oncology Group.
  • BACKGROUND: Gefitinib, an inhibitor of the epidermal growth factor receptor (EGFR) pathway, has single agent activity in non-small cell lung cancer (NSCLC).
  • The primary objective was to evaluate the overall response rate; secondary objectives included estimation of progression free survival, overall survival, and to assess the toxicity of this regimen.
  • Two additional patients discontinued treatment due to adverse events (elevated liver enzymes).
  • CONCLUSION: Gefitinib plus celecoxib in an unselected population of chemotherapy naive patients with advanced NSCLC and a PS of 0-1 has a lower response rate and overall efficacy compared with historical controls of combination chemotherapy.
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Adult. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / secondary. Celecoxib. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Pyrazoles / administration & dosage. Quinazolines / administration & dosage. Sulfonamides / administration & dosage. Survival Rate

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CELECOXIB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18379355.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Pyrazoles; 0 / Quinazolines; 0 / Sulfonamides; JCX84Q7J1L / Celecoxib; S65743JHBS / gefitinib
  •  go-up   go-down


39. Choi BO, Choi IB, Jang HS, Kang YN, Jang JS, Bae SH, Yoon SK, Chai GY, Kang KM: Stereotactic body radiation therapy with or without transarterial chemoembolization for patients with primary hepatocellular carcinoma: preliminary analysis. BMC Cancer; 2008;8:351
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stereotactic body radiation therapy with or without transarterial chemoembolization for patients with primary hepatocellular carcinoma: preliminary analysis.
  • BACKGROUND: The objectives of this retrospective study was to evaluate the efficacy of stereotactic body radiation therapy (SBRT) for small non-resectable hepatocellular carcinoma (HCC) and SBRT combined with transarterial chemoembolization (TACE) for advanced HCC with portal vein tumor thrombosis (PVTT).
  • We studied 32 HCC lesions, where 23 lesions (22 patients) were treated targeting small non-resectable primary HCC, and 9 lesions (9 patients) targeting PVTT using the Cyberknife.
  • All the 9 patients targeting PVTT received TACE for the advanced HCC.
  • The overall response rate was 71.9% [small HCC: 82.6% (19/23), advanced HCC with PVTT: 44.4% (4/9)], with the complete and partial response rates of 31.3% [small HCC: 26.1% (6/23), advanced HCC with PVTT: 11.1% (1/9)], and 50.0% [small HCC: 56.5% (13/23), advanced HCC with PVTT: 33.3% (3/9)], respectively.
  • The median survival period of small HCC and advanced HCC with PVTT patients was 12 months and 8 months, respectively.
  • CONCLUSION: SBRT for small HCC and SBRT combined with TACE for advanced HCC with PVTT showed feasible treatment modalities with minimal side effects in selected patients with primary HCC.
  • [MeSH-major] Carcinoma, Hepatocellular / radiotherapy. Carcinoma, Hepatocellular / therapy. Chemoembolization, Therapeutic / methods. Liver Neoplasms / surgery. Liver Neoplasms / therapy. Radiosurgery / methods
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Aug 1;48(1):81-7 [10924975.001]
  • [Cites] Hepatology. 2008 Jan;47(1):71-81 [18027884.001]
  • [Cites] J Clin Oncol. 2001 Jan 1;19(1):164-70 [11134209.001]
  • [Cites] Eur J Ultrasound. 2001 Jun;13(2):149-58 [11369526.001]
  • [Cites] J Gastroenterol Hepatol. 2001 Jun;16(6):660-5 [11422619.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Feb 1;52(2):522-31 [11872300.001]
  • [Cites] Gastroenterology. 2002 May;122(6):1609-19 [12016426.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Sep 1;54(1):150-5 [12182985.001]
  • [Cites] Neurosurgery. 2003 Jan;52(1):140-6; discussion 146-7 [12493111.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Sep 1;57(1):113-9 [12909223.001]
  • [Cites] Radiology. 1983 Aug;148(2):397-401 [6306721.001]
  • [Cites] Radiother Oncol. 1983 Nov;1(2):187-91 [6680223.001]
  • [Cites] J Clin Oncol. 2008 Feb 1;26(4):657-64 [18172187.001]
  • [Cites] Cancer. 1985 Aug 15;56(4):918-28 [2990661.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 May 15;21(1):109-22 [2032882.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Nov;21(6):1425-34 [1938550.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1249-56 [7713786.001]
  • [Cites] Scand J Gastroenterol. 1997 Jun;32(6):598-603 [9200294.001]
  • [Cites] Hepatology. 1998 Jun;27(6):1578-83 [9620330.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Oct 1;63(2):320-3 [16168826.001]
  • [Cites] Semin Radiat Oncol. 2005 Oct;15(4):273-8 [16183481.001]
  • [Cites] World J Gastroenterol. 2005 Dec 21;11(47):7391-400 [16437707.001]
  • [Cites] Jpn J Clin Oncol. 2006 Mar;36(3):154-8 [16520355.001]
  • [Cites] Cancer. 2006 Apr 15;106(8):1653-63 [16541431.001]
  • [Cites] Acta Oncol. 2006;45(7):961-5 [16982564.001]
  • [Cites] J Clin Oncol. 2007 Mar 10;25(8):938-46 [17350942.001]
  • [Cites] J Am Coll Radiol. 2007 Aug;4(8):563-5 [17660122.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Nov 1;48(4):1187-95 [11072178.001]
  • (PMID = 19038025.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2615783
  •  go-up   go-down


40. Hoffmann K, Glimm H, Radeleff B, Richter G, Heining C, Schenkel I, Zahlten-Hinguranage A, Schirrmacher P, Schmidt J, Büchler MW, Jaeger D, von Kalle C, Schemmer P: Prospective, randomized, double-blind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation - HeiLivCa [ISRCTN24081794]. BMC Cancer; 2008;8:349
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective, randomized, double-blind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation - HeiLivCa [ISRCTN24081794].
  • BACKGROUND: Disease progression of hepatocellular cancer (HCC) in patients eligible for liver transplantation (LTx) occurs in up to 50% of patients, resulting in withdrawal from the LTx waiting list.
  • The oral multikinase inhibitor sorafenib significantly increases overall survival and time-to-progression in patients with advanced hepatocellular cancer.
  • Evaluation of time-to-progression as primary endpoint (TTP) will be performed at 120 events.
  • DISCUSSION: As TACE is the most widely used primary treatment of HCC before LTx and sorafenib is the only proven effective systemic treatment for advanced HCC there is a strong rational to combine both treatment modalities.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Benzenesulfonates / therapeutic use. Carcinoma, Hepatocellular / therapy. Chemoembolization, Therapeutic. Liver Neoplasms / therapy. Pyridines / therapeutic use
  • [MeSH-minor] Adult. Combined Modality Therapy. Double-Blind Method. Female. Humans. Liver Transplantation. Male. Niacinamide / analogs & derivatives. Phenylurea Compounds. Research Design

  • Genetic Alliance. consumer health - Liver cancer.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer. 2004 Nov;40(16):2439-44 [15519517.001]
  • [Cites] N Engl J Med. 1999 Mar 11;340(10):745-50 [10072408.001]
  • [Cites] Am J Transplant. 2005 Apr;5(4 Pt 1):795-804 [15760404.001]
  • [Cites] Liver Transpl. 2005 Jul;11(7):767-75 [15973710.001]
  • [Cites] Transplantation. 2005 Sep 27;80(1 Suppl):S105-8 [16286885.001]
  • [Cites] Liver Transpl. 2005 Dec;11(12):1505-14 [16315294.001]
  • [Cites] Liver Transpl. 2006 Apr;12(4):665-73 [16482577.001]
  • [Cites] N Engl J Med. 2008 Jul 24;359(4):378-90 [18650514.001]
  • [Cites] Hepatology. 2003 Feb;37(2):429-42 [12540794.001]
  • [Cites] Liver Transpl. 2003 Jun;9(6):557-63 [12783395.001]
  • [Cites] Lancet. 2003 Dec 6;362(9399):1907-17 [14667750.001]
  • [Cites] Liver Transpl. 2004 Mar;10(3):449-55 [15004776.001]
  • [Cites] Cancer. 1985 Aug 15;56(4):918-28 [2990661.001]
  • [Cites] J Natl Cancer Inst. 1993 Mar 3;85(5):365-76 [8433390.001]
  • [Cites] N Engl J Med. 1995 May 11;332(19):1256-61 [7708069.001]
  • [Cites] N Engl J Med. 1996 Mar 14;334(11):693-9 [8594428.001]
  • [Cites] Ann Surg. 1997 Dec;226(6):688-701; discussion 701-3 [9409568.001]
  • [Cites] Hepatology. 1998 Jun;27(6):1578-83 [9620330.001]
  • [Cites] J Hepatol. 1998 Jul;29(1):129-34 [9696501.001]
  • [Cites] Am J Transplant. 2005 Apr;5(4 Pt 1):788-94 [15760403.001]
  • (PMID = 19036146.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Databank-accession-numbers] ISRCTN/ ISRCTN24081794
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib
  • [Other-IDs] NLM/ PMC2630329
  •  go-up   go-down


41. Evans MD, Escofet X, Karandikar SS, Stamatakis JD: Outcomes of resection and non-resection strategies in management of patients with advanced colorectal cancer. World J Surg Oncol; 2009;7:28
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes of resection and non-resection strategies in management of patients with advanced colorectal cancer.
  • BACKGROUND: The management of patients with surgically incurable bowel cancer at presentation is controversial.
  • It has been believed that the most effective palliation is achieved by resection of the primary cancer in order to pre-empt future complications.
  • This study reviews and compares the outcomes of patients with incurable bowel cancer managed by resection and non-resection strategies over a 7-year period in a single District General Hospital.
  • PATIENTS AND METHODS: All patients with surgically incurable bowel cancer at presentation were identified from the prospectively collected local ACPGBI database.
  • Survival, using Kaplan-Meier method and log-rank test, was compared between patients managed by resection of the primary, non-resectional intervention (surgery, stent & oncological treatments) and those managed with supportive care only.
  • The primary endpoint of the study was survival on an intention to treat basis, compared using Kaplan-Meier and log-rank tests.
  • RESULTS: Of 646 consecutive newly diagnosed bowel cancer patients over a 7 year period 154 cases (24%) were deemed surgically incurable at presentation.
  • Only one patient (2%) managed by non-resectional intervention required later surgery to treat primary tumour related complications.
  • CONCLUSION: In an unselected bowel cancer population surgical resection of the primary tumour in patients presenting with incurable disease does not improve survival and is associated with a high risk of post-operative mortality.
  • [MeSH-major] Colorectal Neoplasms / pathology. Colorectal Neoplasms / surgery. Liver Neoplasms / secondary. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Prospective Studies. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Surg. 2002 Sep;89(9):1096-102 [12190673.001]
  • [Cites] Colorectal Dis. 2007 Jun;9(5):430-7 [17504340.001]
  • [Cites] J Am Coll Surg. 2003 May;196(5):722-8 [12742204.001]
  • [Cites] Int J Colorectal Dis. 2004 May;19(3):197-202 [14618348.001]
  • [Cites] Gastroenterol Clin Biol. 2004 May;28(5):434-7 [15243315.001]
  • [Cites] Dis Colon Rectum. 1988 Aug;31(8):636-52 [3042304.001]
  • [Cites] Br J Surg. 1994 Mar;81(3):343-52 [7513600.001]
  • [Cites] Br J Surg. 1997 Dec;84(12):1731-6 [9448628.001]
  • [Cites] Dis Colon Rectum. 1964 May-Jun;7:211-7 [14159372.001]
  • [Cites] Gut. 2005 Aug;54(8):1194-202 [16009693.001]
  • [Cites] Ann Surg Oncol. 2005 Aug;12(8):637-45 [15965730.001]
  • [Cites] Br J Surg. 2005 Sep;92(9):1155-60 [16035135.001]
  • [Cites] Ann Surg Oncol. 1999 Oct-Nov;6(7):651-7 [10560850.001]
  • [Cites] BMJ. 2000 Sep 2;321(7260):531-5 [10968812.001]
  • [Cites] Br J Surg. 2001 Feb;88(2):163-4 [11167862.001]
  • [Cites] Br J Surg. 2001 Oct;88(10):1352-6 [11578291.001]
  • [Cites] Br J Surg. 2006 Apr;93(4):465-74 [16523446.001]
  • [Cites] Ann Surg Oncol. 2007 Feb;14(2):766-70 [17103261.001]
  • [Cites] Gut. 2003 Apr;52(4):568-73 [12631671.001]
  • (PMID = 19284542.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2657129
  •  go-up   go-down


42. Vonderheide RH, Flaherty KT, Khalil M, Stumacher MS, Bajor DL, Hutnick NA, Sullivan P, Mahany JJ, Gallagher M, Kramer A, Green SJ, O'Dwyer PJ, Running KL, Huhn RD, Antonia SJ: Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol; 2007 Mar 1;25(7):876-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody.
  • PATIENTS AND METHODS: Patients with advanced solid tumors received single doses of CP-870,893 intravenously.
  • The primary objective was to determine safety and the maximum-tolerated dose (MTD).
  • Transient laboratory abnormalities affecting lymphocytes, monocytes, platelets, D-dimer and liver function tests were observed 24 to 48 hours after infusion.
  • [MeSH-minor] Adult. Aged. Cytokines / secretion. Dose-Response Relationship, Drug. Female. Humans. Liver / drug effects. Male. Maximum Tolerated Dose. Middle Aged


43. Marrinucci D, Bethel K, Bruce RH, Curry DN, Hsieh B, Humphrey M, Krivacic RT, Kroener J, Kroener L, Ladanyi A, Lazarus NH, Nieva J, Kuhn P: Case study of the morphologic variation of circulating tumor cells. Hum Pathol; 2007 Mar;38(3):514-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A previously healthy 38-year-old woman was diagnosed with breast cancer.
  • Five years later, a bone marrow biopsy revealed involvement of bone marrow by metastatic breast carcinoma, and shortly thereafter, metastases were identified in the liver and lung hilum.
  • In addition, in comparison with her tumor cells in other sites, the full morphologic spectrum of cancer cells present in primary and metastatic tumor is also present in peripheral blood circulation.
  • [MeSH-minor] Adult. Cytophotometry. Fatal Outcome. Female. Fiber Optic Technology. Humans. Optical Fibers


44. Lee YC, Pan HW, Peng SY, Lai PL, Kuo WS, Ou YH, Hsu HC: Overexpression of tumour-associated trypsin inhibitor (TATI) enhances tumour growth and is associated with portal vein invasion, early recurrence and a stage-independent prognostic factor of hepatocellular carcinoma. Eur J Cancer; 2007 Mar;43(4):736-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • By RT-PCR in the linear range, TATI was found to be overexpressed in 176 of 258 unifocal primary HCCs (68%).
  • We conclude that TATI overexpression contributes to cell growth advantage, enhances the metastatic potential of tumours and leads to advanced HCC with PV invasion.
  • [MeSH-major] Carcinoma, Hepatocellular / metabolism. Liver Neoplasms / metabolism. Neoplasm Proteins / metabolism. Portal Vein. Trypsin Inhibitor, Kazal Pancreatic / metabolism
  • [MeSH-minor] Adult. Aged. Disease Progression. Female. HeLa Cells / metabolism. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local / metabolism. Neoplasm Recurrence, Local / pathology. Osteopontin / metabolism. Prognosis. Survival Analysis. alpha-Fetoproteins / metabolism

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17267202.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / alpha-Fetoproteins; 106441-73-0 / Osteopontin; 50936-63-5 / Trypsin Inhibitor, Kazal Pancreatic
  •  go-up   go-down


45. Thomas ES, Gomez HL, Li RK, Chung HC, Fein LE, Chan VF, Jassem J, Pivot XB, Klimovsky JV, de Mendoza FH, Xu B, Campone M, Lerzo GL, Peck RA, Mukhopadhyay P, Vahdat LT, Roché HH: Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol; 2007 Nov 20;25(33):5210-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment.
  • PURPOSE: Effective treatment options for patients with metastatic breast cancer resistant to anthracyclines and taxanes are limited.
  • This study was designed to compare ixabepilone plus capecitabine versus capecitabine alone in anthracycline-pretreated or -resistant and taxane-resistant locally advanced or metastatic breast cancer.
  • The primary end point was progression-free survival evaluated by blinded independent review.
  • Grade 3/4 treatment-related sensory neuropathy (21% v 0%), fatigue (9% v 3%), and neutropenia (68% v 11%) were more frequent with combination therapy, as was the rate of death as a result of toxicity (3% v 1%, with patients with liver dysfunction [>/= grade 2 liver function tests] at greater risk).
  • CONCLUSION: Ixabepilone plus capecitabine demonstrates superior efficacy to capecitabine alone in patients with metastatic breast cancer pretreated or resistant to anthracyclines and resistant to taxanes.
  • [MeSH-minor] Adult. Aged. Anthracyclines / therapeutic use. Bridged Compounds / therapeutic use. Capecitabine. Disease Progression. Female. Humans. Middle Aged. Neoplasm Metastasis. Taxoids / therapeutic use

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. Ixabepilone .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2008 May 1;26(13):2223 [18445853.001]
  • (PMID = 17968020.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anthracyclines; 0 / Bridged Compounds; 0 / Epothilones; 0 / Taxoids; 0W860991D6 / Deoxycytidine; 1605-68-1 / taxane; 6804DJ8Z9U / Capecitabine; K27005NP0A / ixabepilone; U3P01618RT / Fluorouracil
  •  go-up   go-down


46. Italiano A, Saint-Paul MC, Caroli-Bosc FX, François E, Bourgeon A, Benchimol D, Gugenheim J, Michiels JF: Epidermal growth factor receptor (EGFR) status in primary colorectal tumors correlates with EGFR expression in related metastatic sites: biological and clinical implications. Ann Oncol; 2005 Sep;16(9):1503-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidermal growth factor receptor (EGFR) status in primary colorectal tumors correlates with EGFR expression in related metastatic sites: biological and clinical implications.
  • BACKGROUND: Epidermal growth factor receptor (EGFR) plays an important role in the pathogenesis of colorectal cancer (CRC).
  • However, monoclonal antibodies and low molecular weight tyrosine kinase inhibitors are the most advanced in clinical development.
  • The detection of EGFR expression is usually performed by immunohistochemistry (IHC) in the primary tumor.
  • Metastatic sites analyzed (n=80) were liver (79 patients) and lung (one patient).
  • RESULTS: EGFR reactivity was similar in the primary tumor and the related metastases.
  • Among the 80 paired primary/metastatic tumors, only five (6.3%) showed discordance in EGFR status: two cases with EGFR expression in the primary tumor but not in the metastasis, and three samples with EGFR expression in the metastasis but not in the primary tumor.
  • CONCLUSIONS: Between the paired primary tumors and distant metastatic lesions, 94% of samples had concordant EGFR status when analyzed by IHC.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15980160.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


47. Galetta D, Giotta F, Rosati G, Gebbia V, Manzione L, Di Bisceglie M, Borsellino N, Colucci G: Carboplatin in combination with raltitrexed in recurrent and metastatic head and neck squamous cell carcinoma: A multicentre phase II study of the Gruppo Oncologico Dell'Italia Meridionale (G.O.I.M.). Anticancer Res; 2005 Nov-Dec;25(6C):4445-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Raltitrexed (R) is a potent and specific thymidylate synthase inhibitor with activity comparable to that of 5-FU in colorectal cancer; moreover, it showed activity as a single agent in HNSCC.
  • Patients had a histo/cytologically proven recurrent or metastatic HNSCC; patients with locally advanced disease not amenable to CDDP+5-FU treatment were also included.
  • Patients had to be >18 years old with ECOG PS of 0-2 and adequate bone marrow, renal and liver functions.
  • The oral cavity/oropharynx were the primary site in 20 patients and the larynx in 10 patients.
  • [MeSH-minor] Adult. Aged. Carboplatin / administration & dosage. Carboplatin / adverse effects. Female. Humans. Male. Middle Aged. Quinazolines / administration & dosage. Quinazolines / adverse effects. Survival Rate. Thiophenes / administration & dosage. Thiophenes / adverse effects

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16334124.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Quinazolines; 0 / Thiophenes; BG3F62OND5 / Carboplatin; FCB9EGG971 / raltitrexed
  •  go-up   go-down


48. Mihai R, Stevens J, McKinney C, Ibrahim NB: Expression of the calcium receptor in human breast cancer--a potential new marker predicting the risk of bone metastases. Eur J Surg Oncol; 2006 Jun;32(5):511-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of the calcium receptor in human breast cancer--a potential new marker predicting the risk of bone metastases.
  • AIMS: This study investigates whether the calcium-sensing receptor (CaR) is commonly expressed in primary breast cancers.
  • The CaR controls secretion of PTHrP in several breast cancer cell lines and PTHrP is known to stimulate osteolysis during metastatic bone resorption.
  • METHODS: With Ethical Committee approval, immunohistochemistry was performed using a commercially available antiCaR antibody (AffinityBioReagents, Cambridge, UK) on archived histological sections of primary tumours from patients who died with advanced breast cancer.
  • RESULTS: One hundred and eight patients with breast cancer were found to have positive bone scans, 42 patients had died.
  • Of the patients with negative bone scans, 23 had liver or lung metastases.
  • CONCLUSIONS: CaR expression is common in a selected group of patients with advanced primary breast cancers.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Ductal, Breast / metabolism. Carcinoma, Ductal, Breast / secondary. Carcinoma, Lobular / metabolism. Carcinoma, Lobular / secondary. Cause of Death. Female. Forecasting. Humans. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Lymphatic Metastasis / pathology. Middle Aged. Parathyroid Hormone-Related Protein / secretion. Receptor, ErbB-2 / analysis. Receptors, Estrogen / analysis. Receptors, Progesterone / analysis. Retrospective Studies. Risk Factors

  • Genetic Alliance. consumer health - Bone Cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16564154.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Parathyroid Hormone-Related Protein; 0 / Receptors, Calcium-Sensing; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


49. El-Bassiouny AE, Zoheiry MM, Nosseir MM, El-Ahwany EG, Ibrahim RA, El-Bassiouni NE: Expression of cyclooxygenase-2 and transforming growth factor-beta1 in HCV-induced chronic liver disease and hepatocellular carcinoma. MedGenMed; 2007;9(3):45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of cyclooxygenase-2 and transforming growth factor-beta1 in HCV-induced chronic liver disease and hepatocellular carcinoma.
  • Fifteen wedge liver biopsies, taken during laparoscopic cholecystectomy, were included in the study as normal controls.
  • Immunohistochemistry using primary antibodies against both factors revealed weak to faint immunoreactivity to COX-2 and TGF-beta1 in normal hepatic tissue (< 30% and < 50% of the cells, respectively).
  • Higher COX-2 expression was observed in well-differentiated HCC cases (80%) with marked staining intensity (75%) compared with advanced HCC tumors (P < .001).
  • CONCLUSION: These findings may suggest that TGF-beta1 plays a role in hepatic cell damage following HCV infection thus stressing the usefulness of this cytokine as a prognostic marker for liver cell injury.
  • However, COX-2 is a predictive marker for malignant transformation and has a role in the early stages of hepatocarcinogenesis, but not in the advanced stages.
  • [MeSH-major] Carcinoma, Hepatocellular / metabolism. Cyclooxygenase 2 / biosynthesis. Hepatitis C, Chronic / metabolism. Liver Cirrhosis / metabolism. Liver Neoplasms / metabolism. Transforming Growth Factor beta1 / biosynthesis
  • [MeSH-minor] Adult. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Liver Disease.
  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Oncol. 2000 Mar;16(3):599-610 [10675495.001]
  • [Cites] Biochem J. 2006 Sep 15;398(3):371-80 [16800815.001]
  • [Cites] Am J Pathol. 2000 Jul;157(1):29-35 [10880372.001]
  • [Cites] Clin Cancer Res. 2001 May;7(5):1410-8 [11350912.001]
  • [Cites] Nat Genet. 2001 Oct;29(2):117-29 [11586292.001]
  • [Cites] Cancer. 2001 Sep 15;92(6):1475-83 [11745225.001]
  • [Cites] Gastroenterology. 2002 Feb;122(2):366-75 [11832451.001]
  • [Cites] Front Biosci. 2002 Apr 1;7:d793-807 [11897555.001]
  • [Cites] Anticancer Drugs. 2002 Feb;13(2):127-37 [11901304.001]
  • [Cites] J Lab Clin Med. 2002 Apr;139(4):234-43 [12024111.001]
  • [Cites] J Gastroenterol Hepatol. 2002 Oct;17(10):1110-6 [12201873.001]
  • [Cites] Hepatology. 2002 Oct;36(4 Pt 1):885-94 [12297835.001]
  • [Cites] World J Gastroenterol. 2002 Oct;8(5):815-7 [12378621.001]
  • [Cites] J Clin Invest. 2002 Dec;110(12):1831-8 [12488433.001]
  • [Cites] Clin Cancer Res. 2003 Apr;9(4):1566-72 [12684433.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):8621-3 [12861075.001]
  • [Cites] Viral Immunol. 2003;16(4):447-60 [14733733.001]
  • [Cites] Mod Pathol. 2004 Oct;17(10):1169-79 [15218507.001]
  • [Cites] Gut. 2004 Nov;53(11):1665-72 [15479690.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Aug 15;89(16):7384-8 [1380156.001]
  • [Cites] Cancer. 1992 Sep 15;70(6):1488-92 [1325272.001]
  • [Cites] Rev Gastroenterol Mex. 1994 Jan-Mar;59(1):17-22 [8209148.001]
  • [Cites] Radiology. 1994 Aug;192(2):379-87 [8029401.001]
  • [Cites] Cancer Res. 1995 Apr 1;55(7):1452-7 [7882352.001]
  • [Cites] Gastroenterology. 1995 Jul;109(1):285-301 [7797026.001]
  • [Cites] J Clin Invest. 1995 Jul;96(1):491-503 [7615821.001]
  • [Cites] J Hepatol. 1995 Jun;22(6):696-9 [7560864.001]
  • [Cites] East Afr Med J. 1995 Sep;72(9):584-7 [7498046.001]
  • [Cites] Hepatology. 1996 Jun;23(6):1384-92 [8675155.001]
  • [Cites] Nihon Rinsho. 1996 Jun;54(6):1499-504 [8691600.001]
  • [Cites] Br J Pharmacol. 1997 Mar;120(5):910-6 [9138698.001]
  • [Cites] FASEB J. 1998 Sep;12(12):1063-73 [9737710.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 1999 Apr;28(4):386-92 [10204502.001]
  • [Cites] Gut. 2005 Jan;54(1):134-41 [15591519.001]
  • [Cites] J Virol. 2005 Aug;79(15):9725-34 [16014934.001]
  • [Cites] Cancer Res. 2006 Feb 15;66(4):2202-9 [16489022.001]
  • [Cites] J Biol Chem. 2006 Mar 17;281(11):7468-78 [16407286.001]
  • [Cites] Cytokine Growth Factor Rev. 2000 Mar-Jun;11(1-2):159-68 [10708963.001]
  • (PMID = 18092051.001).
  • [ISSN] 1531-0132
  • [Journal-full-title] MedGenMed : Medscape general medicine
  • [ISO-abbreviation] MedGenMed
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Transforming Growth Factor beta1; EC 1.14.99.1 / Cyclooxygenase 2
  • [Other-IDs] NLM/ PMC2100111
  •  go-up   go-down


50. Hartwig W, Hackert T, Hinz U, Hassenpflug M, Strobel O, Büchler MW, Werner J: Multivisceral resection for pancreatic malignancies: risk-analysis and long-term outcome. Ann Surg; 2009 Jul;250(1):81-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To evaluate the safety and outcome of multivisceral pancreatic resections for primary pancreatic malignancies.
  • BACKGROUND: Curative resection is the only potential cure for patients with pancreatic cancer, but some patients present with advanced tumors that are not resectable by a standard pancreatic resection.
  • RESULTS: Colon, stomach, adrenal gland, liver, hepatic or celiac artery, kidney, or small intestine were resected in 37.6%, 33.7%, 27.7%, 18.8%, 16.8%, 11.9%, and 6.9% of the 101 patients with multivisceral resection, respectively.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Germany. Humans. Kaplan-Meier Estimate. Logistic Models. Male. Middle Aged. Risk Assessment. Risk Factors. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19561478.001).
  • [ISSN] 1528-1140
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Stintzing S, Hoffmann RT, Heinemann V, Kufeld M, Muacevic A: Frameless single-session robotic radiosurgery of liver metastases in colorectal cancer patients. Eur J Cancer; 2010 Apr;46(6):1026-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frameless single-session robotic radiosurgery of liver metastases in colorectal cancer patients.
  • INTRODUCTION: Due to advanced chemotherapy regimens, patients presenting with residual liver metastases of colorectal cancer (CRC) has increased.
  • We investigated in a selected patient cohort local control of liver metastasis from CRC using robotic radiosurgery.
  • METHODS AND MATERIALS: In this study patients with colorectal liver metastases were prospectively followed after having been treated with single-session radiosurgery using a robotic image-guided device and real-time tumour tracking.
  • The primary end-point was local control (LC); secondary end-points were toxicity, progression-free survival (PFS) and overall survival (OS).
  • Follow up was done by liver MRI every 3 months post-treatment.
  • RESULTS: Fourteen patients (median age 65 years), with a total of 19 colorectal liver metastases were treated with 24 Gy in one fraction.
  • DISCUSSION: Frameless robotic image-guided radiosurgery with real-time tumour tracking as an effective treatment for patients with colorectal liver metastases.
  • [MeSH-major] Colorectal Neoplasms / pathology. Liver Neoplasms / surgery. Radiosurgery / methods. Robotics / methods
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Female. Humans. Male. Middle Aged. Prognosis. Prospective Studies. Surgery, Computer-Assisted / instrumentation. Treatment Outcome


52. Ziarkiewicz-Wroblewska B, Gornicka B, Suleiman W, Wroblewski T, Morton M, Wilczynski GM, Heleniak H, Skwarek A, Koperski L, Dudek K, Krawczyk M, Jedrzejczak WW, Dwilewicz-Trojaczek J, Wasiutynski A: Primary lymphoma of the liver -- morphological and clinical analysis of 6 cases. Success of aggressive treatment. Neoplasma; 2005;52(3):267-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary lymphoma of the liver -- morphological and clinical analysis of 6 cases. Success of aggressive treatment.
  • Histological, clinical and immunohistochemical analysis of 6 cases of primary liver lymphomas (PLL) are presented.
  • PLL represents 4.3% of primary malignant liver tumors diagnosed in our department.
  • There were no signs of scirrhosis, and cancer markers were normal.
  • Despite clinically advanced stage at the time of diagnosis, if treated appropriately, the primary lymphoma of the liver has relatively good prognosis (five of our patients are alive).
  • [MeSH-major] Liver Neoplasms / diagnosis. Liver Neoplasms / surgery. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Antigens, CD59 / metabolism. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Immunohistochemistry. Male. Prognosis. Proto-Oncogene Proteins c-bcl-2 / metabolism. Proto-Oncogene Proteins c-myc / metabolism. Stem Cell Transplantation. bcl-2-Associated X Protein


53. Wang B, Tian HQ, Liang GW: [Effect of ganji recipe combined with Fructus Bruceae oil emulsion intervention on quality of life in patients with advanced primary hepatic cancer]. Zhongguo Zhong Xi Yi Jie He Za Zhi; 2009 Mar;29(3):257-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effect of ganji recipe combined with Fructus Bruceae oil emulsion intervention on quality of life in patients with advanced primary hepatic cancer].
  • OBJECTIVE: To observe and compare the quality of life (QOL) and survival time in patients with advanced primary hepatic cancer (PHC) after they have been treated by the combination of ganji recipe and interventional therapy with Fructus Bruceae Oil Emulsion (FBE) or by the trans-hepatic arterial chemical embolization (TACE) adopting Seldinger's technique.
  • METHODS: Seventy-seven patients with advanced PHC were randomly assigned to two groups, 37 patients in the control group treated with TACE alone, and 40 in the treatment group with the combined therapy.

  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19548447.001).
  • [ISSN] 1003-5370
  • [Journal-full-title] Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine
  • [ISO-abbreviation] Zhongguo Zhong Xi Yi Jie He Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Drugs, Chinese Herbal; 0 / Plant Oils
  •  go-up   go-down


54. Sun HW, Chen LH, Wei CJ, Zheng XK, Li QS, Guan J: [Three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for massive primary liver cancer]. Nan Fang Yi Ke Da Xue Xue Bao; 2009 Jun;29(6):1133-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for massive primary liver cancer].
  • OBJECTIVE: To evaluate the outcomes of patients with unresectable massive primary liver cancer (PLC) receiving three-dimensional conformal radiotherapy (3-DCRT) combined with transcatheter arterial chemoembolization (TACE).
  • Child-Pugh grade A of liver cirrhosis was present in 64 cases and grade B in 20 cases.
  • CONCLUSION: 3-DCRT combined with TACE has definite therapeutic effect on advanced massive PLC, and Child-Pugh grade is an independent prognostic factor in such cases.
  • [MeSH-major] Chemoembolization, Therapeutic / methods. Liver Neoplasms / therapy. Radiotherapy Planning, Computer-Assisted / methods. Radiotherapy, Conformal / methods
  • [MeSH-minor] Adult. Aged. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Carcinoma, Hepatocellular / therapy. Combined Modality Therapy. Female. Fluorouracil / administration & dosage. Humans. Imaging, Three-Dimensional / methods. Male. Middle Aged. Mitomycin / administration & dosage. Radiotherapy Dosage. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19726341.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / hydroxycamptothecinum; 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


55. Kanda M, Nomoto S, Nishikawa Y, Sugimoto H, Kanazumi N, Takeda S, Nakao A: Correlations of the expression of vascular endothelial growth factor B and its isoforms in hepatocellular carcinoma with clinico-pathological parameters. J Surg Oncol; 2008 Sep 1;98(3):190-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The vascular endothelial growth factor (VEGF) is involved in the growth of cancer cells through angiogenesis.
  • We examined the mRNA expression of total VEGF-B, VEGF-B167 and VEGF-B186 in primary HCC and non-cancerous tissues using quantitative real-time reverse transcription polymerase chain reaction (RT-PCR) analysis.
  • RESULTS: In 16 (33.3%) of 48 HCCs, the expression of total VEGF-B increased compared with the corresponding non-cancerous liver tissues.
  • Cases with high expression level of total VEGF-B in HCC significantly correlated with the advanced pathological stage (P < 0.018), tumor multiplicity (P < 0.033), vascular invasion (P < 0.045) and lack of capsule formation (P < 0.027).
  • [MeSH-major] Carcinoma, Hepatocellular / genetics. Liver Neoplasms / genetics. Vascular Endothelial Growth Factor B / genetics
  • [MeSH-minor] Adult. Aged. Alternative Splicing. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Case-Control Studies. Female. Humans. Liver / metabolism. Liver / pathology. Male. Middle Aged. Neoplasm Staging. Prognosis. Protein Isoforms. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Neoplasm / genetics. RNA, Neoplasm / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Survival Rate

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18537151.001).
  • [ISSN] 1096-9098
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Protein Isoforms; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / VEGFB protein, human; 0 / Vascular Endothelial Growth Factor B
  •  go-up   go-down


56. Wu J, Henderson C, Feun L, Van Veldhuizen P, Gold P, Zheng H, Ryan T, Blaszkowsky LS, Chen H, Costa M, Rosenzweig B, Nierodzik M, Hochster H, Muggia F, Abbadessa G, Lewis J, Zhu AX: Phase II study of darinaparsin in patients with advanced hepatocellular carcinoma. Invest New Drugs; 2010 Oct;28(5):670-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of darinaparsin in patients with advanced hepatocellular carcinoma.
  • We conducted a multi-center phase II study with darinaparsin in patients with advanced HCC.
  • The primary end point was response rate.
  • CONCLUSIONS: Darinaparsin could be safely administered with tolerable toxicity profiles, and no QTc prolongation in patients with advanced HCC.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Arsenicals / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Carcinoma, Hepatocellular / pathology. Glutathione / analogs & derivatives. Liver Neoplasms / drug therapy. Liver Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Staging. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 [10655437.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Jan 5;352(1):188-92 [17107663.001]
  • [Cites] Cancer Sci. 2006 Jul;97(7):675-81 [16827809.001]
  • [Cites] World J Gastroenterol. 2004 Dec 15;10(24):3677-9 [15534931.001]
  • [Cites] Med Oncol. 2009;26(2):178-85 [18937079.001]
  • [Cites] Cancer Sci. 2003 Nov;94(11):1010-4 [14611680.001]
  • [Cites] Carcinogenesis. 2004 Sep;25(9):1779-86 [15073043.001]
  • [Cites] Zhonghua Zhong Liu Za Zhi. 2001 Nov;23(6):487-9 [11859717.001]
  • [Cites] J Clin Oncol. 2009 Mar 20;27(9):1485-91 [19224838.001]
  • [Cites] Environ Health Perspect. 2004 Aug;112(12):1255-63 [15345372.001]
  • [Cites] Ann Intern Med. 2003 Nov 18;139(10):817-23 [14623619.001]
  • [Cites] N Engl J Med. 2008 Jul 24;359(4):378-90 [18650514.001]
  • [Cites] Chin Med J (Engl). 2007 Dec 20;120(24):2181-4 [18167198.001]
  • [Cites] Invest New Drugs. 2007 Feb;25(1):77-84 [16937079.001]
  • [Cites] J Gastroenterol Hepatol. 2000 Apr;15(4):357-68 [10824878.001]
  • [Cites] Anticancer Agents Med Chem. 2008 Dec;8(8):904-9 [19075572.001]
  • [Cites] Lancet Oncol. 2009 Jan;10(1):25-34 [19095497.001]
  • [Cites] Mutat Res. 1998 Jul 31;415(3):213-8 [9714811.001]
  • [Cites] World J Gastroenterol. 2005 Oct 14;11(38):5938-43 [16273603.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] J Natl Cancer Inst. 2003 Sep 3;95(17):1276-99 [12953083.001]
  • [Cites] J Exp Clin Cancer Res. 2003 Mar;22(1):61-8 [12725324.001]
  • [Cites] J Clin Oncol. 2003 Oct 1;21(19):3609-15 [14512391.001]
  • [Cites] Leukemia. 2008 Oct;22(10 ):1853-63 [18633430.001]
  • (PMID = 19565187.001).
  • [ISSN] 1573-0646
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Arsenicals; 9XX54M675G / darinaparsin; GAN16C9B8O / Glutathione
  •  go-up   go-down


57. Mentha G, Roth AD, Terraz S, Giostra E, Gervaz P, Andres A, Morel P, Rubbia-Brandt L, Majno PE: 'Liver first' approach in the treatment of colorectal cancer with synchronous liver metastases. Dig Surg; 2008;25(6):430-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 'Liver first' approach in the treatment of colorectal cancer with synchronous liver metastases.
  • BACKGROUND: In patients with synchronous colorectal liver metastases, an approach reversing the traditional therapeutic order - i.e. starting with chemotherapy first, doing the liver surgery second, and performing the colorectal surgery last - is theoretically appealing as it avoids the risk of metastatic progression during treatment of the primary tumor.
  • PATIENTS AND METHODS: 35 patients with advanced synchronous colorectal metastases and nonobstructive colorectal tumors were treated with the reversed approach.
  • Five patients could not complete the program (one death from sepsis during chemotherapy, 3 cases of progressive disease under treatment, and one case of vanishing liver metastases).
  • The remaining 30 patients responded and underwent R0 liver resections with no major complications.
  • Potential problems, in particular regrowth of vanishing metastases and primary tumors, chemotherapy-associated liver damage, and large bowel obstruction, can be minimized by careful multidisciplinary selection, planning and execution.
  • [MeSH-major] Colorectal Neoplasms / pathology. Colorectal Neoplasms / therapy. Hepatectomy / methods. Liver Neoplasms / secondary. Liver Neoplasms / therapy. Neoadjuvant Therapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Colectomy / methods. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Pilot Projects. Prospective Studies. Risk Assessment. Survival Analysis. Time Factors. Treatment Outcome


58. Guo Q, Tang W, Inagaki Y, Midorikawa Y, Kokudo N, Sugawara Y, Nakata M, Konishi T, Nagawa H, Makuuchi M: Clinical significance of subcellular localization of KL-6 mucin in primary colorectal adenocarcinoma and metastatic tissues. World J Gastroenterol; 2006 Jan 7;12(1):54-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical significance of subcellular localization of KL-6 mucin in primary colorectal adenocarcinoma and metastatic tissues.
  • AIM: To assess subcellular localization of KL-6 mucin and its clinicopathological significance in colorectal carcinoma as well as metastatic lymph node and liver tissues.
  • METHODS: Colorectal carcinoma tissues as well as metastatic lymph node and liver tissues were collected from 82 patients who underwent colorectomy or hepatectomy.
  • Statistical analysis between clinicopathological factors and subcellular localization of KL-6 mucin showed that KL-6 localization in the circumferential membrane and/or cytoplasm was significantly associated with the presence of venous invasion (P = 0.0003), lymphatic invasion (P<0.0001), lymph node metastasis (P<0.0001), liver metastasis (P = 0.058), and advanced histological stage (P<0.0001).
  • Positive staining was observed in all metastatic lesions tested as well as in the primary colorectal carcinoma tissues.
  • CONCLUSION: The subcellular staining pattern of KL-6 in colorectal adenocarcinoma may be an important indicator for unfavorable behaviors such as lymph node and liver metastasis, as well as for the prognosis of patients.
  • [MeSH-minor] Adult. Aged. Antigens, Neoplasm. Female. Humans. Immunohistochemistry. Lymphatic Metastasis. Male. Middle Aged. Mucin-1. Survival Rate

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 1988 Mar 25;263(9):4215-22 [3346246.001]
  • [Cites] World J Gastroenterol. 2005 Sep 21;11(35):5450-4 [16222735.001]
  • [Cites] J Biol Chem. 1990 Sep 5;265(25):15286-93 [1697589.001]
  • [Cites] Int J Oncol. 2000 Mar;16(3):455-9 [10675475.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2000 Mar;278(3):L625-9 [10710536.001]
  • [Cites] Cancer. 2001 Jun 1;91(11):1973-82 [11391575.001]
  • [Cites] Am J Surg Pathol. 2002 Apr;26(4):466-71 [11914624.001]
  • [Cites] World J Gastroenterol. 2001 Jun;7(3):425-30 [11819805.001]
  • [Cites] Biochem Biophys Res Commun. 2002 May 17;293(4):1183-90 [12054500.001]
  • [Cites] Histopathology. 2003 Mar;42(3):239-45 [12605643.001]
  • [Cites] Cancer Res. 2003 Aug 15;63(16):5011-20 [12941828.001]
  • [Cites] Nat Rev Cancer. 2004 Jan;4(1):45-60 [14681689.001]
  • [Cites] World J Gastroenterol. 2004 Oct 15;10(20):3044-7 [15378790.001]
  • [Cites] Hybridoma. 1984 Fall;3(3):223-32 [6094338.001]
  • [Cites] J Biol Chem. 1990 Sep 5;265(25):15294-9 [2394722.001]
  • [Cites] J Clin Oncol. 1991 Jul;9(7):1113-23 [2045853.001]
  • [Cites] Cancer Res. 1992 Apr 15;52(8):2318-24 [1559234.001]
  • [Cites] Cancer Res. 1992 May 1;52(9):2563-8 [1373671.001]
  • [Cites] Cancer. 1993 Apr 1;71(7):2191-9 [8384065.001]
  • [Cites] Gastroenterology. 1994 Feb;106(2):353-61 [7905449.001]
  • [Cites] J Clin Endocrinol Metab. 1994 Feb;78(2):337-42 [8106621.001]
  • [Cites] J Cell Biol. 1995 Apr;129(1):255-65 [7698991.001]
  • [Cites] Annu Rev Physiol. 1995;57:607-34 [7778880.001]
  • [Cites] J Surg Oncol. 1996 Jul;62(3):171-6 [8667623.001]
  • [Cites] Nat Med. 1998 Jan;4(1):43-9 [9427605.001]
  • [Cites] Oncology. 1998 Jul-Aug;55(4):307-19 [9663420.001]
  • [Cites] Dis Colon Rectum. 1998 Oct;41(10):1262-72 [9788390.001]
  • [Cites] Hepatogastroenterology. 2005 Jan-Feb;52(61):67-71 [15782996.001]
  • [Cites] Jpn J Clin Oncol. 1988 Sep;18(3):203-16 [3411786.001]
  • (PMID = 16440417.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens; 0 / Antigens, Neoplasm; 0 / Glycoproteins; 0 / MUC1 protein, human; 0 / Mucin-1; 0 / Mucins
  • [Other-IDs] NLM/ PMC4077483
  •  go-up   go-down


59. Sakai Y, Saotome T, Fujimori M, Shimizu S, Inkyo T, Yugeta H, Ohbu M, Koma Y, Sato T, Nagashima F, Hayasaka A, Fukuyama Y, Tsuchiya S, Tsuyuguchi T, Saisho H: [A pilot study of TS-1+CDDP therapy for highly advanced stage IV gastric cancer]. Gan To Kagaku Ryoho; 2005 Sep;32(9):1319-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A pilot study of TS-1+CDDP therapy for highly advanced stage IV gastric cancer].
  • We performed a pilot study of combination chemotherapy with TS-1 and cisplatin for highly advanced gastric cancer.
  • From June 2002, 12 patients with multiple liver metastases, carcinomatous lymphangitis or peritoneal dissemination, were enrolled in the study.
  • An objective response was obtained in 9 cases (75.0%) of primary sites and 6 cases of metastatic sites.
  • The TS-1/CDDP regimen had almost no survival benefits, but may induce relief of symptoms due to cancer and better quality of life.
  • [MeSH-minor] Administration, Oral. Adult. Aged. Cisplatin / administration & dosage. Combined Modality Therapy. Drug Administration Schedule. Drug Combinations. Female. Humans. Male. Middle Aged. Oxonic Acid / administration & dosage. Paclitaxel / administration & dosage. Pilot Projects. Pyridines / administration & dosage. Quality of Life. Tegafur / administration & dosage

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16184932.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


60. Jiao LR, Szyszko T, Al-Nahhas A, Tait P, Canelo R, Stamp G, Wasan H, Lowdell C, Philips R, Thillainayagam A, Bansi D, Rubello D, Limongelli P, Woo K, Habib NA: Clinical and imaging experience with yttrium-90 microspheres in the management of unresectable liver tumours. Eur J Surg Oncol; 2007 Jun;33(5):597-602
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and imaging experience with yttrium-90 microspheres in the management of unresectable liver tumours.
  • MATERIAL AND METHODS: From June 2004, patients whose liver tumours were no longer amenable for any conventional treatment with either chemotherapy or surgery were considered for yttrium-90 microspheres treatment after discussion at our multidisciplinary meeting.
  • RESULT: Twenty-one patients (F=11, M=10; age range 40-75 years, mean=58 years) received yttrium-90 microspheres consisting of liver metastases from colorectal primary (n=10) and non-colorectal primaries (n=8), and primary liver tumours (n=3).
  • Injection of microspheres had no immediate effect on either clinical haematology or liver function tests.
  • For patients with colorectal liver metastases, there was no significant reduction in CEA level (127+/-115 vs 75+/-72 micro/l, p=0.39).
  • CONCLUSION: SIRT should be considered for patients with advanced liver cancer.
  • It has a significant effect on liver disease in the absence of extrahepatic disease.
  • [MeSH-major] Liver Neoplasms / radiotherapy. Microspheres. Yttrium Radioisotopes / therapeutic use
  • [MeSH-minor] Adult. Aged. Colorectal Neoplasms. Female. Humans. Male. Middle Aged. Survival Analysis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17433608.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Yttrium Radioisotopes
  •  go-up   go-down


61. Guan CN, Cai LZ, Yue LQ, Zhang Y: [Clinicel study on treatment of advanced primary liver cancer by Yanshu injection combining with chemotherapy]. Zhongguo Zhong Yao Za Zhi; 2006 Mar;31(6):510-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicel study on treatment of advanced primary liver cancer by Yanshu injection combining with chemotherapy].
  • OBJECTIVE: To study the effects of Yanshu injection on the combined treatment in the advanced primary liver cancer.
  • METHOD: Eighty-five cases of advanced primary liver cancer were treated with Yanshu injection combining with chemotherapy or only chemotherapy.
  • CONCLUSION: Yanshu injection combination with chemotherapy can raise the curative effect, one year survival rate and cellular immune function, reduce pain genesic rate and toxicity of chemotherapy, and improve the quality of life of the patients with advanced primary liver cancer, which is worthy to be recommended for clinical application.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Drugs, Chinese Herbal / therapeutic use. Liver Neoplasms / drug therapy. Phytotherapy. Sophora
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Drug Therapy, Combination. Female. Humans. Injections, Intravenous. Male. Middle Aged. Neoplasm Staging. Plants, Medicinal / chemistry. Quality of Life. Survival Rate

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16722388.001).
  • [ISSN] 1001-5302
  • [Journal-full-title] Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica
  • [ISO-abbreviation] Zhongguo Zhong Yao Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Randomized Controlled Trial
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Drugs, Chinese Herbal
  •  go-up   go-down


62. Alberts SR, Suman VJ, Pitot HC, Camoriano JK, Rubin J: Use of KW-2189, a DNA minor groove-binding agent, in patients with hepatocellular carcinoma: a north central cancer treatment group (NCCTG) phase II clinical trial. J Gastrointest Cancer; 2007;38(1):10-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of KW-2189, a DNA minor groove-binding agent, in patients with hepatocellular carcinoma: a north central cancer treatment group (NCCTG) phase II clinical trial.
  • BACKGROUND: Hepatocellular carcinoma (HCC) is a common cancer in certain portions of the world.
  • Currently no effective therapies exist for patients with advanced or metastatic HCC.
  • METHODS: A phase II study was conducted to evaluate the activity of KW-2189 in patients with histologic or cytologic confirmed advanced or metastatic HCC who had no prior systemic therapy.
  • The primary endpoint of the trial was objective regression.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carcinoma, Hepatocellular / drug therapy. Liver Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Pyrrolidinones / administration & dosage. Pyrrolidinones / adverse effects. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Invest New Drugs. 2000 May;18(2):193-7 [10857997.001]
  • [Cites] Invest New Drugs. 1996;13(4):321-6 [8824350.001]
  • [Cites] Ann Intern Med. 1998 Oct 15;129(8):643-53 [9786813.001]
  • [Cites] Cancer Res. 1994 May 1;54(9):2404-10 [8162588.001]
  • [Cites] J Antibiot (Tokyo). 1990 Aug;43(8):1037-8 [2211354.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Apr 25;92(9):3642-9 [7731958.001]
  • [Cites] Cancer Chemother Pharmacol. 1998;41(5):377-84 [9523733.001]
  • [Cites] Biometrics. 1982 Mar;38(1):143-51 [7082756.001]
  • [Cites] Jpn J Cancer Res. 1994 Dec;85(12):1304-11 [7852193.001]
  • [Cites] Chem Pharm Bull (Tokyo). 1995 Mar;43(3):378-91 [7774022.001]
  • [Cites] J Antibiot (Tokyo). 1991 Oct;44(10):1045-53 [1955385.001]
  • [Cites] Cancer Res. 1988 Jan 1;48(1):109-16 [2446739.001]
  • [Cites] Anticancer Drugs. 1998 Oct;9(9):779-82 [9840723.001]
  • [Cites] J Antibiot (Tokyo). 1988 Dec;41(12):1915-7 [3209484.001]
  • [Cites] Ann Oncol. 1997 Feb;8(2):117-36 [9093719.001]
  • [Cites] Clin Cancer Res. 2002 Mar;8(3):712-7 [11895900.001]
  • [Cites] Ann Oncol. 2003 May;14(5):775-82 [12702533.001]
  • [Cites] Clin Cancer Res. 1998 Sep;4(9):2111-7 [9748127.001]
  • [Cites] Anticancer Drugs. 1997 Jul;8(6):588-96 [9300573.001]
  • [Cites] Science. 1984 Nov 16;226(4676):843-4 [6494915.001]
  • [Cites] Cancer Chemother Pharmacol. 2000;46(2):167-71 [10972487.001]
  • [Cites] Br J Cancer. 1999 Mar;79(9-10):1454-61 [10188890.001]
  • [Cites] Anticancer Drugs. 1994 Feb;5(1):10-4 [8186423.001]
  • [Cites] J Antibiot (Tokyo). 1989 Aug;42(8):1299-301 [2759911.001]
  • [Cites] Am J Clin Oncol. 2002 Jun;25(3):308-12 [12040295.001]
  • (PMID = 19065716.001).
  • [ISSN] 1941-6628
  • [Journal-full-title] Journal of gastrointestinal cancer
  • [ISO-abbreviation] J Gastrointest Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA25224; United States / NCI NIH HHS / CA / CA37404; United States / NCI NIH HHS / CA / CA60276
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Pyrrolidinones; 154889-68-6 / KW 2189
  •  go-up   go-down


63. Wheler J, Tsimberidou AM, Hong D, Naing A, Jackson T, Liu S, Feng L, Kurzrock R: Survival of patients in a Phase 1 Clinic: the M. D. Anderson Cancer Center experience. Cancer; 2009 Mar 1;115(5):1091-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival of patients in a Phase 1 Clinic: the M. D. Anderson Cancer Center experience.
  • BACKGROUND: Patients with advanced malignancies for whom standard therapy is ineffective may participate in phase 1 trials.
  • Anderson Cancer Center were reviewed, and their characteristics and survival were analyzed.
  • In univariate analysis, the factors that predicted shorter survival were primary tumor in the gastrointestinal tract; a history of thrombosis, liver metastases, and elevated levels of serum lactate dehydrogenase; platelet count; carbohydrate antigen 9 (Ca19-9) and Ca-125 levels; aspartate aminotransferase levels, and alkaline phosphatase levels (P < .05 for each).
  • In multivariate analysis, independent factors that predicted shorter survival were a history of thromboembolism (hazard ratio [HR], 2.38; 95% CI, 1.29-4.39; P = .005), platelets >or=440 x 10(9)/L (HR, 1.72; 95% CI, 1.12-2.65; P = .014), and the presence of liver metastases (HR, 1.51; 95% CI, 1.09-2.09; P = .013).
  • Patients with thrombocytosis, liver metastases, and a history of thromboembolism had worse outcomes.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 American Cancer Society.
  • [ErratumIn] Cancer. 2009 Apr 1;115(7):1588
  • (PMID = 19165805.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672; United States / NCRR NIH HHS / RR / RR024148
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


64. Hwang JP, Hassan MM: Survival and hepatitis status among Asian Americans with hepatocellular carcinoma treated without liver transplantation. BMC Cancer; 2009;9:46
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival and hepatitis status among Asian Americans with hepatocellular carcinoma treated without liver transplantation.
  • Anderson Cancer Center.
  • RESULTS: Of 82 Asian American HCC patients, most had advanced disease (65%) and received treatment (68%); however, only 11% had surgical resection.
  • CONCLUSION: The survival rate of Asian American patients with advanced HCC, for whom transplantation was not available, was low.
  • Timely hepatitis screening and interventions by primary care physicians may be the most logical solution to reduce the burden of hepatitis-associated HCC among Asian Americans.
  • [MeSH-major] Carcinoma, Hepatocellular / ethnology. Carcinoma, Hepatocellular / mortality. Hepatitis / complications. Liver Transplantation
  • [MeSH-minor] Adult. Aged. Asian Americans. Female. Humans. Male. Middle Aged. Prognosis. Risk Factors. Survival. alpha-Fetoproteins / metabolism


65. Stapley S, Peters TJ, Sharp D, Hamilton W: The mortality of colorectal cancer in relation to the initial symptom at presentation to primary care and to the duration of symptoms: a cohort study using medical records. Br J Cancer; 2006 Nov 20;95(10):1321-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The mortality of colorectal cancer in relation to the initial symptom at presentation to primary care and to the duration of symptoms: a cohort study using medical records.
  • The association between the staging of colorectal cancer and mortality is well known.
  • We performed a cohort study of 349 patients with primary colorectal cancer in whom all their prediagnostic symptoms and investigation results were known.
  • Survival data for 3-8 years after diagnosis were taken from the cancer registry.
  • Rectal bleeding as an initial symptom was associated with less advanced staging (odds ratio from one Duke's stage to the next 0.50, 95% confidence interval 0.31, 0.79; P=0.003) and with reduced mortality (Cox's proportional hazard ratio (HR) 0.56 (0.41, 0.79); P=0.001.
  • Mild anaemia, with a haemoglobin of 10.0-12.9 g dl(-1), was associated with more advanced staging (odds ratio 2.2 (1.2, 4.3); P=0.021) and worse mortality (HR 1.5 (0.98, 2.3): P=0.064).
  • [MeSH-minor] Abdominal Pain / etiology. Adult. Aged. Aged, 80 and over. Case-Control Studies. Cohort Studies. Constipation / etiology. Diarrhea / etiology. Female. Gastrointestinal Hemorrhage / etiology. Humans. Male. Medical Records. Middle Aged. Neoplasm Staging. Occult Blood. Predictive Value of Tests. Weight Loss

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Aust N Z J Surg. 1991 Feb;61(2):137-40 [2001199.001]
  • [Cites] Eur J Surg Oncol. 1989 Oct;15(5):441-5 [2551743.001]
  • [Cites] Eur J Surg Oncol. 1999 Apr;25(2):173-8 [10218461.001]
  • [Cites] Am J Gastroenterol. 1999 Oct;94(10):3039-45 [10520866.001]
  • [Cites] Colorectal Dis. 2005 Mar;7(2):169-71 [15720357.001]
  • [Cites] Br J Cancer. 2005 Aug 22;93(4):399-405 [16106247.001]
  • [Cites] Fam Pract. 2006 Feb;23(1):15-9 [16286462.001]
  • [Cites] Colorectal Dis. 2006 Jun;8(5):423-9 [16684087.001]
  • [Cites] Colorectal Dis. 2006 Jul;8(6):518-21 [16784474.001]
  • [Cites] BMJ. 2006 Jul 8;333(7558):69-70 [16790459.001]
  • [Cites] Colorectal Dis. 2006 Oct;8(8):688-95 [16970580.001]
  • [Cites] BMJ. 2001 Jun 30;322(7302):1555-6 [11431280.001]
  • [Cites] Dig Liver Dis. 2000 May;32(4):312-7 [11515629.001]
  • [Cites] Postgrad Med J. 2002 Sep;78(923):533-7 [12357013.001]
  • [Cites] Ann R Coll Surg Engl. 2002 Nov;84(6):381-5 [12484575.001]
  • [Cites] Scand J Gastroenterol. 2004 Mar;39(3):252-8 [15074395.001]
  • [Cites] World J Surg. 2004 Jul;28(7):716-20 [15383871.001]
  • [Cites] Eur J Surg Oncol. 1986 Jun;12(2):127-30 [3709816.001]
  • [Cites] Eur J Cancer. 1997 Aug;33(9):1461-7 [9337690.001]
  • (PMID = 17060933.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2360591
  •  go-up   go-down


66. Morise Z, Sugioka A, Fujita J, Hoshimoto S, Kato T, Ikeda M: S-1 plus cisplatin combination therapy for the patients with primary liver carcinomas. Hepatogastroenterology; 2007 Dec;54(80):2315-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] S-1 plus cisplatin combination therapy for the patients with primary liver carcinomas.
  • BACKGROUND/AIMS: 5-FU plus Cisplatin combination therapy had been employed against primary liver carcinomas for years.
  • S-1 is a fourth-generation oral fluoropyrimidine and attracts considerable interest for the activity against gastric cancer.
  • We herein examined the effect and adverse effects of S-1 plus Cisplatin combination therapy for primary liver carcinomas.
  • They all had far-advanced diseases in and/or out of the liver at the time of the therapy initiation.
  • CONCLUSIONS: S-1 plus Cisplatin combination therapy is a potential therapy for advanced primary liver carcinomas.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Liver Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Drug Combinations. Female. Humans. Lung Neoplasms / secondary. Male. Middle Aged. Oxonic Acid / administration & dosage. Prognosis. Tegafur / administration & dosage. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18265655.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


67. Alberts SR, Roh MS, Mahoney MR, O'Connell MJ, Nagorney DM, Wagman L, Smyrk TC, Weiland TL, Lai LL, Schwarz RE, Molina R, Dentchev T, Bolton JS: Alternating systemic and hepatic artery infusion therapy for resected liver metastases from colorectal cancer: a North Central Cancer Treatment Group (NCCTG)/ National Surgical Adjuvant Breast and Bowel Project (NSABP) phase II intergroup trial, N9945/CI-66. J Clin Oncol; 2010 Feb 10;28(5):853-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alternating systemic and hepatic artery infusion therapy for resected liver metastases from colorectal cancer: a North Central Cancer Treatment Group (NCCTG)/ National Surgical Adjuvant Breast and Bowel Project (NSABP) phase II intergroup trial, N9945/CI-66.
  • Oxaliplatin combined with capecitabine has demonstrated activity in advanced colorectal cancer.
  • The primary end point was 2-year survival.
  • PATIENTS AND METHODS Patients with liver-only metastases from colorectal cancer amenable to resection or cryoablation were eligible.
  • With a median follow-up of 4.8 years, a total of 30 patients have had disease recurrence, 11 involving the liver.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Catheter Ablation. Colorectal Neoplasms / pathology. Cryosurgery. Hepatectomy. Liver Neoplasms / drug therapy
  • [MeSH-minor] Administration, Oral. Adult. Aged. Capecitabine. Chemotherapy, Adjuvant. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Dexamethasone / administration & dosage. Drug Administration Schedule. Feasibility Studies. Female. Floxuridine / administration & dosage. Fluorouracil / administration & dosage. Fluorouracil / analogs & derivatives. Hepatic Artery. Humans. Infusions, Intra-Arterial. Infusions, Intravenous. Kaplan-Meier Estimate. Male. Middle Aged. Organoplatinum Compounds / administration & dosage. Proportional Hazards Models. Risk Assessment. Time Factors. Treatment Outcome. United States

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Liver cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. FLOXURIDINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1999 Dec 30;341(27):2039-48 [10615075.001]
  • [Cites] J Clin Oncol. 2002 Mar 15;20(6):1499-505 [11896097.001]
  • [Cites] J Clin Oncol. 2002 Dec 1;20(23):4591-6 [12454117.001]
  • [Cites] Eur J Surg Oncol. 2003 Apr;29(3):248-53 [12657235.001]
  • [Cites] Colorectal Dis. 2003 Jan;5(1):2-23 [12780921.001]
  • [Cites] Surg Clin North Am. 2004 Apr;84(2):659-71 [15062667.001]
  • [Cites] Clin Colorectal Cancer. 2012 Mar;11(1):31-7 [21729678.001]
  • [Cites] Cancer. 1993 Jun 15;71(12 Suppl):4252-66 [8508388.001]
  • [Cites] Semin Oncol. 1999 Oct;26(5):514-23 [10528899.001]
  • [Cites] N Engl J Med. 2005 Feb 17;352(7):734-5 [15716576.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):7125-34 [16192596.001]
  • [Cites] J Clin Oncol. 2008 Apr 20;26(12):2006-12 [18421053.001]
  • [Cites] Arch Surg. 1976 Apr;111(4):330-4 [1259571.001]
  • (PMID = 20048179.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00026234
  • [Grant] United States / NCI NIH HHS / CA / U10 CA052352; United States / NCI NIH HHS / CA / CA-37404; United States / NCI NIH HHS / CA / U10 CA012027; United States / NCI NIH HHS / CA / CA-52352; United States / NCI NIH HHS / CA / U10 CA037404; United States / NCI NIH HHS / CA / U10 CA035448; United States / NCI NIH HHS / CA / CA-35103; United States / NCI NIH HHS / CA / CA-25224; United States / NCI NIH HHS / CA / U10-CA-12027; United States / NCI NIH HHS / CA / CA25224-18; United States / NCI NIH HHS / CA / U10 CA035272; United States / NCI NIH HHS / CA / U10 CA035101; United States / NCI NIH HHS / CA / CA-35272; United States / NCI NIH HHS / CA / CA-35101; United States / NCI NIH HHS / CA / U10 CA025224; United States / NCI NIH HHS / CA / U10 CA035103
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 039LU44I5M / Floxuridine; 04ZR38536J / oxaliplatin; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; 7S5I7G3JQL / Dexamethasone; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2834397
  •  go-up   go-down


68. Zhu J, Wang Y, Hou M, Li HY, Zhang J: Imatinib mesylate treatment for advanced gastrointestinal stromal tumor: a pilot study focusing on patients experiencing sole liver metastasis after a prior radical resection. Oncology; 2007;73(5-6):324-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imatinib mesylate treatment for advanced gastrointestinal stromal tumor: a pilot study focusing on patients experiencing sole liver metastasis after a prior radical resection.
  • BACKGROUND: About 80% of patients with gastrointestinal stromal tumor (GIST) experience tumor recurrence or metastasis after a prior radical resection, and the most common metastatic site is the liver.
  • Imatinib mesylate has been proven to be effective in advanced GIST.
  • The current pilot study was designed to observe imatinib mesylate treatment for GIST patients who experienced sole liver metastasis after primary tumor resection.
  • The primary end points were grade 3-4 hematological or non-hematological toxicity and progression-free survival; the secondary end points were response rate and overall survival.
  • CONCLUSIONS: Imatinib mesylate treatment proved safe and effective for GIST patients who had liver metastasis alone.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Gastrointestinal Stromal Tumors / drug therapy. Gastrointestinal Stromal Tumors / surgery. Liver Neoplasms / secondary. Piperazines / therapeutic use. Pyrimidines / therapeutic use
  • [MeSH-minor] Adult. Aged. Benzamides. Female. Humans. Imatinib Mesylate. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Pilot Projects. Postoperative Complications / drug therapy. Postoperative Complications / pathology

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2008 S. Karger AG, Basel.
  • (PMID = 18497504.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


69. Lencioni R, Crocetti L, Cioni R, Suh R, Glenn D, Regge D, Helmberger T, Gillams AR, Frilling A, Ambrogi M, Bartolozzi C, Mussi A: Response to radiofrequency ablation of pulmonary tumours: a prospective, intention-to-treat, multicentre clinical trial (the RAPTURE study). Lancet Oncol; 2008 Jul;9(7):621-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Radiofrequency ablation is an accepted treatment for non-surgical patients with liver cancer.
  • Diagnoses included non-small-cell lung cancer (NSCLC) in 33 patients, metastasis from colorectal carcinoma in 53 patients, and metastasis from other primary malignancies in 20 patients.
  • Primary endpoints were technical success (defined as correct placement of the ablation device into all tumour targets with completion of the planned ablation protocol), safety (including identification of treatment-related complications and changes in pulmonary function), and confirmed complete response of tumours (according to modified Response Evaluation Criteria in Solid Tumors).
  • Secondary endpoints were overall survival, cancer-specific survival, and quality of life.
  • Cancer-specific survival was 92% (78-98%) at 1 year and 73% (54-86%) at 2 years in patients with NSCLC, 91% (78-96%) at 1 year and 68% (54-80%) at 2 years in patients with colorectal metastases, and 93% (67-99%) at 1 year and 67% (48-84%) at 2 years in patients with other metastases.
  • Patients with stage I NSCLC (n=13) had a 2-year overall survival of 75% (45-92%) and a 2-year cancer-specific survival of 92% (66-99%).
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cohort Studies. Feasibility Studies. Female. Humans. Male. Middle Aged. Survival Rate. Tomography, X-Ray Computed. Treatment Outcome


70. Burcoveanu C, Stefan S, Ursache A, Pricop A: [Primary and secondary hepatic cancer--specifics of surgical treatment in correlation with disease stage]. Rev Med Chir Soc Med Nat Iasi; 2009 Oct-Dec;113(4):1131-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary and secondary hepatic cancer--specifics of surgical treatment in correlation with disease stage].
  • Given the necessity of increasing their resectability, there are evaluated the possibilities of surgical treatment for these types of hepatic cancer, in the context of dominant clinical presence of advanced hepatic tumors.
  • MATERIAL AND METHOD: The study comprises 190 patients during 01.01.2000-31.12.2007, in the IIIrd Surgical Clinic, Iaşi, with primary and secondary hepatic tumors.
  • [MeSH-major] Anti-Infective Agents, Local / administration & dosage. Catheter Ablation. Ethanol / administration & dosage. Hepatectomy / methods. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Retrospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. ETHANOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20191887.001).
  • [ISSN] 0048-7848
  • [Journal-full-title] Revista medico-chirurgicală̆ a Societă̆ţ̜ii de Medici ş̧i Naturaliş̧ti din Iaş̧i
  • [ISO-abbreviation] Rev Med Chir Soc Med Nat Iasi
  • [Language] rum
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Anti-Infective Agents, Local; 3K9958V90M / Ethanol
  •  go-up   go-down


71. Akiyoshi T, Oya M, Fujimoto Y, Kuroyanagi H, Ueno M, Yamaguchi T, Koyama M, Tanaka H, Matsueda K, Muto T: Comparison of preoperative whole-body positron emission tomography with MDCT in patients with primary colorectal cancer. Colorectal Dis; 2009 Jun;11(5):464-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of preoperative whole-body positron emission tomography with MDCT in patients with primary colorectal cancer.
  • OBJECTIVE: Preoperative use of emission tomography with(18)F-fluorodeoxyglucose (FDG-PET) in patients with primary colorectal cancer remains controversial.
  • This study evaluated the additional value of FDG-PET in comparison with routine multidetector row computed tomography (MDCT) in patients with primary colorectal cancer.
  • METHOD: Retrospective analysis was performed in 65 patients with colorectal cancer who underwent whole-body FDG-PET.
  • Results of FDG-PET were compared with routine preoperative evaluation by MDCT regarding detection of primary tumour, lymph node involvement and distant metastases.
  • Liver metastases were present in 22 patients.
  • CONCLUSION: Preoperative FDG-PET is not superior to MDCT for detection of primary tumour, lymph node involvement or liver metastases, but may have potential clinical value in patients with advanced colorectal cancer by detecting extrahepatic distant metastases.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Fluorodeoxyglucose F18. Humans. Liver Neoplasms / radiography. Liver Neoplasms / radionuclide imaging. Liver Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Radiopharmaceuticals. Retrospective Studies. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18637927.001).
  • [ISSN] 1463-1318
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


72. van der Pool AE, Lalmahomed ZS, Ozbay Y, de Wilt JH, Eggermont AM, Jzermans JN, Verhoef C: 'Staged' liver resection in synchronous and metachronous colorectal hepatic metastases: differences in clinicopathological features and outcome. Colorectal Dis; 2010 Oct;12(10 Online):e229-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 'Staged' liver resection in synchronous and metachronous colorectal hepatic metastases: differences in clinicopathological features and outcome.
  • AIM: Approximately 25% of the patients with colorectal cancer already have liver metastases at diagnosis and another 30% will develop them subsequently.
  • The features and prognosis of patients with synchronous and metachronus colorectal liver metastases, treated with primary resection first followed by partial liver resection were analysed.
  • METHOD: Curative staged resection of liver metastases was performed in 272 consecutive patients.
  • Demographics, characteristics of the primary tumour and metastatic tumours, surgery-related data and outcome were analysed.
  • More patients in the synchronous group had an advanced primary tumour (T3/T4 and/or node positivity), more than three liver metastases and bilobar distribution.
  • CONCLUSION: Although patients with synchronous colorectal liver metastases may have poorer biological features, there was no difference in 5-year disease-free and overall survival compared with patients with metachronous metastases.
  • [MeSH-major] Carcinoma / secondary. Carcinoma / surgery. Colorectal Neoplasms / pathology. Colorectal Neoplasms / surgery. Liver Neoplasms / secondary. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Hepatectomy. Humans. Male. Middle Aged. Neoadjuvant Therapy. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 The Authors. Colorectal Disease © 2010 The Association of Coloproctology of Great Britain and Ireland.
  • (PMID = 19912286.001).
  • [ISSN] 1463-1318
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


73. Perey L, Paridaens R, Hawle H, Zaman K, Nolé F, Wildiers H, Fiche M, Dietrich D, Clément P, Köberle D, Goldhirsch A, Thürlimann B: Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00). Ann Oncol; 2007 Jan;18(1):64-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00).
  • RESULTS: All patients were pretreated with AI and 84% also with tamoxifen or toremifene; 67% had bone metastases and 45% liver metastases.


74. Cacheux W, Gourmel B, Alexandre J, Germann N, Rabillon F, Duffau B, Goldwasser F: An original administration of ifosfamide given once every other week: a clinical and pharmacological study. Anticancer Drugs; 2008 Mar;19(3):295-302
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ifosfamide (IFOS) is a bifunctional alkylator with a wide spectrum of activity in solid tumors and has an autoinductive liver metabolism through P450 cytochromes.
  • A phase I trial was investigated with interpatient dose escalation of a single dose of IFOS given every 2 weeks in advanced solid tumor patients.
  • The primary tumor was most often ovarian (5), peritoneal (3), sarcoma (2), melanoma (2) or miscellaneous (8).
  • One objective response was noted in a pancreatic cancer patient and one sustained CA125 decline in a heavily pretreated ovarian cancer patient.
  • [MeSH-minor] Adult. Aged. Area Under Curve. Chromatography, Gas. Cytochrome P-450 Enzyme System / drug effects. Dose-Response Relationship, Drug. Enzyme Induction / drug effects. Female. Humans. Male. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18510176.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 9035-51-2 / Cytochrome P-450 Enzyme System; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


75. Pourhoseingholi MA, Moghimi-Dehkordi B, Safaee A, Hajizadeh E, Solhpour A, Zali MR: Prognostic factors in gastric cancer using log-normal censored regression model. Indian J Med Res; 2009 Mar;129(3):262-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors in gastric cancer using log-normal censored regression model.
  • BACKGROUND & OBJECTIVE: Gastric cancer is one of the most common cancers in the world.
  • We used log normal regression model in this study to evaluate prognostic factors in gastric cancer and compared with Cox model.
  • METHODS: We retrospectively studied the 746 patients diagnosed with gastric cancer admitted in a referral hospital in Tehran, Iran, from February 2003 through January 2007.
  • Patients with greater tumour size were also in higher risk of death followed by those with poorly differentiated and moderately differentiated in tumour grade and advanced pathologic stage.
  • INTERPRETATION & CONCLUSION: Our results suggest that early detection of patients in younger age and in primary stages and grade of tumour could be important to decrease the risk of death in patients with gastric cancer.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Iran / epidemiology. Logistic Models. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Prognosis. Proportional Hazards Models. Retrospective Studies. Risk Factors. Young Adult

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19491418.001).
  • [ISSN] 0971-5916
  • [Journal-full-title] The Indian journal of medical research
  • [ISO-abbreviation] Indian J. Med. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] India
  •  go-up   go-down


76. Guo DL, Zhang J, Yuen ST, Tsui WY, Chan AS, Ho C, Ji J, Leung SY, Chen X: Reduced expression of EphB2 that parallels invasion and metastasis in colorectal tumours. Carcinogenesis; 2006 Mar;27(3):454-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, we examined the expression of EphB2 in normal colon, adenomas, primary colorectal cancers (CRCs), lymph node metastases and liver metastases using immunohistochemistry on tissue microarrays.
  • In addition, EphB2 was overexpressed in SW480 colon cancer cells to study its effect in vitro.
  • We found that EphB2 was expressed in 100% of normal colon crypt base cells, 78% of adenomas, 55.4% of primary CRCs, 37.8% of lymph node metastases and 32.9% of liver metastases (all differences were statistically significant at P < 0.001 compared with primary CRCs).
  • Patients with CRCs that lose EphB2 expression had more advanced tumour stage (P = 0.005), poor differentiation (P < 0.001), poor overall survival (P = 0.005) and disease-free survival (P = 0.001), with the latter being independent of tumour stage.
  • In vitro studies showed that overexpression of EphB2 inhibited colon cancer cell growth in colony formation assay and activation of EphB2 receptor inhibited colon cancer cell adhesion and migration.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Survival. Cell Transformation, Neoplastic. Colon / enzymology. Disease-Free Survival. Down-Regulation. Female. Gene Expression Profiling. Humans. Liver Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Prognosis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16272170.001).
  • [ISSN] 0143-3334
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, EphB2
  •  go-up   go-down


77. Nukaya H, Hirashima N, Tanaka Y, Endo M, Matsunaga S, Hasegawa I, Kato A, Sakakibara K, Sakamoto T, Kondo H: [An investigation of TS-1 single-agent therapy administered as first-line therapy for unresectable advanced gastric cancer]. Gan To Kagaku Ryoho; 2005 Oct;32(10):1421-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [An investigation of TS-1 single-agent therapy administered as first-line therapy for unresectable advanced gastric cancer].
  • We report an investigation of the therapeutic efficacy and safety of TS-1 single-agent therapy administered as first-line therapy in 23 cases of unresectable advanced gastric cancer treated at our institution.
  • By site, the response rate was 43.5% for primary tumors (10/23), 33.3% for lymph nodes (3/9), and 16.7% for liver metastasis (1/6).
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Drug Administration Schedule. Drug Combinations. Drug-Induced Liver Injury. Female. Humans. Leukopenia / chemically induced. Male. Middle Aged. Survival Rate

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16227741.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  • [Number-of-references] 12
  •  go-up   go-down


78. Lygidakis NJ, Bhagat AD, Vrachnos P, Grigorakos L: Challenges in everyday surgical practice: synchronous bilobar hepatic colorectal metastases--newer multimodality approach. Hepatogastroenterology; 2007 Jun;54(76):1020-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND/AIMS: This study was designed to assess the efficacy of two-stage liver surgery and hepatic directed chemo-biological therapy in treatment of synchronous bilobar hepatic metastases of colorectal origin.
  • During stage one surgery along with excision of primary colorectal carcinoma; ligation and transection of main portal branch on side of bulky metastases disease (right branch in 28 and left in 4 patients) was performed.
  • The metastatic nodules in the opposite lobe were ablated by microwave therapy and a hepatic arterial jet port catheter was introduced via the gastroduodenal artery for liver directed chemo-biological therapy.
  • CONCLUSIONS: Combined approach of ligating the portal branch, microwave ablation, hepatic regional chemo-biological therapy and staged liver surgery (a multimodality approach) in the treatment of advanced liver metastatic disease synchronous with colorectal cancer is an effective method of treatment which improves the overall survival and quality of life of the patient with hepatic bilobar metastases synchronous with colorectal carcinoma.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antibodies, Monoclonal / therapeutic use. Carcinoma / surgery. Colorectal Neoplasms / pathology. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Humanized. Bevacizumab. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Survival Analysis. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17629030.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V / Bevacizumab
  •  go-up   go-down


79. Park SS, Kim CS, Mok YJ, Kim SJ, Kim HI: Gastric cancer confined to the muscularis propria: a possible candidate for laparoscopic surgery or adjuvant therapy. Scand J Gastroenterol; 2005 Apr;40(4):450-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastric cancer confined to the muscularis propria: a possible candidate for laparoscopic surgery or adjuvant therapy.
  • OBJECTIVE: Gastric cancer confined to the muscularis propria (mp) has a favorable prognosis, but still belongs to the advanced category.
  • Many oncologists have difficulties in selecting treatment modalities owing to the confused situation of mp cancer.
  • To clarify the therapeutic strategy, the clinicopathological characteristics were investigated, and the risk factors, of this intermediate-stage gastric cancer, evaluated.
  • MATERIAL AND METHODS: A total of 155 patients who underwent curative resection for primary gastric cancer between 1993 and 2001 were diagnosed with mp cancer.
  • A multivariate analysis disclosed only lymphatic metastasis as an independent risk factor for recurrence of mp cancer.
  • Hematogenous metastasis accounted for 37% of the recurrent patterns, and the liver (83.3%) was the most common organ.
  • The 5-year survival rate of all mp cancer patients was 80.9%, but that of patients with recurrent disease was 19.2%.
  • CONCLUSIONS: Lymph node metastasis is the only significant risk factor of mp cancer.
  • On the other hand, patients with mp cancer without lymph node involvement have an excellent prognosis and could be candidates for laparoscopic gastric surgery.
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Gastrectomy. Humans. Liver Neoplasms / secondary. Lymph Node Excision. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local / prevention & control. Neoplasm Staging. Radiotherapy, Adjuvant. Retrospective Studies. Risk Factors. Survival Analysis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16028440.001).
  • [ISSN] 0036-5521
  • [Journal-full-title] Scandinavian journal of gastroenterology
  • [ISO-abbreviation] Scand. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Norway
  •  go-up   go-down


80. Sleijfer S, Ray-Coquard I, Papai Z, Le Cesne A, Scurr M, Schöffski P, Collin F, Pandite L, Marreaud S, De Brauwer A, van Glabbeke M, Verweij J, Blay JY: Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol; 2009 Jul 1;27(19):3126-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043).
  • PURPOSE Given the importance of angiogenesis in soft tissue sarcoma (STS), pazopanib, an oral angiogenesis inhibitor that targets vascular endothelial growth factor receptor and platelet-derived growth factor receptor, was explored in patients with advanced STS.
  • PATIENTS AND METHODS Patients with intermediate- or high-grade advanced STS who were ineligible for chemotherapy or who had received no more than two prior cytotoxic agents for advanced disease, who had documented progression, who had adequate performance status, and who had good organ function were eligible.
  • The primary end point was progression-free rate at 12 weeks (PFR(12 weeks)).
  • Compared with historical controls who were treated with second-line chemotherapy, progression-free and overall survivals were prolonged in the three cohorts in which the primary end point was reached.
  • Other toxicities included liver enzyme elevations, myelosuppression, and proteinuria, all of which were mostly grades 1 to 2.
  • CONCLUSION Pazopanib is well tolerated in patients with relapsed, advanced STS and demonstrates interesting activity that warrants additional study in patients with leiomyosarcomas, synovial sarcomas, and other STS types.
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / mortality


81. Sheah K, Ouellette HA, Torriani M, Nielsen GP, Kattapuram S, Bredella MA: Metastatic myxoid liposarcomas: imaging and histopathologic findings. Skeletal Radiol; 2008 Mar;37(3):251-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The mean time from the diagnosis of primary tumor to the first metastasis was 4.4 years.
  • Sixty-seven percent of patients had bone and soft tissue metastases, 33% had pulmonary metastases, 33% had liver metastases, 25% had intra-abdominal, and 16% retroperitoneal metastases.
  • In cases of osseous metastases, CT showed mixed lytic and sclerotic foci, with bone destruction in advanced cases.
  • The bones and soft tissues were the most common site of involvement, followed by the lungs and liver.
  • [MeSH-minor] Adult. Female. Fluorodeoxyglucose F18. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Radiopharmaceuticals. Retrospective Studies. Tomography, Emission-Computed. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2000 Jul;6(7):2788-93 [10914725.001]
  • [Cites] Cancer. 1989 Oct 1;64(7):1514-20 [2776110.001]
  • [Cites] Clin Orthop Relat Res. 1989 Jun;(243):204-7 [2721066.001]
  • [Cites] J Mol Diagn. 2000 Aug;2(3):132-8 [11229517.001]
  • [Cites] Am Surg. 2006 Jan;72(1):68-70 [16494187.001]
  • [Cites] Hinyokika Kiyo. 2006 Sep;52(9):727-31 [17040061.001]
  • [Cites] Sarcoma. 2007;2007:36785 [17641744.001]
  • [Cites] Radiographics. 2005 Sep-Oct;25(5):1371-95 [16160117.001]
  • [Cites] J Oral Maxillofac Surg. 2007 Aug;65(8):1660-4 [17656299.001]
  • [Cites] J Laryngol Otol. 2006 Jun;120(6):511-3 [16563196.001]
  • [Cites] AJR Am J Roentgenol. 1995 Jan;164(1):129-34 [7998525.001]
  • [Cites] Skeletal Radiol. 1990;19(2):113-6 [2321040.001]
  • [Cites] Ann Surg Oncol. 1998 Jan-Feb;5(1):37-40 [9524706.001]
  • [Cites] J Surg Oncol. 2002 Jun;80(2):89-93 [12173385.001]
  • [Cites] Auris Nasus Larynx. 2004 Dec;31(4):443-6 [15571922.001]
  • [Cites] Eur Radiol. 2003 Dec;13 Suppl 4:L185-91 [15018186.001]
  • [Cites] Cancer. 2007 Oct 15;110(8):1815-22 [17724681.001]
  • [Cites] Clin Cancer Res. 2001 Dec;7(12):3977-87 [11751490.001]
  • [Cites] Ann Surg Oncol. 2007 Apr;14(4):1507-14 [17252290.001]
  • [Cites] Radiology. 2004 Nov;233(2):493-502 [15459325.001]
  • (PMID = 18097662.001).
  • [ISSN] 0364-2348
  • [Journal-full-title] Skeletal radiology
  • [ISO-abbreviation] Skeletal Radiol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


82. Morizane C, Okusaka T, Furuse J, Ishii H, Ueno H, Ikeda M, Nakachi K, Najima M, Ogura T, Suzuki E: A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer. Cancer Chemother Pharmacol; 2009 Jan;63(2):313-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer.
  • PURPOSE: Gemcitabine monotherapy or gemcitabine-containing combination chemotherapy is the standard first-line therapy for advanced pancreatic cancer.
  • In a previous phase II trial, S-1 has been reported to show considerable efficacy, achieving a response rate of 37.5% in chemo-naïve patients with pancreatic cancer.
  • This study evaluated the efficacy and toxicity of S-1 in patients with gemcitabine-refractory metastatic pancreatic cancer.
  • METHODS: Eligibility criteria were histologically proven pancreatic adenocarcinoma with confirmation of progressive disease while receiving gemcitabine-based first-line chemotherapy, 20-74 years of age, Karnofsky performance status of 80-100 points, with measurable metastatic lesions, adequate hematological, renal and liver functions, and written informed consent.
  • The primary endpoint of this study was an objective response, and secondary endpoints included toxicity, progression-free survival (PFS) and overall survival, as well as clinical benefit response in symptomatic patients.
  • CONCLUSION: S-1 as monotherapy had marginal anti-tumor activity with tolerable toxicity in patients with gemcitabine refractory metastatic pancreatic cancer.
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Drug Combinations. Female. Humans. Male. Middle Aged. Neoplasm Metastasis


83. Fléchon A, Rivoire M, Berger N: [Surgery of residual masses after chemotherapy in patients with testicular cancer]. Rev Prat; 2007 Feb 28;57(4):389-98
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgery of residual masses after chemotherapy in patients with testicular cancer].
  • [Transliterated title] Chirurgie des masses résiduelles après chimiothérapie du cancer du testicule.
  • Advanced non seminomatous germ cell tumours are rare diseases affecting young men.
  • Advanced disease is curable in 80% of the cases.
  • The primary site of metastases is the retroperitoneal lymph nodes.
  • [MeSH-minor] Adult. Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Brain Neoplasms / secondary. Brain Neoplasms / surgery. Combined Modality Therapy. Controlled Clinical Trials as Topic. Follow-Up Studies. Humans. Liver Neoplasms / radiography. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Lung Neoplasms / radiography. Lung Neoplasms / secondary. Lung Neoplasms / surgery. Lymphatic Metastasis. Male. Positron-Emission Tomography. Postoperative Complications. Prognosis. Prospective Studies. Radiotherapy Dosage. Retroperitoneal Space. Seminoma / drug therapy. Seminoma / radionuclide imaging. Seminoma / surgery. Teratoma / surgery. Time Factors. Treatment Outcome


84. Kehoe SM, Zivanovic O, Ferguson SE, Barakat RR, Soslow RA: Clinicopathologic features of bone metastases and outcomes in patients with primary endometrial cancer. Gynecol Oncol; 2010 May;117(2):229-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic features of bone metastases and outcomes in patients with primary endometrial cancer.
  • OBJECTIVE: Patients with advanced or recurrent endometrial cancer often have distant metastases found within the lymph nodes, liver, and/or lung.
  • However, there have been reported cases of primary endometrial cancer with metastasis to the bone.
  • The objective of this study was to describe the clinical and pathologic features of endometrial cancer metastatic to bone.
  • METHODS: A retrospective chart review of our clinical and pathology database was performed to identify women diagnosed with endometrial cancer metastatic to the bone between 1990 and 2007.
  • RESULTS: Twenty-one patients with endometrial cancer metastatic to the bone were identified; in 12 patients (57%), the diagnosis was confirmed by a bone biopsy.
  • The median age of diagnosis of primary endometrial cancer was 60 years (range, 32-84).
  • The overall survival of those patients with bone metastases at primary diagnosis was 17 months (95% CI: 2-32) compared to 32 months (95% CI: 14-49) for those with a recurrent bone metastasis.
  • CONCLUSION: Although a rare event, endometrial cancer can metastasize to the bone.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Endometrial cancer.
  • Genetic Alliance. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20199802.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


85. Artigas V, Marín-Hargreaves G, Marcuello E, Pey A, González JA, Rodríguez M, Moral A, Monill JM, Sancho J, Pericay C, Trias M: [Surgical resection of liver metastases from colorectal carcinoma. Experience in Sant Pau Hospital]. Cir Esp; 2007 Jun;81(6):339-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical resection of liver metastases from colorectal carcinoma. Experience in Sant Pau Hospital].
  • INTRODUCTION: Surgical resection is the only available treatment that improves survival in patients with liver metastases from colorectal cancer, particularly when carried out by a multidisciplinary team.
  • MATERIAL AND METHOD: We retrospectively analyzed a consecutive series of 116 patients who underwent 138 liver resections (65.4% minor and 35.5% major) for hepatic metastases from colorectal cancer between 1998 and 2004.
  • In 67.3% of the patients, the primary tumor was at an advanced stage (III-IV).
  • Survival rates varied according to whether the patients had < 4 or > or = 4 colorectal liver metastases (50 and 43 months respectively), tumor size (more or less than 5 cm) (60 and 50.6 months respectively) and whether the site was monolobar or bilobar (60 and 43.11 months respectively).
  • In 16 patients, recurrence of liver metastases led to 22 rehepatectomies.
  • CONCLUSIONS: These results confirm that multidisciplinary decisions and interventions by specialist liver surgeons, as in our hospital, reduce postoperative morbidity and mortality and increase survival in patients requiring surgical removal of liver metastases from colorectal cancer.
  • [MeSH-major] Colorectal Neoplasms / pathology. Colorectal Neoplasms / secondary. Colorectal Neoplasms / surgery. Liver Neoplasms / secondary. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Hospitalization. Humans. Male. Middle Aged. Neoplasm Staging. Neoplasms, Second Primary. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17553407.001).
  • [ISSN] 0009-739X
  • [Journal-full-title] Cirugía española
  • [ISO-abbreviation] Cir Esp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


86. Zhou L, Yang YP, Feng YY, Lu YY, Wang CP, Wang XZ, An LJ, Zhang X, Wang FS: Efficacy of argon-helium cryosurgical ablation on primary hepatocellular carcinoma: a pilot clinical study. Ai Zheng; 2009 Jan;28(1):45-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of argon-helium cryosurgical ablation on primary hepatocellular carcinoma: a pilot clinical study.
  • BACKGROUND AND OBJECTIVE: Recent years, great progression has been made in treating primary hepatocellular carcinoma (HCC) with argon-helium cryosurgical ablation.
  • This study was to evaluate its efficacy on unresectable primary HCC.
  • METHODS: A total of 124 primary HCC patients were divided into early stage, middle stage and advanced stage groups according to BCLC staging classification.
  • The median survival time was 31.25 months in early stage group, 17.41 months in middle stage group and 6.82 months in advanced stage group.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Cryosurgery / methods. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Argon. Female. Helium. Humans. Liver / physiopathology. Male. Middle Aged. Pilot Projects. Postoperative Complications / epidemiology. Survival Rate. alpha-Fetoproteins / analysis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. Argon, Elemental .
  • Hazardous Substances Data Bank. HELIUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19448416.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / alpha-Fetoproteins; 206GF3GB41 / Helium; 67XQY1V3KH / Argon
  •  go-up   go-down


87. Kleespies A, Füessl KE, Seeliger H, Eichhorn ME, Müller MH, Rentsch M, Thasler WE, Angele MK, Kreis ME, Jauch KW: Determinants of morbidity and survival after elective non-curative resection of stage IV colon and rectal cancer. Int J Colorectal Dis; 2009 Sep;24(9):1097-109
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Determinants of morbidity and survival after elective non-curative resection of stage IV colon and rectal cancer.
  • PURPOSE: The benefit of elective primary tumor resection for non-curable stage IV colorectal cancer (CRC) remains largely undefined.
  • RESULTS: Patients with colon cancer (CC = 156) and rectal cancer (RC = 77) were comparable with regard to age, sex, comorbidity, American Society of Anesthesiologists score, carcinoembryonic antigen levels, hepatic spread, tumor grade, resection margins, 30-day mortality (CC 5.1%, RC 3.9%) and postoperative chemotherapy. pT4 tumors, carcinomatosis, and non-anatomical resections were more common in colon cancer patients, whereas enterostomies (CC 1.3%, RC 67.5%, p < 0.0001), anastomotic leaks (CC 7.7%, RC 24.2%, p = 0.002), and total surgical complications (CC 19.9%, RC 40.3%, p = 0.001) were more frequent after rectal surgery.
  • Independent determinants of an increased postoperative morbidity were primary rectal cancer, hepatic tumor load >50%, and comorbidity >1 organ.
  • CONCLUSIONS: Palliative resection is associated with a particularly unfavorable outcome in rectal cancer patients presenting with a locally advanced tumor (pT4, expected R2 resection) or an extensive comorbidity, and in all CRC patients who show a hepatic tumor load >50%.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Comorbidity. Female. Humans. Liver Neoplasms. Male. Middle Aged. Morbidity. Prognosis. Risk Assessment. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Rectal Cancer.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Surg. 2002 Sep;89(9):1096-102 [12190673.001]
  • [Cites] Colorectal Dis. 2007 Jun;9(5):430-7 [17504340.001]
  • [Cites] Arch Surg. 2000 May;135(5):530-4; discussion 534-5 [10807276.001]
  • [Cites] Dis Colon Rectum. 2003 Dec;46(12):1646-52 [14668590.001]
  • [Cites] Dis Colon Rectum. 1982 Nov-Dec;25(8):749-54 [7172942.001]
  • [Cites] J Surg Oncol. 2002 Sep;81(1):3-7 [12210018.001]
  • [Cites] Br J Surg. 1997 Dec;84(12):1731-6 [9448628.001]
  • [Cites] J Am Coll Surg. 2003 Aug;197(2):233-41; discussion 241-2 [12892803.001]
  • [Cites] Ann Surg Oncol. 2008 Apr;15(4):1099-106 [18181002.001]
  • [Cites] Br J Surg. 2001 Oct;88(10 ):1352-6 [11578291.001]
  • [Cites] BMJ. 2000 Sep 2;321(7260):531-5 [10968812.001]
  • [Cites] Ann Surg. 2003 Aug;238(2):203-13 [12894013.001]
  • [Cites] J Gastrointest Surg. 2004 Mar-Apr;8(3):262-5 [15019919.001]
  • [Cites] Ann Surg Oncol. 2002 Dec;9(10):954-60 [12464586.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Jan 1;49(1):107-16 [11163503.001]
  • [Cites] Int J Colorectal Dis. 2009 Jun;24(6):699-709 [19221767.001]
  • [Cites] Dis Colon Rectum. 1990 Oct;33(10):846-50 [1698594.001]
  • [Cites] Br J Surg. 2000 Sep;87(9):1142-55 [10971419.001]
  • [Cites] Am J Surg. 2000 Dec;180(6):407-11; discussion 412 [11182388.001]
  • [Cites] Br J Surg. 2005 Sep;92(9):1155-60 [16035135.001]
  • [Cites] Dis Colon Rectum. 1997 Feb;40(2):156-60 [9075749.001]
  • [Cites] Z Gastroenterol. 2002 Aug;40(8):551-6 [12297977.001]
  • [Cites] Int J Colorectal Dis. 2004 May;19(3):197-202 [14618348.001]
  • [Cites] J Surg Oncol. 2006 Jun 1;93(7):523-8 [16705728.001]
  • [Cites] Gut. 2003 Apr;52(4):568-73 [12631671.001]
  • [Cites] Dis Colon Rectum. 1988 Nov;31(11):842-7 [2460299.001]
  • [Cites] Br J Surg. 1996 Aug;83(8):1116-20 [8869321.001]
  • [Cites] J Am Coll Surg. 2003 May;196(5):722-8 [12742204.001]
  • [Cites] Arch Surg. 1987 Jun;122(6):640-3 [2437881.001]
  • [Cites] Br J Surg. 2001 Feb;88(2):163-4 [11167862.001]
  • [Cites] Ann Surg Oncol. 2005 Aug;12(8):637-45 [15965730.001]
  • [Cites] Semin Oncol. 2006 Oct;33(5 Suppl 10):S26-34 [17145522.001]
  • [Cites] Gastrointest Endosc. 2000 May;51(5):580-5 [10805846.001]
  • [Cites] Dis Colon Rectum. 1997 Dec;40(12):1425-9 [9407979.001]
  • [Cites] Ann Surg Oncol. 1999 Oct-Nov;6(7):651-7 [10560850.001]
  • [Cites] Surg Endosc. 2008 Aug;22(8):1818-25 [18095024.001]
  • [Cites] Dis Colon Rectum. 1981 Jul-Aug;24(5):355-60 [6167412.001]
  • [Cites] ANZ J Surg. 2004 Apr;74(4):229-32 [15043733.001]
  • [Cites] Dis Colon Rectum. 1981 Nov-Dec;24(8):606-9 [6172244.001]
  • [Cites] Dis Colon Rectum. 2004 Sep;47(9):1455-61 [15486741.001]
  • [Cites] Br J Surg. 1995 Oct;82(10):1397-400 [7489177.001]
  • [Cites] Dis Colon Rectum. 1997 Jan;40(1):11-4 [9102251.001]
  • [Cites] Lancet Oncol. 2001 Sep;2(9):533-43 [11905707.001]
  • [Cites] Endoscopy. 2008 Mar;40(3):184-91 [18322873.001]
  • [Cites] Surgery. 2005 Jan;137(1):42-7 [15614280.001]
  • [Cites] Surg Gynecol Obstet. 1981 Dec;153(6):864-8 [6171042.001]
  • [Cites] J Surg Oncol. 2005 Mar 15;89(4):211-7 [15726622.001]
  • [Cites] Z Gastroenterol. 2004 Oct;42(10 ):1129-77 [15508058.001]
  • [Cites] Ann Surg. 2004 Oct;240(4):644-57; discussion 657-8 [15383792.001]
  • (PMID = 19495779.001).
  • [ISSN] 1432-1262
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


88. Verset G, Verslype C, Reynaert H, Borbath I, Langlet P, Vandebroek A, Peeters M, Houbiers G, Francque S, Arvanitakis M, Van Laethem JL: Efficacy of the combination of long-acting release octreotide and tamoxifen in patients with advanced hepatocellular carcinoma: a randomised multicentre phase III study. Br J Cancer; 2007 Sep 3;97(5):582-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of the combination of long-acting release octreotide and tamoxifen in patients with advanced hepatocellular carcinoma: a randomised multicentre phase III study.
  • To assess the efficacy of the combination of long-acting release (LAR) octreotide and tamoxifen (TMX) for the treatment of advanced hepatocellular carcinoma (HCC).
  • A total of 109 patients with advanced HCC were randomised to receive octreotide LAR combined with TMX (n=56) (experimental treatment group) or TMX alone (n=53; control group).
  • Primary end point was patient survival; secondary end points were the impact of therapy on tumour response, quality of life and variceal bleeding episodes.
  • The combination of octreotide LAR and TMX does not influence survival, tumour progression or quality of life in patients with advanced HCC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Liver Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diarrhea / chemically induced. Female. Humans. Male. Middle Aged. Multivariate Analysis. Nausea / chemically induced. Neoplasm Staging. Octreotide / administration & dosage. Octreotide / adverse effects. Patient Compliance / statistics & numerical data. Prognosis. Quality of Life. Survival Analysis. Tamoxifen / administration & dosage. Tamoxifen / adverse effects. Treatment Outcome. alpha-Fetoproteins / metabolism

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 1998;77(1):115-22 [9459155.001]
  • [Cites] Digestion. 1996;57 Suppl 1:29-33 [8813463.001]
  • [Cites] Aliment Pharmacol Ther. 1998 Feb;12(2):111-26 [9692685.001]
  • [Cites] Lancet. 1998 Jul 4;352(9121):17-20 [9800740.001]
  • [Cites] Cancer. 1999 Mar 15;85(6):1284-92 [10189133.001]
  • [Cites] Gut. 1999 Nov;45(5):766-74 [10517918.001]
  • [Cites] Hepatology. 2004 Dec;40(6):1361-9 [15565568.001]
  • [Cites] Eur J Cancer. 2005 Mar;41(5):694-701 [15763644.001]
  • [Cites] Cancer. 2005 Apr 1;103(7):1408-14 [15744746.001]
  • [Cites] J Clin Oncol. 2005 Jul 1;23(19):4338-46 [15994145.001]
  • [Cites] Biochem Pharmacol. 2006 May 14;71(10):1435-48 [16530734.001]
  • [Cites] Hepatology. 2007 Jan;45(1):9-15 [17187405.001]
  • [Cites] Am J Gastroenterol. 2000 Jan;95(1):218-22 [10638587.001]
  • [Cites] Hepatology. 2000 Jan;31(1):54-8 [10613728.001]
  • [Cites] Am J Gastroenterol. 2007 Jul;102(7):1397-405 [17488248.001]
  • [Cites] Int J Oncol. 2000 Jun;16(6):1197-201 [10811995.001]
  • [Cites] J Hepatol. 2000 Nov;33(5):846-52 [11097497.001]
  • [Cites] Bull Cancer. 2000 Dec;87(12):881-6 [11174117.001]
  • [Cites] Mol Pathol. 2001 Jun;54(3):138-44 [11376124.001]
  • [Cites] J Hepatol. 2001 Sep;35(3):421-30 [11592607.001]
  • [Cites] Hepatology. 2002 May;35(5):1164-71 [11981766.001]
  • [Cites] Lancet. 2002 May 18;359(9319):1734-9 [12049862.001]
  • [Cites] Z Gastroenterol. 2002 Jun;40(6):395-400 [12055662.001]
  • [Cites] Oncol Rep. 2002 Jul-Aug;9(4):903-7 [12066229.001]
  • [Cites] Hepatology. 2002 Sep;36(3):687-91 [12198662.001]
  • [Cites] Hepatogastroenterology. 2002 Sep-Oct;49(47):1245-50 [12239914.001]
  • [Cites] J Hepatol. 2003;38 Suppl 1:S136-49 [12591191.001]
  • [Cites] J Cancer Res Clin Oncol. 2003 Jun;129(6):327-34 [12811549.001]
  • [Cites] Acta Gastroenterol Belg. 2004 Jan-Mar;67(1):14-25 [15149081.001]
  • [Cites] Eur J Cancer. 2004 Jul;40(10):1474-84 [15196530.001]
  • [Cites] Gut. 2004 Aug;53(8):1180-9 [15247189.001]
  • [Cites] J Hepatol. 2004 Jul;41(1):112-8 [15246216.001]
  • [Cites] Cancer. 1985 Aug 15;56(4):918-28 [2990661.001]
  • [Cites] Endocrinology. 1992 Nov;131(5):2479-81 [1385103.001]
  • [Cites] Biochem Biophys Res Commun. 1994 Aug 30;203(1):253-9 [8074663.001]
  • [Cites] Cancer Res. 1994 Dec 15;54(24):6334-7 [7987824.001]
  • [Cites] Hepatology. 1995 Jun;21(6):1535-42 [7768497.001]
  • [Cites] Gut. 1998 Mar;42(3):442-7 [9577356.001]
  • (PMID = 17687341.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / alpha-Fetoproteins; 094ZI81Y45 / Tamoxifen; RWM8CCW8GP / Octreotide
  • [Other-IDs] NLM/ PMC2360361
  •  go-up   go-down


89. Bock O, Neuse J, Hussein K, Brakensiek K, Buesche G, Buhr T, Wiese B, Kreipe H: Aberrant collagenase expression in chronic idiopathic myelofibrosis is related to the stage of disease but not to the JAK2 mutation status. Am J Pathol; 2006 Aug;169(2):471-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Membrane type 1-MMP (MMP-14) was overexpressed by up to 80-fold in advanced stages that progressed to fibrosis (P < 0.001), and megakaryocytes and endothelial cells were unmasked as the major cellular source.
  • [MeSH-major] Collagenases / genetics. Mutation / genetics. Primary Myelofibrosis / enzymology. Primary Myelofibrosis / genetics. Protein-Tyrosine Kinases / genetics. Proto-Oncogene Proteins / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bone Marrow Cells / enzymology. Disease Progression. Endothelial Cells / enzymology. Endothelial Cells / pathology. Female. Fibrosis / pathology. Hematopoiesis / genetics. Humans. Janus Kinase 2. Male. Matrix Metalloproteinases / genetics. Megakaryocytes / enzymology. Megakaryocytes / pathology. Middle Aged. Protein Transport. RNA, Messenger / genetics. RNA, Messenger / metabolism. Tissue Inhibitor of Metalloproteinases / genetics. Up-Regulation / genetics

  • Genetic Alliance. consumer health - Myelofibrosis.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Mol Diagn. 2006 May;8(2):170-7 [16645202.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):248-58 [16397238.001]
  • [Cites] Blood. 2000 Nov 15;96(10):3374-80 [11071630.001]
  • [Cites] J Immunol. 2001 Mar 1;166(5):3491-8 [11207308.001]
  • [Cites] Anal Biochem. 2001 Aug 1;295(1):116-7 [11476553.001]
  • [Cites] Br J Haematol. 2001 Oct;115(1):195-204 [11722433.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Methods. 2001 Dec;25(4):409-18 [11846610.001]
  • [Cites] Br J Haematol. 2002 Dec;119(3):709-12 [12437648.001]
  • [Cites] Am J Clin Pathol. 2003 Jan;119(1):152-8 [12520711.001]
  • [Cites] Circ Res. 2003 May 2;92(8):827-39 [12730128.001]
  • [Cites] J Pathol. 2003 Jul;200(4):448-64 [12845612.001]
  • [Cites] Eur J Haematol. 2003 Oct;71(4):276-82 [12950237.001]
  • [Cites] Acta Haematol. 2004;111(3):155-9 [15034237.001]
  • [Cites] Cell Adhes Commun. 1993 Sep;1(2):93-9 [8081879.001]
  • [Cites] Cell. 1998 Feb 6;92(3):391-400 [9476898.001]
  • [Cites] Blood. 1998 Dec 15;92(12):4641-51 [9845530.001]
  • [Cites] Blood. 1999 Apr 15;93(8):2627-36 [10194442.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2004 Dec;287(6):G1227-37 [15284024.001]
  • [Cites] J Cell Biol. 2004 Nov 22;167(4):757-67 [15545316.001]
  • [Cites] Lancet. 2005 Mar 19-25;365(9464):1054-61 [15781101.001]
  • [Cites] J Pathol. 2005 Apr;205(5):548-57 [15726648.001]
  • [Cites] Cancer Cell. 2005 Apr;7(4):387-97 [15837627.001]
  • [Cites] N Engl J Med. 2005 Apr 28;352(17):1779-90 [15858187.001]
  • [Cites] Nature. 2005 Apr 28;434(7037):1144-8 [15793561.001]
  • [Cites] Blood. 2005 Jun 1;105(11):4508-15 [15705794.001]
  • [Cites] Blood. 2005 Jun 1;105(11):4187-90 [15817681.001]
  • [Cites] Br J Haematol. 2005 Jul;130(1):76-82 [15982347.001]
  • [Cites] Haematologica. 2005 Aug;90(8):1128-32 [16079113.001]
  • [Cites] Leuk Lymphoma. 2005 Sep;46(9):1261-8 [16109602.001]
  • [Cites] J Exp Med. 2005 Sep 5;202(5):663-71 [16147977.001]
  • [Cites] Semin Hematol. 2005 Oct;42(4):248-58 [16210038.001]
  • [Cites] FEBS Lett. 2005 Oct 24;579(25):5487-93 [16213498.001]
  • [Cites] Blood. 2005 Nov 15;106(10):3370-3 [16037387.001]
  • [Cites] J Cell Physiol. 2006 Jan;206(1):1-8 [15920734.001]
  • [Cites] J Clin Oncol. 2005 Nov 20;23(33):8520-30 [16293880.001]
  • [Cites] Nat Cell Biol. 2000 Oct;2(10):737-44 [11025665.001]
  • (PMID = 16877349.001).
  • [ISSN] 0002-9440
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins; 0 / RNA, Messenger; 0 / Tissue Inhibitor of Metalloproteinases; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.2 / JAK2 protein, human; EC 2.7.10.2 / Janus Kinase 2; EC 3.4.24.- / Collagenases; EC 3.4.24.- / Matrix Metalloproteinases
  • [Other-IDs] NLM/ PMC1780160
  •  go-up   go-down


90. Yuan RH, Jeng YM, Chen HL, Hsieh FJ, Yang CY, Lee PH, Hsu HC: Opposite roles of human pancreatitis-associated protein and REG1A expression in hepatocellular carcinoma: association of pancreatitis-associated protein expression with low-stage hepatocellular carcinoma, beta-catenin mutation, and favorable prognosis. Clin Cancer Res; 2005 Apr 1;11(7):2568-75
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • EXPERIMENTAL DESIGN: PAP and REG1A mRNA levels were measured in 265 surgically removed unifocal primary HCCs using reverse transcription-PCR.
  • CONCLUSIONS: These data suggest that PAP expression designate a subset of low-grade, low-stage HCC with frequent beta-catenin mutation and hence more favorable prognosis, whereas further genetic or epigenetic alterations, such as p53 mutation and REG1A expression, lead to more advanced HCCs.
  • [MeSH-major] Antigens, Neoplasm / genetics. Biomarkers, Tumor / genetics. Calcium-Binding Proteins / genetics. Carcinoma, Hepatocellular / pathology. Lectins, C-Type / genetics. Liver Neoplasms / pathology. Nerve Tissue Proteins / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cytoskeletal Proteins / genetics. Disease Progression. Female. Gene Expression Regulation, Neoplastic / physiology. Humans. Lithostathine. Male. Middle Aged. Mutation. Neoplasm Staging. Prognosis. RNA, Messenger / genetics. RNA, Messenger / metabolism. Survival Analysis. Trans-Activators / genetics. Tumor Suppressor Protein p53 / genetics. beta Catenin

  • Genetic Alliance. consumer health - Pancreatitis.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15814635.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / CTNNB1 protein, human; 0 / Calcium-Binding Proteins; 0 / Cytoskeletal Proteins; 0 / Lectins, C-Type; 0 / Lithostathine; 0 / Nerve Tissue Proteins; 0 / REG1A protein, human; 0 / RNA, Messenger; 0 / Trans-Activators; 0 / Tumor Suppressor Protein p53; 0 / beta Catenin; 0 / pancreatitis-associated protein
  •  go-up   go-down


91. Fan LX, Shen L, Li JY, Pan KF, Dong B, Zhang Y: [Role of KAI1 gene expression and loss of heterozygosity of KAI1 in metastatic potential and prognosis of pancreatic cancer]. Zhonghua Bing Li Xue Za Zhi; 2009 Jan;38(1):42-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Role of KAI1 gene expression and loss of heterozygosity of KAI1 in metastatic potential and prognosis of pancreatic cancer].
  • OBJECTIVE: To investigate the role of KAI1 gene expression and loss of heterozygosity (LOH) of KAI1 in metastatic potential and prognosis of pancreatic cancer.
  • RESULTS: The positivity rate of CD82 in primary pancreatic cancer was 76% (47/62).
  • CD82 expression was significantly higher (P < 0.01) in earlier tumor stages (I and II), as compared to the advanced tumor stages ( III and IV) in which nodal or distant metastases were present.
  • CONCLUSIONS: The abnormal expression of CD82 which participates in malignant progression of pancreatic cancer is probably associated with LOH of KAI1 gene.
  • Detection of CD82 expression and LOH of KAI1 gene may carry potential clinical significance in evaluating the metastatic potential and prognosis of pancreatic cancer.
  • [MeSH-minor] Adult. Aged. Female. Humans. Liver Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19489224.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD82; 0 / CD82 protein, human
  •  go-up   go-down


92. Guan-Zhen Y, Ying C, Can-Rong N, Guo-Dong W, Jian-Xin Q, Jie-Jun W: Reduced protein expression of metastasis-related genes (nm23, KISS1, KAI1 and p53) in lymph node and liver metastases of gastric cancer. Int J Exp Pathol; 2007 Jun;88(3):175-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reduced protein expression of metastasis-related genes (nm23, KISS1, KAI1 and p53) in lymph node and liver metastases of gastric cancer.
  • PURPOSE: Metastasis remains an incurable common complication in patients with gastric cancer.
  • To compare protein expression of metastasis-related genes (nm23, KISS1, KAI1 and p53) between primary tumours and metastatic tumours may be useful in illustrating these theories.
  • METHODS: Metastasis-related tissue microarrays (including normal tissues, primary tumours, nodal metastases and liver metastases) were constructed.
  • The protein expression of nm23, KISS1, KAI1 and p53 in lymph node and liver metastases from advanced gastric cancer specimens was mainly examined by immunohistochemical staining in relation to primary tumours.
  • RESULTS: Immunohistochemical staining showed reduced protein expression of nm23, KISS1 and KAI1 in lymph node and liver metastases compared with primary tumours.
  • CONCLUSIONS: Our investigations revealed a tendency of reduced protein expression of metastasis suppressor genes nm23, KISS1 and KAI1 in gastric cancer with the progress of metastasis.
  • [MeSH-major] Biomarkers, Tumor / analysis. Liver Neoplasms / metabolism. Liver Neoplasms / secondary. Stomach Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD82 / analysis. Antigens, CD82 / genetics. Female. Gene Expression. Gene Expression Profiling. Genetic Markers. Humans. Immunohistochemistry. Kisspeptins. Lymphatic Metastasis. Male. Middle Aged. NM23 Nucleoside Diphosphate Kinases. Nucleoside-Diphosphate Kinase / analysis. Nucleoside-Diphosphate Kinase / genetics. Oligonucleotide Array Sequence Analysis. Staining and Labeling. Tumor Suppressor Protein p53 / analysis. Tumor Suppressor Protein p53 / genetics. Tumor Suppressor Proteins / analysis. Tumor Suppressor Proteins / genetics

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surgery. 1999 Nov;126(5):869-80 [10568187.001]
  • [Cites] Cancer Res. 1996 Apr 15;56(8):1751-5 [8620488.001]
  • [Cites] Oncol Rep. 2000 Jan-Feb;7(1):99-103 [10601600.001]
  • [Cites] Clin Cancer Res. 2000 Sep;6(9):3424-9 [10999724.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Nov 30;278(3):499-502 [11095940.001]
  • [Cites] J Biol Chem. 2001 Jan 12;276(2):1164-72 [11060311.001]
  • [Cites] Eur J Surg Oncol. 2001 Mar;27(2):170-4 [11289754.001]
  • [Cites] Nature. 2001 May 31;411(6837):613-7 [11385580.001]
  • [Cites] Cancer Res. 2001 Jul 1;61(13):5284-8 [11431371.001]
  • [Cites] J Biol Chem. 2001 Sep 14;276(37):34631-6 [11457843.001]
  • [Cites] Int J Cancer. 2001 Oct 1;94(1):16-23 [11668473.001]
  • [Cites] Zhonghua Zhong Liu Za Zhi. 2001 May;23(3):224-7 [11783092.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2001 Oct;6(4):441-51 [12013533.001]
  • [Cites] BMC Cancer. 2001;1:9 [11518545.001]
  • [Cites] Pathology. 2002 Oct;34(5):427-32 [12408341.001]
  • [Cites] Am J Pathol. 2003 Feb;162(2):609-17 [12547718.001]
  • [Cites] Clin Exp Metastasis. 2003;20(1):11-8 [12650602.001]
  • [Cites] World J Gastroenterol. 2003 Jun;9(6):1231-6 [12800230.001]
  • [Cites] J Bioenerg Biomembr. 2003 Feb;35(1):19-30 [12848338.001]
  • [Cites] Oncol Rep. 2003 Sep-Oct;10(5):1257-63 [12883690.001]
  • [Cites] Cancer. 1996 Jun 1;77(11):2246-50 [8635091.001]
  • [Cites] J Korean Med Sci. 1995 Dec;10(6):406-13 [8924224.001]
  • [Cites] Am J Gastroenterol. 1997 Jul;92(7):1182-6 [9219795.001]
  • [Cites] Aust N Z J Surg. 1998 Mar;68(3):180-2 [9563444.001]
  • [Cites] Cancer Lett. 1998 Jun 5;128(1):23-9 [9652789.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 15;95(19):11307-11 [9736732.001]
  • [Cites] Oncology. 1999;56(2):122-8 [9949298.001]
  • [Cites] Ann Surg. 1999 Aug;230(2):179-84 [10450731.001]
  • [Cites] J Cancer Res Clin Oncol. 2005 Mar;131(3):191-8 [15592684.001]
  • [Cites] Oncology. 2005;68(2-3):87-96 [15886500.001]
  • [Cites] J Cancer Res Clin Oncol. 2003 Sep;129(9):531-5 [12898236.001]
  • [Cites] Cancer Lett. 2003 Oct 28;200(2):97-105 [14568162.001]
  • [Cites] Int J Cancer. 2004 Jan 10;108(2):207-11 [14639604.001]
  • [Cites] Clin Cancer Res. 2004 Feb 15;10(4):1379-83 [14977840.001]
  • [Cites] Pancreas. 2004 May;28(4):421-6 [15097860.001]
  • [Cites] Ann Diagn Pathol. 2004 Feb;8(1):6-16 [15129904.001]
  • [Cites] Int J Cancer. 2004 Oct 10;111(6):868-72 [15300798.001]
  • [Cites] Br J Cancer. 1993 Mar;67(3):589-93 [8439509.001]
  • [Cites] J Natl Cancer Inst. 1994 Dec 21;86(24):1838-44 [7990158.001]
  • [Cites] Cancer Res. 1999 Nov 15;59(22):5724-31 [10582691.001]
  • (PMID = 17504447.001).
  • [ISSN] 0959-9673
  • [Journal-full-title] International journal of experimental pathology
  • [ISO-abbreviation] Int J Exp Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD82; 0 / Biomarkers, Tumor; 0 / Genetic Markers; 0 / KISS1 protein, human; 0 / Kisspeptins; 0 / NM23 Nucleoside Diphosphate Kinases; 0 / Tumor Suppressor Protein p53; 0 / Tumor Suppressor Proteins; EC 2.7.4.6 / NME1 protein, human; EC 2.7.4.6 / Nucleoside-Diphosphate Kinase
  • [Other-IDs] NLM/ PMC2517304
  •  go-up   go-down


93. Just T, Bombor I, Pau HW, Klautke G, Fietkau R: Paraneoplastic changes of oropharyngeal mucosa in breast cancer. Strahlenther Onkol; 2006 Feb;182(2):112-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paraneoplastic changes of oropharyngeal mucosa in breast cancer.
  • CASE REPORT: In a 43-year-old woman suffering from breast cancer, extensive changes of oropharyngeal epithelia were apparent 2.5 years after primary surgery and combined radiochemotherapy (RCT) as well as relapse therapy with RCT.
  • Subsequent restaging showed advanced liver metastases.
  • After treatment of the liver metastases, a regression of the extensive oropharyngeal changes became apparent.
  • [MeSH-minor] Adult. Disease Progression. Endoscopy. Female. Humans. Liver Neoplasms / diagnosis. Liver Neoplasms / pathology. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Microscopy, Confocal. Neoplasm Staging

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16447019.001).
  • [ISSN] 0179-7158
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


94. Eisenhauer EL, Abu-Rustum NR, Sonoda Y, Levine DA, Poynor EA, Aghajanian C, Jarnagin WR, DeMatteo RP, D'Angelica MI, Barakat RR, Chi DS: The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer. Gynecol Oncol; 2006 Dec;103(3):1083-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer.
  • OBJECTIVES: To determine the survival impact of adding extensive upper abdominal surgical cytoreduction to standard surgical techniques for advanced ovarian cancer.
  • METHODS: The records of all patients with stages IIIC-IV epithelial ovarian cancer who underwent primary surgery at our institution from 1998 to 2003 were reviewed.
  • Group 1 patients required extensive upper abdominal surgery, such as diaphragm peritonectomy/resection, resection of parenchymal liver or porta hepatis disease and/or splenectomy with or without distal pancreatectomy, to achieve optimal cytoreduction (residual disease<or=1 cm).
  • Primary outcome measures were response to primary chemotherapy, progression-free survival, and overall survival.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Databases, Factual. Diaphragm / surgery. Disease-Free Survival. Female. Humans. Liver / surgery. Middle Aged. Neoplasm Staging. New York City. Pancreas / surgery. Peritoneum / surgery. Spleen / surgery. Survival Analysis. Treatment Outcome


95. Zivanovic O, Eisenhauer EL, Zhou Q, Iasonos A, Sabbatini P, Sonoda Y, Abu-Rustum NR, Barakat RR, Chi DS: The impact of bulky upper abdominal disease cephalad to the greater omentum on surgical outcome for stage IIIC epithelial ovarian, fallopian tube, and primary peritoneal cancer. Gynecol Oncol; 2008 Feb;108(2):287-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact of bulky upper abdominal disease cephalad to the greater omentum on surgical outcome for stage IIIC epithelial ovarian, fallopian tube, and primary peritoneal cancer.
  • OBJECTIVE: To analyze the impact of bulky upper abdominal disease (UAD) cephalad to the greater omentum on surgical outcomes for patients with stage IIIC epithelial ovarian, fallopian tube, and primary peritoneal carcinoma.
  • METHODS: All patients with stage IIIC epithelial ovarian, fallopian tube, and primary peritoneal carcinoma who underwent primary cytoreductive surgery at our institution from 1989 to 2005 were eligible for the study.
  • UAD cephalad to the greater omentum was defined as cancerous lesions involving the diaphragm, liver, porta hepatis, spleen, pancreas, stomach, and lesser sac.
  • These findings emphasize the importance of comprehensive training, preparation, and referral when appropriate to centers that specialize in the surgical management of patients with advanced ovarian, tubal, and peritoneal carcinoma.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Middle Aged. Neoplasm Staging


96. Kinoshita S, Hirano A, Komine K, Kobayashi S, Kyoda S, Takeyama H, Uchida K, Morikawa T, Nagase J, Sakamoto G: Primary small-cell neuroendocrine carcinoma of the breast: report of a case. Surg Today; 2008;38(8):734-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary small-cell neuroendocrine carcinoma of the breast: report of a case.
  • Primary small-cell neuroendocrine carcinoma of the breast is a rare and aggressive neoplasm without an established treatment protocol because so few cases have been described.
  • We report a case of primary small-cell neuroendocrine carcinoma in a 31-year-old woman.
  • The patient came to our hospital 10 days after consulting another clinic, where a diagnosis of locally advanced breast cancer suitable for neoadjuvant chemotherapy had been made.
  • Definitive histopathological examination revealed primary small-cell neuroendocrine carcinoma.
  • Local and mediastinal recurrence with multiple liver metastases developed only 5 weeks after surgery.
  • [MeSH-minor] Adult. Biopsy, Needle. Diagnosis, Differential. Fatal Outcome. Female. Humans. Neoplasm Invasiveness. Ultrasonography, Mammary

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Pathol. 2004 Jan;121(1):117-21 [14750249.001]
  • [Cites] Pathol Int. 1998 Sep;48(9):744-8 [9778114.001]
  • [Cites] Semin Oncol. 2007 Feb;34(1):64-6 [17270668.001]
  • [Cites] Semin Oncol. 2007 Feb;34(1):30-8 [17270663.001]
  • [Cites] J Exp Clin Cancer Res. 2004 Dec;23 (4):691-6 [15743041.001]
  • [Cites] Am J Clin Oncol. 1995 Apr;18(2):133-8 [7534975.001]
  • [Cites] Cancer. 1983 Jul 1;52(1):121-5 [6303551.001]
  • [Cites] Am J Surg Pathol. 2000 Sep;24(9):1231-8 [10976697.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2005 May;17(3):201-2 [15901010.001]
  • [Cites] Histopathology. 2001 Mar;38(3):277-8 [11260311.001]
  • [Cites] Acta Cytol. 1997 Jul-Aug;41(4 Suppl):1341-4 [9990271.001]
  • [Cites] Arch Pathol Lab Med. 2000 Feb;124(2):296-8 [10656743.001]
  • [Cites] Oncol Rep. 2004 Apr;11(4):825-31 [15010880.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2004 Aug 10;115(2):231-3 [15262362.001]
  • [Cites] N Engl J Med. 2002 Jan 10;346(2):85-91 [11784874.001]
  • [Cites] Hum Pathol. 2001 Jul;32(7):753-7 [11486176.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1984;404(2):213-21 [6091325.001]
  • [Cites] Breast. 2004 Apr;13(2):149-51 [15019697.001]
  • [Cites] J Clin Pathol. 2006 Aug;59(8):888 [16873572.001]
  • [Cites] Pathol Int. 2000 Nov;50(11):914-8 [11107070.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1992;420(1):103-8 [1311484.001]
  • [Cites] J Clin Pathol. 2005 Jul;58(7):775-8 [15976350.001]
  • (PMID = 18668318.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 24
  •  go-up   go-down


97. Lin A, Chen HX, Zhu CC, Zhang X, Xu HH, Zhang JG, Wang Q, Zhou WJ, Yan WH: Aberrant human leucocyte antigen-G expression and its clinical relevance in hepatocellular carcinoma. J Cell Mol Med; 2010 Aug;14(8):2162-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hepatocellular carcinoma (HCC) is a major contributor to cancer incidence and mortality worldwide; however, potential roles of HLA-G in HCC remain unknown.
  • In the current study, HLA-G expression in 219 primary HCC lesions and their adjacent non-tumourous samples was analysed with immunohistochemistry.
  • HLA-G expression was observed in 50.2% (110/219) of primary HCC lesions, and undetectable in corresponding adjacent normal liver tissues.
  • Data revealed that HLA-G expression in HCC was strongly correlated to advanced disease stage (I versus II, P= 0.882; I versus III, P= 0.020; II versus III, P= 0.037).
  • Our finding indicated that HLA-G expression was strongly correlated to advanced disease stage, and more frequently observed in elder patients.
  • [MeSH-major] Carcinoma, Hepatocellular / metabolism. HLA Antigens / biosynthesis. Histocompatibility Antigens Class I / biosynthesis. Liver Neoplasms / metabolism
  • [MeSH-minor] Adult. Age Factors. Aged. Antibodies, Monoclonal / immunology. Antibodies, Monoclonal / pharmacology. Blotting, Western. Cytotoxicity, Immunologic / drug effects. Enzyme-Linked Immunosorbent Assay. Female. HLA-G Antigens. Hep G2 Cells. Humans. Immunohistochemistry. K562 Cells. Killer Cells, Natural / cytology. Killer Cells, Natural / immunology. Male. Middle Aged. Neoplasm Staging. Tissue Array Analysis. Transfection

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2009 The Authors Journal compilation © 2010 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd.
  • (PMID = 19799650.001).
  • [ISSN] 1582-4934
  • [Journal-full-title] Journal of cellular and molecular medicine
  • [ISO-abbreviation] J. Cell. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / HLA Antigens; 0 / HLA-G Antigens; 0 / Histocompatibility Antigens Class I
  • [Other-IDs] NLM/ PMC3823007
  •  go-up   go-down


98. van Iersel LB, Hoekman EJ, Gelderblom H, Vahrmeijer AL, van Persijn van Meerten EL, Tijl FG, Hartgrink HH, Kuppen PJ, Nortier JW, Tollenaar RA, van de Velde CJ: Isolated hepatic perfusion with 200 mg melphalan for advanced noncolorectal liver metastases. Ann Surg Oncol; 2008 Jul;15(7):1891-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated hepatic perfusion with 200 mg melphalan for advanced noncolorectal liver metastases.
  • PURPOSE: The liver is one of the most common sites for metastatic solid tumors.
  • If the liver is the only site of metastatic disease, regional treatment options can offer the benefit of high local exposure with limited systemic toxicity, especially for patients without (further) systemic treatment options.
  • We report the results of our experience with isolated hepatic perfusion (IHP) in patients with isolated liver metastases from a variety of primary tumors.
  • PATIENTS AND METHODS: Nineteen patients with isolated unresectable liver metastases from a variety of tumors (13 uveal melanomas, 2 neuroendocrine carcinomas, 2 gastrointestinal stromal tumors, 1 hepatocellular carcinoma, and 1 high-grade sarcoma) were treated with a 60-min IHP using 200 mg melphalan.
  • RESULTS: One melanoma patient was not perfused due to insufficient isolation of the liver.
  • Fifty percent of other primary tumors showed at least partial remission, including one complete remission in a high-grade sarcoma patient.
  • CONCLUSION: IHP with melphalan shows activity in patients with liver metastases from a variety of primary tumors, but other or additional drugs may improve therapeutic outcome.
  • [MeSH-major] Antineoplastic Agents, Alkylating / administration & dosage. Chemotherapy, Cancer, Regional Perfusion. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Melphalan / administration & dosage
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Female. Humans. Male. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. MELPHALAN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1998 Apr;16(4):1479-89 [9552055.001]
  • [Cites] Am J Clin Oncol. 1998 Feb;21(1):36-8 [9499254.001]
  • [Cites] Ann Surg. 1999 Jun;229(6):815-21; discussion 822-3 [10363895.001]
  • [Cites] Surgery. 2004 Dec;136(6):1176-82 [15657573.001]
  • [Cites] J Clin Oncol. 2005 Mar 1;23(7):1358-64 [15684312.001]
  • [Cites] Int Ophthalmol Clin. 2006 Winter;46(1):151-66 [16365561.001]
  • [Cites] Arch Surg. 2006 Feb;141(2):181-90 [16490897.001]
  • [Cites] Semin Nucl Med. 2006 Apr;36(2):147-56 [16517236.001]
  • [Cites] Ann Oncol. 2006 Apr;17(4):578-83 [16469752.001]
  • [Cites] Dig Dis Sci. 2006 Jun;51(6):1033-8 [16865563.001]
  • [Cites] Lancet. 2006 Oct 14;368(9544):1329-38 [17046465.001]
  • [Cites] Eur J Surg Oncol. 2007 Sep;33(7):874-81 [17400422.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Br J Cancer. 2000 May;82(9):1539-46 [10789721.001]
  • [Cites] Digestion. 2000;62 Suppl 1:92-7 [10940694.001]
  • [Cites] Clin Cancer Res. 2000 Aug;6(8):3062-70 [10955785.001]
  • [Cites] Surg Oncol. 2000 Aug;9(2):67-70 [11094325.001]
  • [Cites] J Surg Res. 2001 Jan;95(1):8-12 [11120628.001]
  • [Cites] Arch Ophthalmol. 2001 May;119(5):670-6 [11346394.001]
  • [Cites] Radiology. 2001 Oct;221(1):159-66 [11568334.001]
  • [Cites] J Gastroenterol. 2000 Dec;35(12):907-11 [11573726.001]
  • [Cites] Lancet. 2001 Oct 27;358(9291):1421-3 [11705489.001]
  • [Cites] N Engl J Med. 2002 Aug 15;347(7):472-80 [12181401.001]
  • [Cites] World J Surg. 2002 Aug;26(8):985-90 [12016479.001]
  • [Cites] World J Surg. 2002 Aug;26(8):1052-6 [12016482.001]
  • [Cites] Am Surg. 2002 Sep;68(9):827-31 [12356160.001]
  • [Cites] AJR Am J Roentgenol. 2003 Oct;181(4):1005-10 [14500219.001]
  • [Cites] Br J Surg. 2003 Nov;90(11):1391-7 [14598420.001]
  • [Cites] Clin Cancer Res. 2003 Dec 15;9(17):6343-9 [14695133.001]
  • [Cites] Am J Surg. 2004 Jan;187(1):39-46 [14706584.001]
  • [Cites] J Gastrointest Surg. 2004 Feb;8(2):200-7 [15036196.001]
  • [Cites] Melanoma Res. 2004 Feb;14(1):67-72 [15091197.001]
  • [Cites] Hepatogastroenterology. 2004 May-Jun;51(57):830-2 [15143927.001]
  • [Cites] Cancer Immunol Immunother. 2004 Sep;53(9):840-1 [15127238.001]
  • [Cites] Cancer. 1983 Jul 15;52(2):334-6 [6190546.001]
  • [Cites